Publications

Here is the full list of publications (co-)authored by CBmed employees and affiliates. Take your time and scroll through that impressing collection of multidisciplinary knowledge.

CBmed publications on PubMed

Reviewed Scientific Journals Reviewed Conference Papers Books

Reviewed Scientific Journals

2020 2019 2018 2017 2016 2015
Title Author(s) Publication Date Project
Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1 Ozenil M, Aronow J, Piljak D, Vraka C, Holzer W, Spreitzer H, Wadsak W, Hacker M, Pichler V. Pharmaceuticals (Basel). 2020 Nov 30;13(12):E437. 30 November 2020 2.21
Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Pichler V, Vraka C, Hacker M, Haug AR. Eur J Nucl Med Mol Imaging. 2020 Oct 30. doi: 10.1007/s00259-020-05082-5. Online ahead of print. 30 October 2020 2.21
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schlederer M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, Shariat SF, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangermann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L. Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33332. Online ahead of print. 9 October 2020 1.23
Effects of Thyroid Function on Phosphodiester Concentrations in Skeletal Muscle and Liver: An In Vivo NMRS Study Beiglböck H, Wolf P, Pfleger L, Caliskan B, Fellinger P, Zettinig G, Anderwald CH, Kenner L, Trattnig S, Kautzky-Willer A, Krššák M, Krebs M. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa663. 1 December 2020 1.23
Association of dopamine D(2/3) receptor binding potential measured using PET and [(11)C]-(+)-PHNO with post-mortem DRD(2/3) gene expression in the human brain Komorowski A, Weidenauer A, Murgaš M, Sauerzopf U, Wadsak W, Mitterhauser M, Bauer M, Hacker M, Praschak-Rieder N, Kasper S, Lanzenberger R, Willeit M. Neuroimage. 2020 Dec;223:117270. December 2020 2.21
Enhanced arecoline derivatives as muscarinic acetylcholine receptor M1 ligands for potential application as PET radiotracers Ozenil M, Pacher K, Balber T, Vraka C, Roller A, Holzer W, Spreitzer H, Mitterhauser M, Wadsak W, Hacker M, Pichler V. Eur J Med Chem. 2020 Oct 15;204:112623. 15 October 2020 2.21
Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Sternberg C, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O. Leukemia. 2020 Nov;34(11):3105. November 2020 1.23
Corrigendum to “The effect of electroconvulsive therapy on cerebral monoamine oxidase a expression in treatment-resistant depression investigated using positron emission tomography” [Brain Stimul 12 (3) (2019) 714-723] Baldinger-Melich P, Gryglewski G, Philippe C, Murgaš M, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. Brain Stimul. 2020 Sep-Oct;13(5):1280-1281. September-October 2020 2.21
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma Prokoph N, Probst NA, Lee LC, Monahan JM, Matthews JD, Liang HC, Bahnsen K, Montes-Mojarro IA, Karaca-Atabay E, Sharma GG, Malik V, Larose H, Forde SD, Ducray SP, Lobello C, Wang Q, Luan SL, Pospíšilová Š, Gambacorti-Passerini C, Burke GAA, Pervez S, Attarbaschi A, Janíková A, Pacquement H, Landman-Parker J, Lambilliotte A, Schleiermacher G, Klapper W, Jauch R, Woessmann W, Vassal G, Kenner L, Merkel O, Mologni L, Chiarle R, Brugières L, Geoerger B, Barbieri I, Turner SD. Blood. 2020 Oct 1;136(14):1657-1669. 1 October 2020 1.23
STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer Oberhuber M, Pecoraro M, Rusz M, Oberhuber G, Wieselberg M, Haslinger P, Gurnhofer E, Schlederer M, Limberger T, Lagger S, Pencik J, Kodajova P, Högler S, Stockmaier G, Grund-Gröschke S, Aberger F, Bolis M, Theurillat JP, Wiebringhaus R, Weiss T, Haitel A, Brehme M, Wadsak W, Griss J, Mohr T, Hofer A, Jäger A, Pollheimer J, Egger G, Koellensperger G, Mann M, Hantusch B, Kenner L. Mol Syst Biol. 2020 Apr;16(4):e9247. April 2020 1.23
Reconfiguration of functional brain networks and metabolic cost converge during task performance Hahn A, Breakspear M, Rischka L, Wadsak W, Godbersen GM, Pichler V, Michenthaler P, Vanicek T, Hacker M, Kasper S, Lanzenberger R, Cocchi L. Elife. 2020 Apr 21;9:e52443. 21 April 2020 2.21
Machine learning classification of ADHD and HC by multimodal serotonergic data Kautzky A, Vanicek T, Philippe C, Kranz GS, Wadsak W, Mitterhauser M, Hartmann A, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R. Transl Psychiatry. 2020 Apr 7;10(1):104. 7 April 2020 2.21
Epithelial stem cell marker LGR6 expression identifies a low-risk subgroup in human papillomavirus positive oropharyngeal squamous cell carcinoma Jank BJ, Kadletz L, Dunkler D, Haas M, Schnoell J, Kenner L, Heiduschka G. Oral Oncol. 2020 Jun;105:104657. June 2020 1.23
The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray Gruber ES, Oberhuber G, Pils D, Stork T, Sinn K, Gruber S, Nica R, Kolmer D, Turner SD, Schlederer M, Widder J, Doerr W, Teleky B, Kenner L. Cancers (Basel). 2020 Feb 29;12(3):563. 29 February 2020 1.23
On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D(2/3) receptor agonist radioligand study Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer BM, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte HH, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M. Transl Psychiatry. 2020 Jan 8;10(1):2. 8 January 2020 2.21
Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data Unterholzner J, Gryglewski G, Philippe C, Seiger R, Pichler V, Godbersen GM, Berroterán-Infante N, Murgaš M, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Cereb Cortex. 2020 May 18;30(6):3771-3780. 18 May 2020 2.21
Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):713-720. March 2020 2.21
Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Prostate. 2020 Jan;80(1):74-82. January 2020 2.21
Brain glucose uptake during transcranial direct current stimulation measured with functional [(18)F]FDG-PET Kraus C, Hahn A, Sigurdardottir H, Spurny B, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Brain Imaging Behav. 2020 Apr;14(2):477-484. April 2020 2.21
PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D, Raderer M, Preusser M, Hochmair M, Kiesewetter B, Scheuba C, Ba-Ssalamah A, Karanikas G, Kesselbacher J, Prager G, Dieckmann K, Polterauer S, Weber M, Rausch I, Brauner B, Eidherr H, Wadsak W, Haug AR. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):51-60. January 2020 2.21
Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M. Mol Imaging Biol. 2020 Feb;22(1):47-65. February 2020 1.23 + 2.21
Reliability of task-specific neuronal activation assessed with functional PET, ASL, and BOLD imaging. Rischka L, Godbersen GM, Pichler V, Michenthaler P, Klug S, Klöbl M, Ritter V, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Hahn A. Journal of Cerebral Blood Flow & Metabolism; in review. 2020 2.21
Pirenzepine’s doppelgänger: Momentous rearrangement of the most prominent muscarinic M1 antagonist Marius Ozenil, Lukas Skos, Alexander Roller, Natalie Gajic, Wolfgang Holzer, Helmut Spreitzer, Sonja Platzer-Ozenil, Chrysoula Vraka, Marcus Hacker, Wolfgang Wadsak, Verena Pichler Chem Commun; in review 2020 2.21
The implications of PDK1-4 on tumor energy metabolism, aggressiveness, and therapy resistance. Atas, E., Oberhuber, M., Kenner, L. Front Oncol; in press (accepted 13 Nov 2020) 2020 1.23
Discovery of the melanin concentrating hormone receptor 1 in brown adipose tissue Philippe C , Klebermass AM, Balber T, Kulterer OC, Zeilinger M, Egger G, Dumanic M, Herz CT, Kiefer FW, Scheuba C, Scherer T, Fürnsinn C, Vraka C, Pallitsch K, Spreitzer H, Wadsak W, Viernstein H, Hacker M, Mitterhauser M Annals of the New York Academy of Sciences 2020 2.21
RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy Magdalena Paolino, Rubina Koglgruber, Shane J.F. Cronin, Iris Uribesalgo, Esther Rauscher, Jürgen Harreiter, Michael Schuster, Dagmar Bancher-Todesca, Blanka Pranjic, Maria Novatchkova, Juan P. Fededa, Andrea J. White, Verena Sigl, Sabine Dekan, Thomas Penz, Christoph Bock, Lukas Kenner, Georg A. Holländer, Graham Anderson, Alexandra Kautzky-Willer, Josef M. Penninger Nature (2020) 2020 1.22
Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study. Aberer, F; Pferschy, PN; Tripolt, NJ; Sourij, C; Obermayer, AM; Prüller, F; Novak, E; Reitbauer, P; Kojzar, H; Prietl, B; Kofler, S; Brunner, M; Svehlikova, E; Stojakovic, T; Scharnagl, H; Oulhaj, A; Aziz, F; Riedl, R; Sourij, H Diabetes Obes Metab. 2020; 22(2):212-221 2020 3.20
Epidemiology of major lower extremity amputations in individuals with diabetes in Austria, 2014-2017: A retrospective analysis of Health Insurance database. Aziz, F; Reichardt, B; Sourij, C; Dimai, HP; Reichart, D; Köhler, G; Brodmann, M; Sourij, H Diabetes Res Clin Pract. 2020; 108477-108477 2020 3.20
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M; Gerger, A; Pichler, M Cancer Med. 2020; 9(15): 5473-5479. 2020 2.20
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. Daga, S; Rosenberger, A; Kashofer, K; Heitzer, E; Quehenberger, F; Halbwedl, I; Graf, R; Krisper, N; Prietl, B; Höfler, G; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A Am J Hematol. 2020; 2020 1.22
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. Gager, GM; Jilma, B; Winter, MP; Hengstenberg, C; Lang, IM; Toma, A; Prüller, F; Wallner, M; Kolesnik, E; von Lewinski, D; Siller-Matula, JM Eur J Clin Invest. 2020; e13304-e13304 2020 3.21
Effects of Probiotic Strains on Disease Activity and Enteric Permeability in Psoriatic Arthritis-A Pilot Open-Label Study. Haidmayer, A; Bosch, P; Lackner, A; D’Orazio, M; Fessler, J; Stradner, MH Nutrients. 2020; 12(8): 2020 3.23
Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics Haudum, C; Lindheim, L; Ascani, A; Trummer, C; Horvath, A; Munzker, J; Obermayer-Pietsch, B NUTRIENTS. 2020; 12(6): 1622 2020 3.22
Using In Situ Padlock Probe Technology to Detect mRNA Splice Variants in Tumor Cells. Hofmann, L; Kroneis, T; El-Heliebi, A Methods Mol Biol. 2020; 2148: 361-378. 2020 2.20
A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. Hofmann, L; Sallinger, K; Haudum, C; Smolle, M; Heitzer, E; Moser, T; Novy, M; Gesson, K; Kroneis, T; Bauernhofer, T; El-Heliebi, A Cancers (Basel). 2020; 12(8): 2020 2.20
Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. Horvath, A; Durdevic, M; Leber, B; di Vora, K; Rainer, F; Krones, E; Douschan, P; Spindelboeck, W; Durchschein, F; Zollner, G; Stauber, RE; Fickert, P; Stiegler, P; Stadlbauer, V Nutrients. 2020; 12(6): 2020 3.23
The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Horvath, A; Leber, B; Feldbacher, N; Steinwender, M; Komarova, I; Rainer, F; Blesl, A; Stadlbauer, V Sci Rep. 2020; 10(1): 2723-2723. 2020 3.23
Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Horvath, A; Leber, B; Feldbacher, N; Tripolt, N; Rainer, F; Blesl, A; Trieb, M; Marsche, G; Sourij, H; Stadlbauer, V Eur J Nutr. 2020; 59(7):2969-2983 2020 3.23
Synergistic and antagonistic interactions between antibiotics and synbiotics in modifying the murine fecal microbiome. Jačan, A; Kashofer, K; Zenz, G; Fröhlich, EE; Reichmann, F; Hassan, AM; Holzer, P Eur J Nutr. 2020; 59(5):1831-1844 2020 3.23
Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy. Klöckl, MC; Kasparek, AK; Riedl, JM; Moik, F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer, T; Schilcher, G; Zitta, S; Rosenkranz, AR; Friedl, C; Stöger, H; Posch, F Sci Rep. 2020; 10(1): 11219-11219. 2020 2.20
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Koyani, CN; Plastira, I; Sourij, H; Hallström, S; Schmidt, A; Rainer, PP; Bugger, H; Frank, S; Malle, E; von Lewinski, D Pharmacol Res. 2020; 104870-104870 2020 3.21
Character-Level Neural Language Modelling in the Clinical Domain. Kreuzthaler, M; Oleynik, M; Schulz, S Stud Health Technol Inform. 2020; 270: 83-87. 2020 1.20
Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma Kunc, M; Gabrych, A; Rekawiecki, B; Gorczynski, A; Haybaeck, J; Biernat, W; Czapiewski, P WSPOLCZESNA ONKOL. 2020; 24(1): 1-4. 2020 2.5
Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection. Leber, B; Balázs, I; Horvath, A; Posch, A; Streit, A; Spindelböck, W; Feldbacher, N; Stiegler, P; Stauber, RE; Rechberger, GN; Kollroser, M; Sattler, W; Nusshold, C; Stadlbauer, V Transl Res. 2020; 2020 3.23
Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. Lim, MS; Beyer, T; Babayan, A; Bergmann, M; Brehme, M; Buyx, A; Czernin, J; Egger, G; Elenitoba-Johnson, KSJ; Gückel, B; Jačan, A; Haslacher, H; Hicks, RJ; Kenner, L; Langanke, M; Mitterhauser, M; Pichler, BJ; Salih, HR; Schibli, R; Schulz, S; Simecek, J; Simon, J; Soares, MO; Stelzl, U; Wadsak, W; Zatloukal, K; Zeitlinger, M; Hacker, M Mol Imaging Biol. 2020; 22(1):47-65 2020 2.8
Prediction of Postoperative Clinical Outcomes in Resected Stage I Non-Small Cell Lung Cancer Focusing on the Preoperative Glasgow Prognostic Score. Lindenmann, J; Fink-Neuboeck, N; Taucher, V; Pichler, M; Posch, F; Brcic, L; Smolle, E; Koter, S; Smolle, J; Smolle-Juettner, FM Cancers (Basel). 2020; 12(1): 2020 2.20
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C Thromb Res. 2020; 187: 9-17. 2020 2.51
Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy. Mollnar, S; Pondorfer, P; Kasparek, AK; Reinisch, S; Moik, F; Stotz, M; Halm, M; Szkandera, J; Terbuch, A; Eisner, F; Gerger, A; Kapp, KS; Partl, R; Vasicek, S; Weiland, T; Pichler, M; Stöger, H; Thurnher, D; Posch, F Clin Transl Oncol. 2020; 2020 2.2
The Effects of Prebiotic Supplementation with OMNi-LOGiC® FIBRE on Fecal Microbiome, Fecal Volatile Organic Compounds, and Gut Permeability in Murine Neuroblastoma-Induced Tumor-Associated Cachexia. Obermüller, B; Singer, G; Kienesberger, B; Klymiuk, I; Sperl, D; Stadlbauer, V; Horvath, A; Miekisch, W; Gierschner, P; Grabherr, R; Gruber, HJ; Semeraro, MD; Till, H; Castellani, C Nutrients. 2020; 12(7): 2020 3.23
Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. Posch, F; Hofer, S; Thaler, J; Hell, L; Königsbrügge, O; Grilz, E; Mauracher, LM; Gebhart, J; Marosi, C; Jilma, B; Pabinger, I; Ay, C Transl Res. 2020; 215: 41-56. 2020 2.20
Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study. Posch, F; Riedl, J; Reitter, EM; Crowther, MJ; Grilz, E; Quehenberger, P; Jilma, B; Pabinger, I; Ay, C J Thromb Haemost. 2020; 30 Suppl 4: 2020 2.20
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F Cancers (Basel). 2020; 12(8): 2020 2.20
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Wöll, E; Gerger, A Ther Adv Med Oncol. 2020; 12: 1758835919900872-1758835919900872. 2020 2.20
Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes. Schweighofer, N; Genser, B; Maerz, W; Kleber, ME; Trummer, O; Pieber, TR; Obermayer-Pietsch, B Diabetes Metab Syndr Obes. 2020; 13:2069-2080 2020 3.22
Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer. Smolle, E; Leko, P; Stacher-Priehse, E; Brcic, L; El-Heliebi, A; Hofmann, L; Quehenberger, F; Hrzenjak, A; Popper, HH; Olschewski, H; Leithner, K Mol Oncol. 2020; 2020 2.20
COVID-19 in Diabetes in Austria – study group Covid-19 fatality prediction in people with diabetes and prediabetes using a simple score at hospital admission. Sourij, H; Aziz, F; Bräuer, A; Ciardi, C; Clodi, M; Fasching, P; Karolyi, M; Kautzky-Willer, A; Klammer, C; Malle, O; Oulhaj, A; Pawelka, E; Peric, S; Ress, C; Sourij, C; Stechemesser, L; Stingl, H; Stulnig, TM; Tripolt, N; Wagner, M; Wolf, P; Zitterl, A; Kaser, S; COVID-19 in Diabetes in Austria – study group Diabetes Obes Metab. 2020; 2020 3.20
Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study. Stadlbauer, V; Engertsberger, L; Komarova, I; Feldbacher, N; Leber, B; Pichler, G; Fink, N; Scarpatetti, M; Schippinger, W; Schmidt, R; Horvath, A BMC Geriatr. 2020; 20(1):248-248 2020 3.23
Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis. Stadlbauer, V; Komarova, I; Klymiuk, I; Durdevic, M; Reisinger, A; Blesl, A; Rainer, F; Horvath, A Liver Int. 2020; 2020 3.23
Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients. Stelzl, A; Aziz, F; Riedl, JM; Posch, F; Smolle, MA; Stojakovic, T; Terbuch, A; Pichler, M; Bergovec, M; Leithner, A; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Sourij, H; Szkandera, J Sci Rep. 2020; 10(1): 12438-12438. 2020 3.23
The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Stotz, M; Barth, DA; Riedl, JM; Asamer, E; Klocker, EV; Kornprat, P; Hutterer, GC; Prinz, F; Lackner, K; Stöger, H; Gerger, A; Pichler, M Cancers (Basel). 2020; 12(7): 2020 2.20
HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. Trieb, M; Rainer, F; Stadlbauer, V; Douschan, P; Horvath, A; Binder, L; Trakaki, A; Knuplez, E; Scharnagl, H; Stojakovic, T; Heinemann, Á; Mandorfer, M; Paternostro, R; Reiberger, T; Pitarch, C; Amorós, A; Gerbes, A; Caraceni, P; Alessandria, C; Moreau, R; Clària, J; Marsche, G; Stauber, RE J Hepatol. 2020; 73(1):113-120 2020 3.23
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. Tsourdi, E; Zillikens, MC; Meier, C; Body, JJ; Gonzalez Rodriguez, E; Anastasilakis, AD; Abrahamsen, B; McCloskey, E; Hofbauer, LC; Guañabens, N; Obermayer-Pietsch, B; Ralston, SH; Eastell, R; Pepe, J; Palermo, A; Langdahl, B J Clin Endocrinol Metab 2020 3.22
The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. Hatzl, S; Posch, F; Schulz, E; Gornicec, M; Deutsch, A; Beham-Schmid, C; Pichler, M; Greinix, H; Sill, H; Zebisch, A; Neumeister, P; Prochazka, KT Pathol Oncol Res. 2020; 2020 2.20
Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate. Chen, Q; Yang, B; Nass, N; Schatz, C; Haybaeck, J Cancers (Basel). 2020; 12(7): 2020 2.5
Stratifying nutritional restriction in cancer therapy: Next stop, personalized medicine. Krstic, J; Pieber, TR; Prokesch, A Int Rev Cell Mol Biol. 2020; 354: 231-259. 2020 2.22
Diabetes mellitus und Osteoporose: zwei unabhängige Erscheinungen? Malle, O; Fahrleitner-Pammer, A; Aberer, F; Sourij, H Jatros Diabetes & Stoffwechsel. 2020; 23/2020: 30-32. 2020 3.20
The Interplay of Tumor Stroma and Translational Factors in Endometrial Cancer. Sobočan, M; Smolle, MA; Schatz, C; Haybaeck, J Cancers (Basel). 2020; 12(8): 2020 2.5
Personalized medicine in Austria: expectations and limitations. Pot, M; Brehme, M; El-Heliebi, A; Gschmeidler, B; Hofer, P; Kroneis, T; Schirmer, M; Schumann, S; Prainsack, B Per Med. 2020; 2020 2.20
High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype12 (vol 12, pg 256, 2019) Golob-Schwarzl, N; Bettermann, K; Mehta, AK; Kessler, SM; Unterluggauer, J; Krassnig, S; Kojima, K; Chen, X; Hoshida, Y; Bardeesy, NM; Muller, H; Svendova, V; Schimek, MG; Diwoky, C; Lipfert, A; Mahajan, V; Stumptner, C; Thuringer, A; Frohlich, LF; Stojakovic, T; Nilsson, KPR; Kolbe, T; Rulicke, T; Magin, TM; Strnad, P; Kiemer, AK; Moriggl, R; Haybaeck, J TRANSL ONCOL. 2020; 13(2): 490-492. 2020 2.5
Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. Stekovic, S; Hofer, SJ; Tripolt, N; Aon, MA; Royer, P; Pein, L; Stadler, JT; Pendl, T; Prietl, B; Url, J; Schroeder, S; Tadic, J; Eisenberg, T; Magnes, C; Stumpe, M; Zuegner, E; Bordag, N; Riedl, R; Schmidt, A; Kolesnik, E; Verheyen, N; Springer, A; Madl, T; Sinner, F; de Cabo, R; Kroemer, G; Obermayer-Pietsch, B; Dengjel, J; Sourij, H; Pieber, TR; Madeo, F Cell Metab. 2020; 31(4):878-881 2020 2.20
Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, CES; John, JS; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher, MR Nat Commun. 2020; 11(1): 1965-1965. 2020 2.20
Experten-Statement: Diagnostisches Management der nicht-alkoholischen Steatohepatitis (NASH) Aigner, E; Ferlitsch, A; Gschwantler, M; Hofer, H; Maieron, A; Peck-Radosavljevic, M; Stadlbauer-Köllner, V; Wagner, M Update Internationale Zeitschrift für ärztliche Fortbildung. 2020; 2020 3.23
Increased resting respiratory burst and decreased phagocytosis and chemotaxis: how bile acids impair neutrophil response in liver cirrhosis Komarova, I; Horvath, A; Leber, B; Feldbacher, N; Vermeren, S; Stadlbauer, V Zeitschrift für Gastroenterologie. 2020; 58(05):e92–53. Jahrestagung der ÖGGH; JUN 18-19, 2020; Salzburg, AUSTRIA. 2020 3.23
Modelling of the Inflammatory Cell Kinetics Underlying Bleomycin-Induced Lung Fibrosis Reveals Chronic Persistent Inflammation (B34) Marsh, LM; Bordag, N; Biasin, V; Nagy, B; Sharma, N; Jandl, K; Kwapiszewska, G AM J RESP CRIT CARE. 2020; 201: -International Conference of the American-Thoracic-Society; AUG 5-10, 2020; New York, United States of America. 2020 1.5
The FreeStyle Libre 1 isCGM System as the first objective Measuring Instrument for the Diagnosis of Hypoglycemia Unawareness in People with Type 1 Diabetes – A prospective Observational Study Moser, O; Ziko, H; Elsayed, H; Hochfellner, D; Pottler, T; Muller, A; Eckstein, M; Sourij, H; Mader, JK WIEN KLIN WOCHENSCHR. 2020; 132: S343-S344. 2020 3.20
Halving the Basal Insulin Dose before a Running Event in physically active Adults with Type 1 Diabetes minimizes the Risk of Hypoglycaemia – A prospective, clinical, controlled, Observational Study Muller, A; Moser, O; Eckstein, ML; Ziko, H; Aberer, F; Treiber, G; Unteregger, C; Kojzar, H; Mader, JK; Sourij, C; Pferschy, P; Obermayer, A; Tripolt, N; Sourij, H WIEN KLIN WOCHENSCHR. 2020; 132: S364-S364. 2020 3.20
Measurement Accuracy of the intermittently-scanned continuous Glucose Monitoring Devices (isCGM) during a glycemic Challenge in Adults with Type 1 Diabetes – A prospective Analysis Muller, A; Moser, O; Tripolt, N; Pferschy, P; Obermayer, A; Kojzar, H; Yildirim, H; Sourij, C; Eckstein, ML; Sourij, H WIEN KLIN WOCHENSCHR. 2020; 132: S364-S364. 2020 3.20
Disease severity and proton pump inhibitor use impacts strongest on faecal microbiome composition in cirrhosis Stadlbauer, V; Komarova, I; Klymiuk, I; Durdevic, M; Reisinger, A; Blesl, A; Rainer, F; Horvath, A Journal of Hepatology. 2020; 73: S235-S236.-International Liver Congress; AUG 27-29, 2020; London, UK. 2020 3.23
Die Auswirkungen eines multispezies-Synbiotikums auf Mikrobiom-assoziierte Nebenwirkungen einer Langzeit-Protonen-Pumpen-Hemmer Therapie: Eine Pilotstudie Steinwender, M; Leber, B; Feldbacher, N; Komarova, I; Rainer, F; Blesl, A; Horvath, A; Stadlbauer-Köllner, V Zeitschrift für Gastroenterologie . 2020; 58(05):e88–53. Jahrestagung der ÖGGH; JUN 18-19, 2020; Salzburg, AUSTRIA. 2020 3.23
Tregs cells – a double edged sword? Lessons learned from colorectal cancer in comparison to type 1 diabetes mellitus Bauernhofer, T; Stanzer, S; Prietl, B; Kofler, S; Obermayer-Pietsch, B; Pichler, M; Sourij, H; Pieber, T. ONCOL RES TREAT. 2020; 43(SUPPL 4):127-128 2020 3.22
Epidemiology of lower extremity amputations in individuals with diabetes in Austria, 2014-2017 Aziz, F; Reichardt, B; Dimai, HP; Sourij, CC; Reichart, D; Kohler, G; Sourij, H DIABETOLOGIA. 2020; 63(SUPPL 1): S411-S411 2020 3.20
People with type 1 diabetes and impaired awareness of hypoglycaemia have a delayed reaction to perform a glucose scan during hypoglycaemia: a prospective observational study Cigler, M; Ziko, H; Elsayed, H; Hochfellner, D; Pottler, T; Muller, A; Eckstein, ML; Knoll, L; Sourij, H; Mader, JK; Moser, O DIABETOLOGIA. 2020; 63(SUPPL 1): S359-S359 2020 3.20
ABATACEPT ALTERS THE FREQUENCY OF IMMUNOREGULATORY AND EFFECTOR T CELL SUBPOPULATIONS IN RHEUMATOID ARTHRITIS Dreo, B; Prietl, B; Kofler, S; Sourij, H; Lackner, A; Moazedi-Furst, F; D’orazio, M; Stradner, M; Graninger, W; Brezinschek, HP ANN RHEUM DIS. 2020; 79: 225-225 2020 3.20
DISCREPANCY OF GLYCAEMIC RANGES IN REGARD TO CGM METRICS FOR CLINICAL CARE VERSUS GUIDANCE FOR GLYCAEMIC TARGETS WITHIN THE RECENT CONSENSUS ON TIR Eckstein, M; Ziko, H; Moser, O; Elsayed, H; Cigler, M; Hochfellner, D; Pottler, T; Mueller, A; Sourij, H; Mader, J DIABETES TECHNOL THE. 2020; 22: A106-A106 2020 3.20
Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis. Eckstein, ML; Farinha, JB; McCarthy, O; West, DJ; Yardley, JE; Bally, L; Zueger, T; Stettler, C; Boff, W; Reischak-Oliveira, A; Riddell, MC; Zaharieva, DP; Pieber, TR; Müller, A; Birnbaumer, P; Aziz, F; Brugnara, L; Haahr, H; Zijlstra, E; Heise, T; Sourij, H; Roden, M; Hofmann, P; Bracken, RM; Pesta, D; Moser, O Diabetes Care. 2021; 44(1):240-247 2020 3.20
Interpreting the recent consensus on time in range for interstitial glucose right – or wrong? Eckstein, ML; Knoll, L; Pöttler, T; Hochfellner, D; Müller, A; Sourij, H; Moser, O; Mader, JK Diabetes Res Clin Pract. 2020; 108106-108106 2020 3.20
Efficacy of Carbohydrate Supplementation Compared With Bolus Insulin Dose Reduction Around Exercise in Adults With Type 1 Diabetes: A Retrospective, Controlled Analysis. Eckstein, ML; McCarthy, O; Tripolt, NJ; Müller, A; Birnbaumer, P; Pferschy, PN; Hofmann, P; Bracken, RM; Sourij, H; Moser, O Can J Diabetes. 2020; 44(8):697-700 2020 3.20
Differences in physiological responses to cardio-pulmonary exercise testing in adults with type 1 diabetes and healthy controls: a pooled analysis Eckstein, ML; Pesta, D; McCarthy, O; West, DJ; Yardley, J; Zueger, T; Stettler, C; Farinha, JB; Riddell, MC; Brugnara, L; Roden, M; Sourij, H; Bracken, RM; Hofmann, P; Moser, O DIABETOLOGIA. 2020; 63(SUPPL 1): S99-S99 2020 3.20
Type 1 Diabetes and Physical Exercise: Moving (forward) as an Adjuvant Therapy. Moser, O; Eckstein, ML; West, DJ; Goswami, N; Sourij, H; Hofmann, P Curr Pharm Des. 2020; 26(9):946-957 2020 3.20
Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes-A single-centre, prospective, controlled observational study. Moser, O; Mueller, A; Eckstein, ML; Ziko, H; Aberer, F; Treiber, G; Unteregger, C; Kojzar, H; Mader, JK; Sourij, C; Pferschy, P; Obermayer, A; Tripolt, N; Sourij, H PLoS One. 2020; 15(9): e0239091-e0239091 2020 3.20
Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA) Moser, O; Riddell, MC; Eckstein, ML; Adolfsson, P; Rabasa-Lhoret, R; van den Boom, L; Gillard, P; Nørgaard, K; Oliver, NS; Zaharieva, DP; Battelino, T; de Beaufort, C; Bergenstal, RM; Buckingham, B; Cengiz, E; Deeb, A; Heise, T; Heller, S; Kowalski, AJ; Leelarathna, L; Mathieu, C; Stettler, C; Tauschmann, M; Thabit, H; Wilmot, EG; Sourij, H; Smart, CE; Jacobs, PG; Bracken, RM; Mader, JK Diabetologia. 2020 Dec;63(12):2501-2520 2020 3.20
Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Moser, O; Riddell, MC; Eckstein, ML; Adolfsson, P; Rabasa-Lhoret, R; van den Boom, L; Gillard, P; Nørgaard, K; Oliver, NS; Zaharieva, DP; Battelino, T; de Beaufort, C; Bergenstal, RM; Buckingham, B; Cengiz, E; Deeb, A; Heise, T; Heller, S; Kowalski, AJ; Leelarathna, L; Mathieu, C; Stettler, C; Tauschmann, M; Thabit, H; Wilmot, EG; Sourij, H; Smart, CE; Jacobs, PG; Bracken, RM; Mader, JK Pediatr Diabetes. 2020; 21(8):1375-1393 2020 3.20
TIME IN RANGE (TIR) ACHIEVEMENT IN REGARD TO CLINICAL TARGETS IN PEOPLE WITH TYPE 1 DIABETES (PWT1D): A REAL WORLD SETTING Moser, O; Ziko, H; Eckstein, M; Elsayed, H; Cigler, M; Hochfellner, D; Poettler, T; Mueller, A; Sourij, H; Mader, J DIABETES TECHNOL THE. 2020; 22: A231-A231 2020 3.20
People with type 1 diabetes and impaired awareness of hypoglycaemia have a delayed reaction to performing a glucose scan during hypoglycaemia: a prospective observational study. Moser, O; Ziko, H; Elsayed, H; Hochfellner, DA; Pöttler, T; Mueller, A; Eckstein, ML; Sourij, H; Mader, JK Diabet Med. 2020 Dec;37(12):2153-2159 2020 3.20
Acid-base changes during diabetic ketoacidosis in type 1 diabetes with/without SGLT2 inhibitor Mursic, I; Svehlikova, E; Regittnig, W; Urschitz, M; Wolf, M; Brunner, M; Augustin, T; Magnes, C; Eberl, A; Heise, T; Klein, O; Sourij, H; Pieber, T DIABETOLOGIA. 2020; 63(SUPPL 1):S272-S273 2020 3.20
Agreement between cardiovascular disease risk assessment tools: An application to the United Arab Emirates population. Oulhaj, A; Bakir, S; Aziz, F; Suliman, A; Almahmeed, W; Sourij, H; Shehab, A PLoS One. 2020; 15(1):e0228031-e0228031 2020 3.20
Arylesterase Activity of HDL Associated Paraoxonase as a Potential Prognostic Marker in Patients With Sepsis and Septic Shock-A Prospective Pilot Study. Reisinger, AC; Schuller, M; Holzer, M; Stadler, JT; Hackl, G; Posch, F; Marsche, G; Sourij, H; Ekart, R; Eller, K; Eller, P Front Med (Lausanne). 2020 Oct 22; 7:579677-579677 2020 3.20
“Atypical” Diabetes – There’s more than Type 1 and Type 2-A Case Report Treiber, G; Verheyen, N; Verheyen, S; Mader, JK; Sourij, H WIEN KLIN WOCHENSCHR. 2020; 132(SUPPL 2):69-69 2020 3.20
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. Tripolt, NJ; Kolesnik, E; Pferschy, PN; Verheyen, N; Ablasser, K; Sailer, S; Alber, H; Berger, R; Kaulfersch, C; Leitner, K; Lichtenauer, M; Mader, A; Moertl, D; Oulhaj, A; Reiter, C; Rieder, T; Saely, CH; Siller-Matula, J; Weidinger, F; Zechner, PM; von Lewinski, D; Sourij, H; EMMY study group Am Heart J. 2020; 221:39-47 2020 3.20
Adaptive insuline and glucose metabolism upon prolonged fasting in non-obese but not in obese individuals Tripolt, NJ; Pferschy, PN; Obermayer, A; Kojzar, H; Obermayer, B; Zanker, M; Sourij, C; Pieber, TR; Moser, O; Eckstein, ML; Riedl, R; Sourij, H DIABETOLOGIA. 2020; 63(SUPPL 1): S296-S297 2020 3.20
Blood levels of microRNAs associated with ischemic heart disease differ between Austrians and Japanese: a pilot study. Wakabayashi, I; Eguchi, R; Sotoda, Y; von Lewinski, D; Sourij, H; Daimon, T; Groschner, K; Rainer, PP Sci Rep. 2020; 10(1): 13628-13628 2020 3.20
DRUG DEPENDENT ALTERATIONS IN B-CELL REPERTOIRE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH LOW DISEASE ACTIVITY Zenz, S; Dreo, B; Prietl, B; Kofler, S; Sourij, H; Lackner, A; D’orazio, M; Brickmann, K; Gretler, J; Furst-Moazedi, F; Stradner, M; Graninger, W; Brezinsek, HP ANN RHEUM DIS. 2020; 79: 1369-1369 2020 1.22
Arzneimittelabhängige Änderungen im B-Zell-Repertoire bei Patienten mit systemischem Lupus erythematodes mit geringer Krankheitsaktivität Zenz, S; Dreo, B; Prietl, B; Kofler, S; Sourij, H; Lackner, A; D’orazio, M; Brickmann, K; Gretler, J; Furst-Moazedi, F; Stradner, M; Graninger, W; Brezinsek, HP Fakten der Rheumatologie. 2020 2020 1.22
Differential effects of SGLT2 inhibitors on mitochondrial oxidative phosphorylation, glucose uptake, cell energy level and metabolism in HepG2 cells and HUVECs Zugner, E; Hagvall, S; Elmore, CS; Sourij, H; Kotzbeck, P; Esterline, R; Moosmang, S; Yang, HC; Magnes, C DIABETOLOGIA. 2020; 63(SUPPL 1): S277-S277 2020 3.20
Medical Information Extraction in the Age of Deep Learning. Hahn, U; Oleynik, M Yearb Med Inform. 2020; 29(1): 208-220 2020 1.20
Risk prediction of delirium in hospitalized patients using machine learning: An implementation and prospective evaluation study. Jauk, S; Kramer, D; Großauer, B; Rienmüller, S; Avian, A; Berghold, A; Leodolter, W; Schulz, S J Am Med Inform Assoc. 2020; 27(9):1383-1392 2020 1.20
Leveraging PubMed to Create a Specialty-Based Sense Inventory for Spanish Acronym Resolution. Pomares-Quimbaya, A; López-Úbeda, P; Oleynik, M; Schulz, S Stud Health Technol Inform. 2020; 270: 292-296 2020 1.20
How versioning of terminology systems can be supported by ontological models – a case study on TNM tumor classification Zabka, S; Schulz, S; Brunner, O; Boeker, M APPL ONTOL. 2020; 15(1): 41-60 2020 1.20
Distribution and prognostic significance of gluconeogenic and glycolytic phenotypes in non-small cell lung cancer Smolle, E; Leko, P; Stacher-Priehse, E; Brcic, L; El-Heliebi, A; Hofmann, L; Quehenberger, F; Hrzenjak, A; Popper, H; Olschewski, H; Leithner, K WIEN KLIN WOCHENSCHR. 2020; 132(19-20):621-622 2020 2.20
Pitfalls and solutions of the fully-automated radiosynthesis of [(11)C]metoclopramide. Pichler V, Ozenil M, Bamminger K, Vraka C, Hacker M, Langer O, Wadsak W. EJNMMI Radiopharm Chem. 2019 Dec 18;4(1):31. doi: 10.1186/s41181-019-0083-2. 18 December 2019 2.21
STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. Kaltenecker D, Themanns M, Mueller KM, Spirk K, Golob-Schwarzl N, Friedbichler K, Kenner L, Haybaeck J, Moriggl R. Cytokine. 2019 Dec;124:154573. doi: 10.1016/j.cyto.2018.10.014. Epub 2018 Oct 28. December 2019 1.23
Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. Rischka L, Gryglewski G, Berroteran-Infante N, Rausch I, James GM, Klöbl M, Sigurdardottir H, Hartenbach M, Hahn A, Wadsak W, Mitterhauser M, Beyer T, Kasper S, Prayer D, Hacker M, Lanzenberger R. Front Physiol. 2019 Nov 22;10:1422. doi: 10.3389/fphys.2019.01422. eCollection 2019. 22 November 2019 2.21
Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Eur J Nucl Med Mol Imaging. 2019 Nov 28. doi: 10.1007/s00259-019-04584-1. [Epub ahead of print] 28 November 2019 2.21
Brain glucose uptake during transcranial direct current stimulation measured with functional [(18)F]FDG-PET. Kraus C, Hahn A, Sigurdardottir H, Spurny B, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Brain Imaging Behav. 2019 Oct 10. doi: 10.1007/s11682-019-00195-4. [Epub ahead of print] 10 October 2019 2.21
Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15. 15 October 2019 2.21
The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, Tse W, Kenner L. Cells. 2019 Oct 30;8(11). pii: E1357. doi: 10.3390/cells8111357. 30 October 2019 1.23
Correction: Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Transl Psychiatry. 2019 Oct 4;9(1):246. doi: 10.1038/s41398-019-0583-6. 4 October 2019 2.21
Toward the Optimization of (+)-[(11)C]PHNO Synthesis: Time Reduction and Process Validation. Pfaff S, Philippe C, Nics L, Berroteran-Infante N, Pallitsch K, Rami-Mark C, Weidenauer A, Sauerzopf U, Willeit M, Mitterhauser M, Hacker M, Wadsak W, Pichler V. Contrast Media Mol Imaging. 2019 Sep 30;2019:4292596. doi: 10.1155/2019/4292596. eCollection 2019. 30 September 2019 2.21
Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177. doi: 10.1007/s00259-019-04361-0. Epub 2019 Jun 29. September 2019 2.21
Multimodal [(18) F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice. Hayer S, Zeilinger M, Weiss V, Dumanic M, Seibt M, Niederreiter B, Shvets T, Pichler F, Wadsak W, Podesser BK, Helbich TH, Hacker M, Smolen JS, Redlich K, Mitterhauser M. J Bone Miner Res. 2019 Sep;34(9):1632-1645. doi: 10.1002/jbmr.3748. Epub 2019 Jul 30. September 2019 2.21
PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D, Raderer M, Preusser M, Hochmair M, Kiesewetter B, Scheuba C, Ba-Ssalamah A, Karanikas G, Kesselbacher J, Prager G, Dieckmann K, Polterauer S, Weber M, Rausch I, Brauner B, Eidherr H, Wadsak W, Haug AR. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):51-60. doi: 10.1007/s00259-019-04452-y. Epub 2019 Aug 13. 13 August 2019 2.21
(R)-[(18)F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging. Berroteran-Infante N, Kalina T, Fetty L, Janisch V, Velasco R, Vraka C, Hacker M, Haug AR, Pallitsch K, Wadsak W, Mitterhauser M. Eur J Med Chem. 2019 Aug 15;176:410-418. doi: 10.1016/j.ejmech.2019.05.008. Epub 2019 May 10. 15 August 2019 2.21
Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, Gryglewski G, Berroteran-Infante N, Kautzky A, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hartmann AM, Hacker M, Rujescu D, Kasper S, Lanzenberger R. Mol Psychiatry. 2019 Aug 5. doi: 10.1038/s41380-019-0461-x. [Epub ahead of print] 5 August 2019 2.21
[(68)Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery. Li X, Yu W, Wollenweber T, Lu X, Wei Y, Beitzke D, Wadsak W, Kropf S, Wester HJ, Haug AR, Zhang X, Hacker M. Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1616-1625. doi: 10.1007/s00259-019-04322-7. Epub 2019 Apr 19. July 2019 2.21
Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate (11)C-Metoclopramide Assessed with PET Imaging in Humans. Tournier N, Bauer M, Pichler V, Nics L, Klebermass EM, Bamminger K, Matzneller P, Weber M, Karch R, Caille F, Auvity S, Marie S, Jäger W, Wadsak W, Hacker M, Zeitlinger M, Langer O. J Nucl Med. 2019 Jul;60(7):985-991. doi: 10.2967/jnumed.118.219972. Epub 2019 Jan 10. July 2019 2.21
In vitro Radiopharmaceutical Evidence for MCHR1 Binding Sites in Murine Brown Adipocytes. Balber T, Bencurova K, Kiefer FW, Kulterer OC, Klebermass EM, Egger G, Tran L, Wagner KH, Viernstein H, Pallitsch K, Spreitzer H, Hacker M, Wadsak W, Mitterhauser M, Philippe C. Front Endocrinol (Lausanne). 2019 Jun 11;10:324. doi: 10.3389/fendo.2019.00324. eCollection 2019. 11 June 2019 2.21
Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. Sperling S, Fiedler P, Lechner M, Pollithy A, Ehrenberg S, Schiefer AI, Kenner L, Feuchtinger A, Kühn R, Swinerd G, Schmidt-Supprian M, Strobl LJ, Zimber-Strobl U. Blood. 2019 Jun 13;133(24):2597-2609. doi: 10.1182/blood.2018880138. Epub 2019 Apr 8. 13 June 2019 1.23
Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. Gryglewski G, Klöbl M, Berroteran-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass EM, Reed MB, Vraka C, Hienert M, James GM, Silberbauer L, Godbersen GM, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R. Eur Neuropsychopharmacol. 2019 Jun;29(6):711-719. doi: 10.1016/j.euroneuro.2019.04.001. Epub 2019 May 8. June 2019 2.21
The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. Brain Stimul. 2019 May – Jun;12(3):714-723. doi: 10.1016/j.brs.2018.12.976. Epub 2019 Jan 2. May 2019 2.21
Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. May 2019 2.21
Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941. Vraka C, Pichler V, Pfaff S, Balber T, Hacker M, Mitterhauser M, Wadsak W, Philippe C. J Vis Exp. 2019 Apr 28;(146). doi: 10.3791/59557. April 2019 2.21
A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jäger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer O. J Nucl Med. 2019 Apr;60(4):486-491. doi: 10.2967/jnumed.118.216432. Epub 2018 Sep 20. April 2019 2.21
SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [(18)F]FE@SNAP and [(11)C]SNAP-7941. Philippe C, Zeilinger M, Dumanic M, Pichler F, Fetty L, Vraka C, Balber T, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M. Mol Imaging Biol. 2019 Apr;21(2):257-268. doi: 10.1007/s11307-018-1212-0. April 2019 2.21
Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. Kalina T, Berroteran-Infante N, Schmitl S, Vraka C, Hacker M, Mitterhauser M, Pallitsch K, Wadsak W. Future Med Chem. 2019 Mar;11(6):539-550. doi: 10.4155/fmc-2018-0444. Epub 2019 Mar 19. March 2019 2.21
Corrigendum to “Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging”. Gryglewski G, Seiger R, James GM, Godbersen GM, Komorowski A, Unterholzner J, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Neuroimage. 2019 Mar;188:845. doi: 10.1016/j.neuroimage.2018.10.081. Epub 2018 Nov 19. March 2019 2.21
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O. Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21. March 2019 1.23
Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. James GM, Gryglewski G, Vanicek T, Berroteran-Infante N, Philippe C, Kautzky A, Nics L, Vraka C, Godbersen GM, Unterholzner J, Sigurdardottir HL, Spies M, Seiger R, Kranz GS, Hahn A, Mitterhauser M, Wadsak W, Bauer A, Hacker M, Kasper S, Lanzenberger R. Cereb Cortex. 2019 Jan 1;29(1):372-382. doi: 10.1093/cercor/bhy249. 1 January 2019 2.21
Optimization of the Automated Synthesis of [11C]mHED-Administered and Apparent Molar Activities. Vraka C, Pichler V, Berroteran-Infante N, Wollenweber T, Pillinger A, Hohensinner M, Fetty L, Beitzke D, Li X, Philippe C, Pallitsch K, Mitterhauser M, Hacker M, Wadsak W. Pharmaceuticals (Basel). 2019 Jan 14;12(1). pii: E12. doi: 10.3390/ph12010012. 14 January 2019 2.21
Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Transl Psychiatry. 2019 Jan 16;9(1):5. doi: 10.1038/s41398-018-0308-2. 16 January 2019 2.21
Binding Affinity of Some Endogenous and Synthetic TSPO Ligands Regarding the rs6971 Polymorphism. Berroteran-Infante N, Tadic M, Hacker M, Wadsak W, Mitterhauser M. Int J Mol Sci. 2019 Jan 29;20(3). pii: E563. doi: 10.3390/ijms20030563. 29 January 2019 2.21
Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial. Aberer, F; Mader, JK; Holzgruber, J; Trummer, C; Schwetz, V; Pandis, M; Pferschy, PN; Greinix, H; Tripolt, NJ; Pieber, TR; Zebisch, A; Sill, H; Wölfler, A; Sourij, H J Diabetes Investig. 2019; 10(2):339-342 2019 3.20
Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis. Hoenigl, M; Orasch, T; Faserl, K; Prattes, J; Loeffler, J; Springer, J; Gsaller, F; Reischies, F; Duettmann, W; Raggam, RB; Lindner, H; Haas, H J Infect. 2019; 78(2):150-157 2019 3.11
STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. Kaltenecker, D; Themanns, M; Mueller, KM; Spirk, K; Golob-Schwarzl, N; Friedbichler, K; Kenner, L; Haybaeck, J; Moriggl, R Cytokine. 2018; 154573-154573 2019 2.5
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Kleinegger, F; Hofer, E; Wodlej, C; Golob-Schwarzl, N; Birkl-Toeglhofer, AM; Stallinger, A; Petzold, J; Orlova, A; Krassnig, S; Reihs, R; Niedrist, T; Mangge, H; Park, YN; Thalhammer, M; Aigelsreiter, A; Lax, S; Garbers, C; Fickert, P; Rose-John, S; Moriggl, R; Rinner, B; Haybaeck, J Biochim Biophys Acta Mol Basis Dis. 2019; 1865(2):308-321 2019 2.5
High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Golob-Schwarzl, N; Bettermann, K; Mehta, AK; Kessler, SM; Unterluggauer, J; Krassnig, S; Kojima, K; Chen, X; Hoshida, Y; Bardeesy, NM; Müller, H; Svendova, V; Schimek, MG; Diwoky, C; Lipfert, A; Mahajan, V; Stumptner, C; Thüringer, A; Fröhlich, LF; Stojakovic, T; Nilsson, KPR; Kolbe, T; Rülicke, T; Magin, TM; Strnad, P; Kiemer, AK; Moriggl, R; Haybaeck, J Transl Oncol. 2019; 12(2):256-268 2019 2.5
Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study. Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A Clin Transl Oncol. 2019; 21(8):1034-1043 2019 2.5
A single alcohol binge impacts on neutrophil function without changes in gut barrier function and gut microbiome composition in healthy volunteers. Stadlbauer, V; Horvath, A; Komarova, I; Schmerboeck, B; Feldbacher, N; Wurm, S; Klymiuk, I; Durdevic, M; Rainer, F; Blesl, A; Stryeck, S; Madl, T; Stiegler, P; Leber, B PLoS One. 2019; 14(2):e0211703-e0211703 2019 3.23
Dysbiosis in early sepsis can be modulated by a multispecies probiotic: a randomised controlled pilot trial. Stadlbauer, V; Horvath, A; Komarova, I; Schmerboeck, B; Feldbacher, N; Klymiuk, I; Durdevic, M; Rainer, F; Blesl, A; Stiegler, P; Leber, B Benef Microbes. 2019; 10(3):265-278 2019 3.23
LC/MS/MS analyses of open-flow microperfusion samples quantify eicosanoids in a rat model of skin inflammation. Pipper, C; Bordag, N; Reiter, B; Economides, K; Florian, P; Birngruber, T; Sinner, F; Bodenlenz, M; Eberl, A J Lipid Res. 2019; 60(4):758-766 2019 3.21
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML. Daga, S; Rosenberger, A; Quehenberger, F; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A Cancer Med. 2019; 8(4):1771-1778 2019 1.6
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Moik, F; Riedl, JM; Winder, T; Terbuch, A; Rossmann, CH; Szkandera, J; Bauernhofer, T; Kasparek, AK; Schaberl-Moser, R; Reicher, A; Prinz, F; Pichler, M; Stöger, H; Stotz, M; Gerger, A; Posch, F Sci Rep. 2019; 9(1): 5548-5548. 2019 2.2
EHR problem list clustering for improved topic-space navigation. Kreuzthaler, M; Pfeifer, B; Vera Ramos, JA; Kramer, D; Grogger, V; Bredenfeldt, S; Pedevilla, M; Krisper, P; Schulz, S BMC MED INFORM DECIS. 2019; 19(Suppl 3): 72-72. 2019 1.20/1.23
Intermittent Fasting Exacerbates the Acute Immune and Behavioral Sickness Response to the Viral Mimic Poly(I:C) in Mice. Zenz, G; Jačan, A; Reichmann, F; Farzi, A; Holzer, P Front Neurosci. 2019; 13: 359-359. 2019 1.23
Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. Lim, MS; Beyer, T; Babayan, A; Bergmann, M; Brehme, M; Buyx, A; Czernin, J; Egger, G; Elenitoba-Johnson, KSJ; Gückel, B; Jačan, A; Haslacher, H; Hicks, RJ; Kenner, L; Langanke, M; Mitterhauser, M; Pichler, BJ; Salih, HR; Schibli, R; Schulz, S; Simecek, J; Simon, J; Soares, MO; Stelzl, U; Wadsak, W; Zatloukal, K; Zeitlinger, M; Hacker, M Mol Imaging Biol. 2019; 2019 1.23/2.21
Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Horvath, A; Rainer, F; Bashir, M; Leber, B; Schmerboeck, B; Klymiuk, I; Groselj-Strele, A; Durdevic, M; Freedberg, DE; Abrams, JA; Fickert, P; Stiegler, P; Stadlbauer, V Sci Rep. 2019; 9(1): 12000-12000. 2019 3.23
Development of a Machine Learning Model Predicting an ICU Admission for Patients with Elective Surgery and Its Prospective Validation in Clinical Practice. Jauk, S; Kramer, D; Stark, G; Hasiba, K; Leodolter, W; Schulz, S; Kainz, J Stud Health Technol Inform. 2019; 264:173-177 2019 1.20
Evaluating shallow and deep learning strategies for the 2018 n2c2 shared task on clinical text classification. Oleynik, M; Kugic, A; Kasáč, Z; Kreuzthaler, M J Am Med Inform Assoc. 2019; 26(11):1247-1254 2019 1.20
Diagnostic Accuracy of the Aldosterone-to-Active Renin Ratio for Detecting Primary Aldosteronism. Pilz, S; Keppel, MH; Trummer, C; Theiler-Schwetz, V; Pandis, M; Borzan, V; Pittrof, M; Obermayer-Pietsch, B; Grübler, MR; Verheyen, N; Stepan, V; Meinitzer, A; Voelkl, J; März, W; Tomaschitz, A J Endocr Soc. 2019; 3(9):1748-1758 2019 3.20
Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer. Golob-Schwarzl, N; Wodlej, C; Kleinegger, F; Gogg-Kamerer, M; Birkl-Toeglhofer, AM; Petzold, J; Aigelsreiter, A; Thalhammer, M; Park, YN; Haybaeck, J J Cancer Res Clin Oncol. 2019; 145(11):2699-2711 2019 2.5
Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer. Golob-Schwarzl, N; Wodlej, C; Kleinegger, F; Gogg-Kamerer, M; Birkl-Toeglhofer, AM; Petzold, J; Aigelsreiter, A; Thalhammer, M; Park, YN; Haybaeck, J J Cancer Res Clin Oncol. 2019; 145(11):2699-2711 2019 2.5
Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study. Aberer, F; Pferschy, PN; Tripolt, NJ; Sourij, C; Obermayer, AM; Prüller, F; Novak, E; Reitbauer, P; Kojzar, H; Prietl, B; Kofler, S; Brunner, M; Svehlikova, E; Stojakovic, T; Scharnagl, H; Oulhaj, A; Aziz, F; Riedl, R; Sourij, H Diabetes Obes Metab. 2019; 2019 3.20
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells. Vogel, FCE; Bordag, N; Zügner, E; Trajkovic-Arsic, M; Chauvistré, H; Shannan, B; Váraljai, R; Horn, S; Magnes, C; Thomas Siveke, J; Schadendorf, D; Roesch, A J Invest Dermatol. 2019; 139(12):2506-2516 2019 1.5
Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Horvath, A; Leber, B; Feldbacher, N; Tripolt, N; Rainer, F; Blesl, A; Trieb, M; Marsche, G; Sourij, H; Stadlbauer, V Eur J Nutr. 2019; 2019 3.23
The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer. Smolle, MA; Czapiewski, P; Lapińska-Szumczyk, S; Majewska, H; Supernat, A; Zaczek, A; Biernat, W; Golob-Schwarzl, N; Haybaeck, J Int J Mol Sci. 2019; 20(24): 2019 2.5
Hepatic gene expression explains primary drug toxicity in bipolar disorder. Birkl-Toeglhofer, AM; Birkl, C; Llenos, IC; Weis, S; Haybaeck, J Transl Psychiatry. 2019; 9(1): 331-331. 2019 2.5
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M. Clin Cancer Res. 2018 Dec 15;24(24):6300-6307. doi: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23. 15 December 2018 2.8
Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Eur J Nucl Med Mol Imaging. 2018 Dec 19. doi: 10.1007/s00259-018-4236-4. [Epub ahead of print] 19 December 2018 2.8
STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. Kaltenecker D, Themanns M, Mueller KM, Spirk K, Golob-Schwarzl N, Friedbichler K, Kenner L, Haybaeck J, Moriggl R. Cytokine. 2018 Oct 27. pii: S1043-4666(18)30402-2. doi: 10.1016/j.cyto.2018.10.014. [Epub ahead of print] 27 December 2018 2.8
Molar activity – The keystone in (11)C-radiochemistry: An explorative study using the gas phase method. Pichler V, Zenz T, Philippe C, Vraka C, Berroteran-Infante N, Pfaff S, Nics L, Ozenil M, Langer O, Willeit M, Traub-Weidinger T, Lanzenberger R, Mitterhauser M, Hacker M, Wadsak W. Nucl Med Biol. 2018 Dec;67:21-26. doi: 10.1016/j.nucmedbio.2018.09.003. Epub 2018 Oct 12. December 2018 2.8
Reduced task durations in functional PET imaging with [(18)F]FDG approaching that of functional MRI. Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A. Neuroimage. 2018 Nov 1;181:323-330. doi: 10.1016/j.neuroimage.2018.06.079. Epub 2018 Jun 30. 1 November 2018 2.8
Corrigendum to “Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging”. Gryglewski G, Seiger R, James GM, Godbersen GM, Komorowski A, Unterholzner J, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Neuroimage. 2018 Nov 19. pii: S1053-8119(18)32062-7. doi: 10.1016/j.neuroimage.2018.10.081. [Epub ahead of print] 19 November 2018 2.8
Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. Strasser K, Birnleitner H, Beer A, Pils D, Gerner MC, Schmetterer KG, Bachleitner-Hofmann T, Stift A, Bergmann M, Oehler R. Oncoimmunology. 2018 Nov 5;8(2):e1537693. doi: 10.1080/2162402X.2018.1537693. eCollection 2019. 5 November 2018 1.9
L-[S-methyl-(11)C]methionine – An example of radiosynthetic optimization. Pichler V, Vraka C, Berroteran-Infante N, Krcal A, Eidherr H, Traub-Weidinger T, Hacker M, Mitterhauser M, Wadsak W. Appl Radiat Isot. 2018 Nov;141:107-111. doi: 10.1016/j.apradiso.2018.08.021. Epub 2018 Aug 29. November 2018 2.8
Effect of Rifampicin on the Distribution of [(11)C]Erlotinib to the Liver Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. Mol Pharm. 2018 Oct 1;15(10):4589-4598. doi: 10.1021/acs.molpharmaceut.8b00588. Epub 2018 Sep 14. 1 October 2018 2.8
Development and evaluation of a rapid analysis for HEPES determination in (68)Ga-radiotracers. Pfaff S, Nehring T, Pichler V, Cardinale J, Mitterhauser M, Hacker M, Wadsak W. EJNMMI Res. 2018 Oct 23;8(1):95. doi: 10.1186/s13550-018-0449-6. 23 October 2018 2.8
Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, et al. Transl Psychiatry. 2018 Sep 21;8(1):198. doi: 10.1038/s41398-018-0227-2. 21 September 2018 2.8
In silico Prioritization of Transporter-Drug Relationships From Drug Sensitivity Screens. Cäsar-Razquin A, Girardi E, Yang M, Brehme M, Saez-Rodriguez J, Superti-Furga G. Front Pharmacol. 2018 Sep 7;9:1011. doi: 10.3389/fphar.2018.01011. eCollection 2018. 7 September 2018 2.8
An Overview of PET Radiochemistry, Part 1: The Covalent Labels 18F, 11C, and 13N. Pichler V, Berroteran-Infante N, Philippe C, Vraka C, Klebermass EM, Balber T, Pfaff S, Nics L, Mitterhauser M, Wadsak W. J Nucl Med. 2018 Sep;59(9):1350-1354. doi: 10.2967/jnumed.117.190793. Epub 2018 Jul 24. Review. September 2018 2.8
Molecular imaging and molecular diagnostics: two sides of the same coin? Hacker M, Hoermann G, Kenner L. Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1645-1648. doi: 10.1007/s00259-018-4060-x. September 2018 2.8
The AP-1-BATF and -BATF3 module is essential for growth Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, et al. Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28. September 2018 2.8
Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. Gryglewski G, Seiger R, James GM, Godbersen GM, Komorowski A, Unterholzner J, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Neuroimage. 2018 Aug 1;176:259-267. doi: 10.1016/j.neuroimage.2018.04.068. Epub 2018 May 1. 1 August 2018 2.8
Preclinical In Vitro and In Vivo Evaluation of [(18)F]FE@SUPPY for Cancer PET Imaging: Limitations of a Xenograft Model for Colorectal Cancer. Balber T, Singer J, Berroteran-Infante N, Dumanic M, Fetty L, Fazekas-Singer J, Vraka C, Nics L, Bergmann M, Pallitsch K, Spreitzer H, Wadsak W, Hacker M, Jensen-Jarolim E, Viernstein H, Mitterhauser M. Contrast Media Mol Imaging. 2018 Feb 13;2018:1269830. doi: 10.1155/2018/1269830. eCollection 2018. 13 August 2018 2.8
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, et al. Leukemia. 2018 Aug 21. doi: 10.1038/s41375-018-0239-1. [Epub ahead of print] 21 August 2018 2.8
Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos E, Szakacs G, Wadsak W, Hacker M, Zeitlinger M, Langer O. Clin Pharmacol Ther. 2018 Jul;104(1):139-147. doi: 10.1002/cpt.888. Epub 2017 Nov 3. July 2017 2.8
SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [(18)F]FE@SNAP and [(11)C]SNAP-7941. Philippe C, Zeilinger M, Dumanic M, Pichler F, Fetty L, Vraka C, Balber T, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M. Mol Imaging Biol. 2018 Jun 13. doi: 10.1007/s11307-018-1212-0. [Epub ahead of print] 12 June 2018 2.8
Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. Kranz GS, Hahn A, Kraus C, Spies M, Pichler V, Jungwirth J, Mitterhauser M, Wadsak W, Windischberger C, Kasper S, Lanzenberger R. Neuroimage. 2018 May 1;171:1-5. doi: 10.1016/j.neuroimage.2017.12.092. Epub 2017 Dec 29. 1 May 2018 2.8
A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Vraka C, Dumanic M, Racz T, Pichler F, Philippe C, Balber T, Klebermass EM, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. Nucl Med Biol. 2018 May;60:29-36. doi: 10.1016/j.nucmedbio.2018.02.002. Epub 2018 Feb 14. May 2018 2.8
Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. Hahn A, Gryglewski G, Nics L, Rischka L, Ganger S, Sigurdardottir H, Vraka C, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R. Brain Struct Funct. 2018 Apr;223(3):1369-1378. doi: 10.1007/s00429-017-1558-0. Epub 2017 Nov 13. April 2018 2.8
[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, Wei Y, Mitterhauser M, Wadsak W, Kropf S, Wester HJ, Loewe C, Hacker M, Haug AR. Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):558-566. doi: 10.1007/s00259-017-3831-0. Epub 2017 Sep 21. April 2018 2.8
Expanding LogP: Present possibilities. Vraka C, Mijailovic S, Fröhlich V, Zeilinger M, Klebermass EM, Wadsak W, Wagner KH, Hacker M, Mitterhauser M. Nucl Med Biol. 2018 Mar;58:20-32. doi: 10.1016/j.nucmedbio.2017.11.007. Epub 2017 Nov 28. March 2018 2.8
[(18)F]FEPPA: Improved Automated Radiosynthesis and Preliminary in Vitro Evaluation in Colorectal Cancer. Berroteran-Infante N, Balber T, Fürlinger P, Bergmann M, Lanzenberger R, Hacker M, Mitterhauser M, Wadsak W. ACS Med Chem Lett. 2018 Feb 21;9(3):177-181. doi: 10.1021/acsmedchemlett.7b00367. eCollection 2018 Mar 8. 21 February 2018 2.8
Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. Nics L, Steiner B, Klebermass EM, Philippe C, Mitterhauser M, Hacker M, Wadsak W. Nucl Med Biol. 2018 Feb;57:28-33. doi: 10.1016/j.nucmedbio.2017.11.006. Epub 2017 Nov 21. February 2018 2.8
(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making. Grubmüller B, Baltzer P, D’Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26. February 2018 2.8
Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Georg P, Andrzejewski P, Baltzer P, Daniel M, Wadsak W, Mitterhauser M, Sturdza A, Majercakova K, Karanikas G, Pötter R, Hacker M, Helbich T, Georg D, Pinker K. Mol Imaging Biol. 2018 Feb;20(1):160-169. doi: 10.1007/s11307-017-1087-5. February 2018 2.8
Metabolic fingerprinting in pulmonary hypertension* Nagy, B; Bordag, N; Nagaraj, C; Foris, V; Tornyos, A; Narath, S; Gander, E; Magnes, C; Kovacs, G; Klepetko, W; Pieber, TR; Kwapiszewska, G; Olschewski, H; Olschewski, A WIEN KLIN WOCHENSCHR. 2018; 130(19-20): 604-605. 2018 1.5
Combined serum free light chain levels are associated with carotid atherosclerosis in type 2 diabetes mellitus. Aberer, F; Tripolt, NJ; Scharnagl, H; Zedler, J; Eder, M; Oulhaj, A; Stojakovic, T; Sourij, H Diab Vasc Dis Res. 2018; 15(2):162-164 2018 3.2
Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma. Al-Zoughbi, W; Schauer, S; Pichler, M; Hoefler, G Pathobiology. 2018; 85(5-6):342-347 2018 1.8
Improving Fluid Management in Critical Care – Towards the ICU of the Future. Bergmoser, K; Pflanzl-Knizacek, L; Hafner, M; Schilcher, G; Baumgartner, C Stud Health Technol Inform. 2018; 248: 47-54. 2018 3.3
The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. Bluemel, S; Wang, L; Martino, C; Lee, S; Wang, Y; Williams, B; Horvath, A; Stadlbauer, V; Zengler, K; Schnabl, B Hepatol Commun. 2018; 2(4): 393-406. 2018 3.10
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, andKRASPoint Mutations in Circulating Tumor Cells. El-Heliebi, A; Hille, C; Laxman, N; Svedlund, J; Haudum, C; Ercan, E; Kroneis, T; Chen, S; Smolle, M; Rossmann, C; Krzywkowski, T; Ahlford, A; Darai, E; von Amsberg, G; Alsdorf, W; König, F; Löhr, M; de Kruijff, I; Riethdorf, S; Gorges, TM; Pantel, K; Bauernhofer, T; Nilsson, M; Sedlmayr, P Clin Chem. 2018; 64(3):536-546 2018 2.2
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. Gaksch, L; Kashofer, K; Heitzer, E; Quehenberger, F; Daga, S; Hofer, S; Halbwedl, I; Graf, R; Krisper, N; Hoefler, G; Zebisch, A; Sill, H; Wölfler, A Am J Hematol. 2018; 93(1):23-30 2018 2.4
Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression. Gantenbein, N; Bernhart, E; Anders, I; Golob-Schwarzl, N; Krassnig, S; Wodlej, C; Brcic, L; Lindenmann, J; Fink-Neuboeck, N; Gollowitsch, F; Stacher-Priehse, E; Asslaber, M; Gogg-Kamerer, M; Rolff, J; Hoffmann, J; Silvestri, A; Regenbrecht, C; Reinhard, C; Pehserl, AM; Pichler, M; Sokolova, O; Naumann, M; Mitterer, V; Pertschy, B; Bergler, H; Popper, H; Sattler, W; Haybaeck, J Eur J Cancer. 2018; 101:165-180 2018 2.5
High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Golob-Schwarzl, N; Bettermann, K; Mehta, AK; Kessler, SM; Unterluggauer, J; Krassnig, S; Kojima, K; Chen, X; Hoshida, Y; Bardeesy, NM; Müller, H; Svendova, V; Schimek, MG; Diwoky, C; Lipfert, A; Mahajan, V; Stumptner, C; Thüringer, A; Fröhlich, LF; Stojakovic, T; Nilsson, KPR; Kolbe, T; Rülicke, T; Magin, TM; Strnad, P; Kiemer, AK; Moriggl, R; Haybaeck, J Transl Oncol. 2018; 12(2): 256-268. 2018 2.5
Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. Heldt, S; Prattes, J; Eigl, S; Spiess, B; Flick, H; Rabensteiner, J; Johnson, G; Prüller, F; Wölfler, A; Niedrist, T; Boch, T; Neumeister, P; Strohmaier, H; Krause, R; Buchheidt, D; Hoenigl, M J Infect. 2018; 77(3):235-241 2018 3.11
Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Hoenigl, M; Eigl, S; Heldt, S; Duettmann, W; Thornton, C; Prattes, J Mycoses. 2018; 61(1):40-43 2018 3.11
Triacetylfusarinine C: a urine biomarker for diagnosis of invasive aspergillosis. Hoenigl, M; Orasch, T; Faserl, K; Prattes, J; Loeffler, J; Springer, J; Gsaller, F; Reischies, F; Duettmann, W; Raggam, RB; Lindner, H; Haas, H J Infect. 2018; 2018 3.11
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Hoenigl, M; Prattes, J; Neumeister, P; Wölfler, A; Krause, R Mycoses. 2018; 61(3):201-205 2018 3.11
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Kleinegger, F; Hofer, E; Wodlej, C; Golob-Schwarzl, N; Birkl-Toeglhofer, AM; Stallinger, A; Petzold, J; Orlova, A; Krassnig, S; Reihs, R; Niedrist, T; Mangge, H; Park, YN; Thalhammer, M; Aigelsreiter, A; Lax, S; Garbers, C; Fickert, P; Rose-John, S; Moriggl, R; Rinner, B; Haybaeck, J Biochim Biophys Acta Mol Basis Dis. 2018; 2018 2.5
EHR Text Categorization for Enhanced Patient-Based Document Navigation. Kreuzthaler, M; Pfeifer, B; Vera Ramos, JA; Kramer, D; Grogger, V; Bredenfeldt, S; Pedevilla, M; Krisper, P; Schulz, S Stud Health Technol Inform. 2018; 248:100-107 2018 1.2
Antifungal prophylaxis with Posaconazole delayed-release tablet and oral suspension in a Real-life setting: plasma levels, efficacy and tolerability. Lenczuk, D; Zinke-Cerwenka, W; Greinix, H; Wölfler, A; Prattes, J; Zollner-Schwetz, I; Valentin, T; Lin, TC; Meinitzer, A; Hoenigl, M; Krause, R Antimicrob Agents Chemother. 2018; 2018 3.11
A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot. Moser, O; Pandis, M; Aberer, F; Kojzar, H; Hochfellner, D; Elsayed, H; Motschnig, M; Augustin, T; Kreuzer, P; Pieber, TR; Sourij, H; Mader, JK Diabetes Obes Metab. 2018; 2018 3.6
Development of a Clinical Decision Support System in Intensive Care. Pflanzl-Knizacek, L; Bergmoser, K; Mattersdorfer, K; Schilcher, G; Baumgartner, C Stud Health Technol Inform. 2018; 248: 247-254. 2018 3.3
Evaluation of the new AspID polymerase chain reaction assay for detection of Aspergillus species: A pilot study. Prattes, J; Hoenigl, M; Zinke, SE; Heldt, S; Eigl, S; Johnson, GL; Bustin, S; Stelzl, E; Kessler, HH Mycoses. 2018; 61(6):355-359 2018 3.11
Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Rainer, F; Horvath, A; Sandahl, TD; Leber, B; Schmerboeck, B; Blesl, A; Groselj-Strele, A; Stauber, RE; Fickert, P; Stiegler, P; Møller, HJ; Grønbaek, H; Stadlbauer, V Aliment Pharmacol Ther. 2018; 47(5):657-664 2018 3.10
Evaluation of Galactomannan Testing, the Aspergillus-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. Salzer, HJF; Prattes, J; Flick, H; Reimann, M; Heyckendorf, J; Kalsdorf, B; Obersteiner, S; Gaede, KI; Herzmann, C; Johnson, GL; Lange, C; Hoenigl, M Front Microbiol. 2018; 9: 2223-2223. 2018 3.11
The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet and Alcohol. Song, P; Zechner, C; Hernandez, G; Cánovas, J; Xie, Y; Sondhi, V; Wagner, M; Stadlbauer, V; Horvath, A; Leber, B; Hu, MC; Moe, OW; Mangelsdorf, DJ; Kliewer, SA Cell Metab. 2018; 27(6):1338-1347 2018 3.10
NMR spectroscopy enables simultaneous quantification of carbohydrates for diagnosis of intestinal and gastric permeability. Stryeck, S; Horvath, A; Leber, B; Stadlbauer, V; Madl, T Sci Rep. 2018; 8(1): 14650-14650. 2018 3.10
Intermittent Fasting (Alternate Day Fasting) in Healthy, Non-obese Adults: Protocol for a Cohort Trial with an Embedded Randomized Controlled Pilot Trial. Tripolt, NJ; Stekovic, S; Aberer, F; Url, J; Pferschy, PN; Schröder, S; Verheyen, N; Schmidt, A; Kolesnik, E; Narath, SH; Riedl, R; Obermayer-Pietsch, B; Pieber, TR; Madeo, F; Sourij, H Adv Ther. 2018; 35(8): 1265-1283. 2018 3.2
Revisiting the Diabetes-Heart Failure Connection. Wallner, M; Eaton, DM; von Lewinski, D; Sourij, H Curr Diab Rep. 2018; 18(12):134-134 2018 3.2
COMBINED SERUM FREE LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CAROTID ATHEROSCLEROSIS IN TYPE 2 DIABETES MELLITUS Aberer, F; Tripolt, NJ; Scharnagl, H; Zedler, J; Eder, M; Oulhaj, A; Stojakovic, T; Sourij, H ATHEROSCLEROSIS. 2018; 275: E247-E247. 2018 3.2
eIF3p110 expression is elevated in thyroid cancer Bracic, S; Krassnig, S; Gantenbein, N; Mangge, H; Gruber, HJ; Haybaeck, J VIRCHOWS ARCH. 2018; 473: S103-S103. 2018 2.5
GPR56 and CLL-1 (CLEC12A) as putative leukemic stem cell markers in CD34-positive acute myeloid leukemia Daga, S; Rosenberger, A; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wolfler, A ONCOL RES TREAT. 2018; 41: 73-73. 2018 2.4
Are eIFs Ingredients for Neuroendocrine Tumorigenesis? Gantenbein, N; Wodlej, C; Smolle, E; Thalhammer, M; Kornprat, P; Lackner, K; Brcic, I; Spindelboeck, W; Kump, P; Lipp, R; Haybaeck, J NEUROENDOCRINOLOGY. 2018; 106: 5-5.-15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; MAR 07-09, 2018; Barcelona, SPAIN. 2018 2.5
Eukaryotic Translation Initiation Factors Might Represent a Potential Therapeutic Target for Gallbladder Cancer Golob-Schwarzl, N; Wodlej, C; Kleinegger, F; Toeglhofer, AM; Krassnig, S; Thalhammer, M; Aigelsreiter, A; Hayback, J ONCOL RES TREAT. 2018; 41: 68-68.-33. Deutscher Krebs Kongress; FEB 21-24, 2018; Berlin, GERMANY. 2018 2.5
Invasive Aspergillosis: Performance of New and Established Diagnostic Approaches with Same-Day Blood and Bronchoalveolar Lavage – a Prospective Cohort Study Heldt, S; Prattes, J; Eigl, S; Spiess, B; Flick, H; Rabensteiner, J; Johnson, G; Pruller, F; Wolfler, A; Niedrist, T; Boch, T; Neumeister, P; Strohmaier, H; Krause, R; Buchheidt, D; Hoenigl, M MED MYCOL. 2018; 56: S34-S34. 2018 3.11
ACELLULAR GROWTH RETARDATION ABILITY (AGRA) PREDICTS THE OCCURRENCE OF SEVERE BACTERIAL INFECTIONS IN CIRRHOSIS Horvath, A; Rainer, F; Leber, B; Schmerboeck, B; Spindelboeck, W; Stauber, R; Stiegler, P; Stadlbauer, V TRANSPL INT. 2018; 31: 8-9. 2018 3.10
Reducing insulin degludec around regular exercise improves time spent in euglycaemia in people with type 1 diabetes: a randomised cross-over trial Moser, O; Eckstein, ML; Mueller, A; Birnbaumer, P; Aberer, F; Koehler, G; Sourij, C; Kojzar, H; Holler, P; Simi, H; Pferschy, P; Dietz, P; Bracken, RM; Hofmann, P; Sourij, H DIABETOLOGIA. 2018; 61: S42-S43. 2018 3.2
Endobarrier (R) gastrointestinal liner in obese subjects with type 2 diabetes – Sustainable effects on insulin sensitivity after explantation Pferschy, P; Tripolt, N; Url, J; Aberer, F; Hogenauer, C; Schreiber, F; Eherer, A; Sourij, C; Svehlikova, E; Obermayer, AM; Stadlbauer, V; Sourij, H WIEN KLIN WOCHENSCHR. 2018; 130: 374-374. 2018 3.1
EVALUATION OF EARLY POSTPRANDIAL SUPPRESSION OF ENDOGENOUS GLUCOSE PRODUCTION WITH FASTER ASPART VERSUS INSULIN ASPART Pieber, T; Basu, A; Hansen, AK; Sach-Friedl, S; Thomsen, KMD; Basu, R; Haahr, H DIABETES TECHNOL THE. 2018; 20: A33-A33.-ATTD; Vienna, Austria. 2018 3.1
PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF AN ULTRA-CONCENTRATED, RAPID-ACTING INSULIN ASPART FORMULATION Pieber, T; Gerring, D; Howell, S; Jezek, J DIABETES TECHNOL THE. 2018; 20: A139-A139.-ATTD; Vienna, Austria. 2018 3.6
Epidemiology and outcome of lomentospora prolificans and scedosporium apiospermum infections Prattes, J; Jenks, J; Reed, S; Krause, R; Reischies, F; Heldt, S; Mehta, S; Hoenigl, M MYCOSES. 2018; 61: 35-35. 2018 3.11
Low Prevalence of Colonization with C. difficile in Residents of Graz Residential Care Facility for the Elderly Schreiner, E; Leitner-Meyer, E; Neuhold, M; Pux, C; Zollner-Schwetz, I WIEN KLIN WOCHENSCHR. 2018; 130: 262-263. 2018 3.11
Uc-dpMGP is associated with body composition and BMD in type 2 diabetes mellitus Schweighofer, N; Haudum, C; Goschnik, M; Kolesnik, E; Mursic, I; Schmidt, A; Pieber, TR; Obermayer-Pietsch, B J BONE MINER RES. 2018; 33: 224-224. 2018 3.4
Evaluation and Comparison of Four Noninvasive Tests for Detection of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease (NAFLD) Staufer, K; Marculescu, R; Obermayer-Pietsch, B; Stift, J; Lackner, K; Trauner, MH; Stauber, RE HEPATOLOGY. 2018; 68: 1308A-1309A. 2018 3.4
Level of Vitamin D predicts occurrence of atrial high rate episodes in patients with chronic heart failure Sternad, J; Manninger, M; Scherr, D; Zweiker, D; Kolesnik, E; Obermayer-Pietsch, B; Pieber, T; von Lewinski, D; Verheyen, N; Ablasser, K WIEN KLIN WOCHENSCHR. 2018; 130: 55-56. 2018 3.5
Translation initiation factors are over-expressed in aggressive lymphomas and influence their clinical course Unterluggauer, JJ; Prochazka, K; Tomazic, PV; Huber, HJ; Seeboeck, R; Fechter, K; Steinbauer, E; Gruber, V; Feichtinger, J; Pichler, M; Weniger, MA; Kuppers, R; Sill, H; Schicho, R; Neumeister, P; Beham-Schmid, C; Deutsch, A; Haybaeck, J ONCOL RES TREAT. 2018; 41: 164-164. 2018 2.5
Detection of Pneumocystis jiroveci DNA in HIV-uninfected patients: a single center experience Valentin, T; Stelzl, E; Kessler, HH; Krause, R; Zollner-Schwetz, I; Prattes, J; Wunsch, S; Fruhwald, F; Brezinschek, HP; Flick, H WIEN KLIN WOCHENSCHR. 2018; 130: 265-265. 2018 3.11
Antifungal Susceptibility of Candida Bloodstream Isolates Collected During a 10-Year Period in Austria Willinger, B; Beyer, R; Spettel, K; Lass-Floerl, C; Achleitner, D; Krause, R; Schuller, C MYCOSES. 2018; 61: 28-28. 2018 3.11
The Role of Eukaryotic Translation Initiation Factors as Potential Targets in Neuroblastoma Wodlej, C; Krassnig, S; Golob-Schwarzl, N; Kleinegger, F; Toeglhofer, AM; Sygulla, S; Singer, G; Till, H; Izycka-Swieszewska, E; Czapiewski, P; Hayback, J ONCOL RES TREAT. 2018; 41: 131-131.-33. Deutscher Krebs Kongress; FEB, 21-24, 2018; Berlin, GERMANY. 2018 2.5
Comparison of fully-automated radiosyntheses of [(11)C]erlotinib for preclinical and clinical use starting from in target produced [(11)C]CO(2) or [(11)C]CH(4). Philippe C, Mairinger S, Pichler V, Stanek J, Nics L, Mitterhauser M, Hacker M, Wanek T, Langer O, Wadsak W. EJNMMI Radiopharm Chem. 2018;3(1):8. doi: 10.1186/s41181-018-0044-1. Epub 2018 May 30. 2018 2.8
Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. Kranz GS, Hahn A, Kraus C, Spies M, Pichler V, Jungwirth J, Mitterhauser M, Wadsak W, Windischberger C, Kasper S, Lanzenberger R. Neuroimage. 2017;171:1-5. 29 December 2017 2.8
Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. Daniel M, Andrzejewski P, Sturdza A, Majercakova K, Baltzer P, Pinker K, Wadsak W, Mitterhauser M, Pötter R, Georg P, Helbich T, Georg D. Radiother Oncol. 2017;125(3):420-425. December 2017 2.8
Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. Hahn A, Gryglewski G, Nics L, Rischka L, Ganger S, Sigurdardottir H, Vraka C, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R. Brain Struct Funct. 2017. doi: 10.1007/s00429-017-1558-0. [Epub ahead of print] 13 November 2017 2.8
Retrospektive Datenerhebung zu Therapieregimen bei PatientInnen mit steroidinduzierter Hyperglyka¨mie Holzgruber, J; Aberer, F; Mader, JK; Horvath, K; Tripolt, NJ; Pieber, TR; Sourij, H Wiener klinische Wochenschrift 2017; 129 (Suppl. 4) . 2017; (4):170-170.-45. Jahrestagung der Österreichischen Diabetesgesellschaft (ÖDG); Salzburg. 16–18 November 2017 3.2
Evaluation of the Implementation of a new Diabetes Curve in the Hospital by means of a Survey Kopanz, J; Lichtenegger, KM; Sendlhofer, G; Semlitsch, B; Jantscher, L; Pieber, TR; Plank, J WIEN KLIN WOCHENSCHR. 2017; 129: 180-181.-45. Jahrestagung der Österreichischen Diabetes Gesellschaft; Salzburg, AUSTRIA. 16–18 November 2017 3.2
Ergebnisse von drei Monaten Insulintherapie mit PAQ bei PatientInnen mit Typ 2 Diabetes Poettler, T; Lilly, LC; Aberer, F; Trautmann, M; Warner, J; Pieber, TR; Mader, JK Wiener klinische Wochenschrift, Ausgabe 129 (Suppl. 4) . 2017; 173-173.-45. Jahrestagung der Österreichischen Diabetesgesellschaft (ÖDG); Salzburg. 16–18 November 2017 3.2
The IL-2-response in regulatory T cells is specifically impaired in type 1 diabetes Prietl, B; Kofler, S; Stanzer, S; Stradner, M; Munzker, J; Pieber, T; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129: 165-165.-45. Jahrestagung der Österreichischen Diabetes Gesellschaft; Salzburg, AUSTRIA. 16–18 November 2017 1.6
Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. Nics L, Steiner B, Klebermass EM, Philippe C, Mitterhauser M, Hacker M, Wadsak W. Nuclear Medicine and Biology 2017;57:28-33. 21 November 2017 2.8
Expanding LogP: Present possibilities. Vraka C, Mijailovic S, Fröhlich V, Zeilinger M, Klebermass EM, Wadsak W, Wagner KH, Hacker M, Mitterhauser M. Nucl Med Biol. 2017 Nov 28;58:20-32. 28 November 2017 2.8
HCV Treatment with Direct-Acting Antivirals in India is Cost-Saving Chaillon, A; Mehta, SR; Hoenigl, M; Vickerman, P; Hickman, M; Skaathun, B; Martin, NK HEPATOLOGY. 2017; 66: 411A-411A.-68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting; Washington, DC. 20–24 October 2017 3.11
The Cost-effectiveness of General Population HCV Screening in India Chaillon, A; Mehta, SR; Hoenigl, M; Vickerman, P; Hickman, M; Skaathun, B; Martin, NK HEPATOLOGY. 2017; 66: 410A-410A.-68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting; Washington, DC. 20–24 October 2017 3.11
YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis Taniguchi K, Moroishi T, de Jong PR, Krawczyk M, Grebbin BM, Luo H, Xu RH, Golob-Schwarzl N, Schweiger C, Wang K, Di Caro G, Feng Y, Fearon ER, Raz E, Kenner L, Farin HF, Guan KL, Haybaeck J, Datz C, Zhang K, Karin M Proc Natl Acad Sci U S A 27 January 2017 2.5
In Situ Characterization of Tissue-Resident Immune Cells by MALDI Mass Spectrometry Imaging. Holzlechner Matthias, Strasser Katharina, Zareva Elitsa, Steinhäuser Luise, Birnleitner Hanna, Beer Andrea, Bergmann Michael, Oehler Rudolf, Marchetti-Deschmann Martina J Proteome Res. 16(1):65-76. 6 January 2017 1.9
Triacetylfusarinine C determination in urine samples from hematological malignancy patients: a potential new biomarker for invasive aspergillosis Prattes, J; Orasch, T; Faserl, K; Lindner, H; Reischies, F; Duettmann, W; Raggam, RB; Rabensteiner, J; Hoenigl, M; Haas, H MYCOSES. 2017; 60: 35-35.-8th Trends in Medical Mycology; Belgrade, SERBIA. 6–9 October 2017 3.11
Triacetylfusarinine C for aspergillosis: from imaging to Urine analysis Haas, H; Orasch, T; Faserl, K; Petrik, M; Prattes, J; Reischies, FM; Duettmann, W; Raggam, RB; Rabensteiner, J; Lindner, H; Hoenigl, M; Decristoforo, C MYCOSES. 2017; 60: 34-34.-TIMM; Belgrade, SERBIA. 6–9 October 2017 3.11
Galactomannan Hoenigl, M 8th Trends in Medical Mycology; Belgrade, SERBIA. 6–9 October 2017 3.11
ECMM Academy Hoenigl M 8th Trends in Medical mycology; Belgrade, SERBIA. 6–9 October 2017 3.11
The Academy of the European Confederation of Medical Mycology: Big Success in Europe and Abroad. Hoenigl, M; Mikulska, M; Plecko, V; Hagen, F; Vehreschild, JJ; Lagrou, K; Arsic-Arsenijevic, V; Cornely, OA; for the European Confederation of Medical Mycology 8th Trends in Medical Mycology; Belgrade, SERBIA. 6–9 October 2017 3.11
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. Gaksch L, Kashofer K, Heitzer E,Daga S, Hofer S, Halbwedl I, Graf R, Krisper N, Hoefler G, Zebisch A, Sill H, Wölfler A American Journal of Hematology 1 September 2017 2.4
Efficacy and safety of an insulin decision support system in the treatment of steroid hyperglycaemia in patients with graft-versus- host-disease: a randomised pilot trial. Aberer, F; Holzgruber, J; Tripolt, NJ; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Pieber, TR; Wölfler, A; Sourij, H Diabetologia. 2017; 60(S1):S323-S324.-53rd Annual Meeting of the European Association for the Study of Diabetes (EASD); Lisbon, PORTUGAL. 11–15 September 2017 3.2
Response to IL-2-signaling in Tregs is specifically impaired in type 1 diabetes Prietl, B; Kofler, S; Stanzer, S; Brezinschek, HP; Münzker, J; Pieber, TR; Sourij H Proceedings of the 53rd Annual Meeting of the European Association for the Study of Diabetes. 2017; -53rd Annual Meeting of the European Association for the Study of Diabetes; Lisbon, Portugal. 11–15 September 2017 1.6/3.2
Effect of dapagliflozin, saxagliptin, and the combination of both on glucagon, endogenous glucose production (EGP) and glycerol in patients with type 2 diabetes Sach-Friedl, S; Augustin, T; Magnes, C; Ekardt, E; Eberl, A; Narath, S; Brunner, M; Korsatko, S; Svehlikova, E; Treiber, G; Pieber, TR; DIABETOLOGIA. 2017; 60: S412-S412.-53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD); Lisbon, PORTUGAL. 11–15 September 2017 3.6
Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Oncotarget. 2017 ;8(47):83128-83141. 15 September 2017 2.8
Polyclonal serum free light chains levels are associated with carotid atherosclerosis in subjects with type 2 diabetes mellitus Aberer, F; Tripolt, NJ; Eder, M; Scharnagl, H; Stojakovic, T; Sourij, H Abstract Volume, Human health: From laboratory models to clinical studies. 2017; 42-42.-6th International Symposium of the Human Nutrition & Metabolism Research and Training Center (HNMRC); Graz. (ISBN: 978-3-200-05266-6 ) 16 September 2017 3.2
[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, Wei Y, Mitterhauser M, Wadsak W, Kropf S, Wester HJ, Loewe C, Hacker M, Haug AR. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-017-3831-0. [Epub ahead of print] 21 September 2017 2.8
Susceptibility of carbapenem-resistant Pseudomonas aeruginosa clinical isolates to novel cephalosporine antibiotics. Geraldy, P; Krause, R; Zollner-Schwetz, I Wiener Klinische Wochenschrift. 2017; -48. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; Salzburg, Austria. 21–23 September 2017 3.11
Endobarrier® gastrointestinal bypass-liner in obese subjects with type 2 diabetes: short- and mid-term effects on glucose metabolism Tripolt, N; Aberer, F; Url, J; Pferschy, P; Högenauer, C; Schreiber, F; Eherer, A; Sourij, C; Obermayer, AM; Stadlbauer, V; Sourij, H wiener klinische wochenschrift. 2017; 129: -48. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; Salzburg, Austria. 21–23 September 2017 3.1
Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A,Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos E, Szakacs G, Wadsak W, Hacker M, Zeitlinger M, Langer O Clin Pharmacol Ther. doi: 10.1002/cpt.888. [Epub ahead of print] 22 September 2017 2.8
Interleukin-6 Receptor influences cholangiocarcinoma progression Kleinegger, F; Golob-Schwarzl, N; Toeglhofer, AM; Baran, P; Krassnig, S; Niedrist, T; Speicher, I; Rinner, B; Thalhammer, M; Aigelsreiter, A; Lackner, C; Scheller, J; Rose-John, S; Fickert, P; Haybaeck, J VIRCHOWS ARCH. 2017; 471: S325-S326.-29th European Congress of Pathology; Amsterdam, The Netherlands. 2–6 September 2017 2.7
Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[(11) C]verapamil in elderly vs. young subjects. Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O. Br J Clin Pharmacol. 83(9):1991-1999. September 2017 2.8
In vivo evaluation of radiotracers targeting the melanin-concentrating hormone receptor 1: [(11)C]SNAP-7941 and [(18)F]FE@SNAP reveal specific uptake in the ventricular system. Zeilinger M, Dumanic M, Pichler F, Budinsky L, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M, Philippe C Sci Rep.7(1):8054. 14 August 2017 2.8
The academy of the European confederation of medical mycology: Big success in Europe and abroad. Hoenigl, M; Mikulska, M; Plecko, V; Hagen, F; Vehreschild, JJ; Lagrou, K; Arsic-Arsenijevic, V; Cornely, OA; for the European Confederation of Medical Mycology 51. Wissenschaftliche Tagung der Deutschsprachigen Mykologischen Gesellschaft e. V.; Münster, GERMANY. 31 August – 2 September 2017 3.11
Eukaryotic initiation factors (eIFs) impact neuroendocrine tumourigenesis Gantenbein, N; Smolle, E; Brcic, I; Sarocchi, F; Lackner, C; Gogg-Kamerer, M; Thalhammer, M; Kornprat, P; Spindelbock, W; Kump, P; Lipp, R; Haybaeck, J VIRCHOWS ARCH. 2017; 471: S323-S323.-European Conference of Pathology (ECP); Amsterdam, Netherlands. 11–14 July 2017 2.5
Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR System. Lassen ML, Muzik O, Beyer T, Hacker M, Ladefoged CN, Cal-Gonzalez J, Wadsak W, Rausch I, Langer O, Bauer M. Front Neurosci. 11:396. 17 July 2017 2.8
LogP, a yesterday’s value? Vraka C, Nics L, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. Nucl Med Biol.50:1-10. July 2017 2.8
The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Transl Psychiatry. 7(6):e1150. 12 June 2017 2.8
A pilot trial to investigate efficacy and safety of an automized decision support system for the treatment of steroid induced hyperglycemia in patients with acute Graft-versus-host disease Aberer, F; Holzgruber, J; Tripolt, NJ; Mader, JK; Pieber, TR; Greinix ,H; Zebisch, A; Woelfler, A; Sourij, H Diabetes.. 2017; 66(S1):A669-A669.-77th Scientific Sessions of the American Diabetes Association (ADA); San Diego, CA, USA. 9–13 June 2017 3.2
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-vs.-Host Disease. Aberer, F; Mader, JK; Stauber, M; Neumeister, P; Oulhaj, Abderrahim; Zebisch, A; Pieber, TR; Greinix, H; Sill, H; Woelfler, A; Sourij, H Diabetes.. 2017; 66(S1):A24-A25.-77th Scientific Sessions of the American Diabetes Association (ADA); San Diego, CA, USA. 9–13 June 2017 3.2
Polyclonal serum free light chain levels are associated with carotid arterosclerosis in subjects with type 2 diabetes mellitus Aberer, F; Tripolt, NJ; Eder, M; Scharnagl, H; Stojakovic, T; Sourij, H Diabetes. 2017; 66(S1):A117-A117.-76th Scientific Sessions of the American Diabetes Association (ADA); San Diego, CA, USA. 9–13 June 2017 3.2
Early hyperglycaemia after initiation of glucocorticoid therapy predicts adverse outcome in patients with acute graft-versus-host disease. Aberer, F; Mader, JK; Stauber, M; Tripolt, N; Holzgruber, J; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, H; Sill, H; Wölfler, A; Sourij, H 4th International Hospital Diabetes Meeting. 2017; Atlanta, USA. 19–20 May 2017 3.2
Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Georg P, Andrzejewski P, Baltzer P, Daniel M, Wadsak W, Mitterhauser M, Sturdza A, Majercakova K, Karanikas G, Pötter R, Hacker M, Helbich T, Georg D, Pinker K. Mol Imaging Biol. doi: 10.1007/s11307-017-1087-5. [Epub ahead of print] 24 May 2017 2.8
Welche Faktoren beeinflussen die Entscheidung über die Fortsetzung der Insulintherapie bei Entlassung aus dem Krankenhaus bei Patienten mit Diabetes mellitus Typ 2? Mader, JK; Donsa, K; Aberer, F; Lichtenegger, KM; Sourij, H; Höll, B; Lanz, C; Beck, P; Pieber, TR; Plank, J Diabetologie und Stoffwechsel. 2017; 12(S1):S72-S72.-Diabetes Kongress 2017; Hamburg, GERMANY. 24–27 May 2017 3.2
A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes Heise T, Pieber TR, Danne T, Erichsen L, Haahr H Clin Pharmacokinet. 56(5):551-559. doi: 10.1007/s40262-017-0514-8 May 2017 3.6
Simple and rapid quantification of serotonin transporter binding using [(11)C]DASB bolus plus constant infusion. Gryglewski G, Rischka L, Philippe C, Hahn A, James GM, Klebermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, Berroteran-Infante N, Nics L, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Neuroimage. 149:23-32. 1 April 2017 2.8
Carnival meets Oktoberfest: Molecular Epidemiology of the HIV Epidemic in Two German Metropoles. Hoenigl, M; Stecher, M; Bogner, J; Lehmann, C; Eberle, J; Spinner, C; Kaiser, R; Behrens, G; Faetkenheuer, G; Mehta, SR; Vehreschild JJ; Chaillon, A. 27th ECCMID; Vienna, AUSTRIA. 22–25 April 2017 3.11
Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia. Aberer F, Kremser S, Mader JK, Zinke-Cerwenka W, Greinix H, Tripolt NJ, Pieber TR, Zebisch A, Sill H, Oulhaj A, Sourij H, Wölfler A Diabetes Metab. 6 March 2017 2.4
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease Stauber MN, Aberer F, Oulhaj A, Mader JK, Zebisch A, Pieber TR, Neumeister P, Greinix HT, Sill H, Sourij H, Wölfler A Biol Blood Marrow Transplant 8 March 2017 2.4
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML Nat Commun 10 February 2017 2.5
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, Karteris E, Nowikovsky K, Wilfinger-Lutz N, Singer CF, Colomer R, Benhamú B, López-Rodríguez ML, Valent P, Grunt TW Oncotarget.8(7):11600-11613. 14 February 2017 1.9
Closed-loop insulin delivery in well controlled adults with type 1 diabetes: A free-living day-and-night randomised cross-over trial. Bally, L; Thabit, H; Hartnell, S; Tauschmann, M; Mader, JK; Kojzar, H; Wilinska, ME; Pieber, TR; Evans, ML; Hovorka, R Diabetes Technology & Therapeutics. 2017; 19(S01):A-38-A-38.-10th International Conference of Advanced Technologies and Treatments for Diabetes (ATTD); Paris, FRANCE. 15–18 February 2017 3.6
Relationship between glucose variability and glycaemic control during sensor augmented pump therapy (SAP) and closed loop (CL) insulin delivery in adults with type 1 diabetes (T1D). Leelarathna, L; Thabit, H; Hartnell, S; Willinska, M; Dellweg, S; Benesch, C; Mader, JK; Holzer, M; Evans, M; Arnolds, S; Pieber, TR; Hovorka, R Diabetes Technology & Therapeutics. 2017; 19(S01):A-71-A-71.-10th International Conference of Advanced Technologies and Treatments for Diabetes (ATTD); Paris, FRANCE. 15–18 February 2017 3.6
PAQ_x0002_ Insulin delivery device improves glycemic control and diabetes treatment satisfaction in adults wit type 2 diabetes. Mader, JK; Hermanns, N; Lilly, L; Aberer, F; Poettler, T; Lanz, C; Warner, J; Pieber, T Diabetes Technology & Therapeutics. 2017; 19(S01):A-119-A-119.-10th International Conference of Advanced Technologies and Treatments for Diabetes (ATTD); Paris, FRANCE. 15–18 February 2017 3.1
MORPHOMETRISCHE PARAMETER VON MUSKEL UND KNOCHEN BEI KRITISCH KRANKEN – POSTHOC-ANALYSE DER VITdAL-ICU STUDIE Malle, O; Maurer, D; Wagner, D; Schnedl, C; Amrein, S; Pieber, TR; Fahrleitner- Pammer, A; Dimai, HP; Dobnig, D; Amrein, K Wiener Klinische Wochenschrift Supplement. 2017. 2017; -Wiener Intensivmedizinische Tage 2017;Vienna, Austria. 15–18 February 2017 3.4
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making. Grubmüller B, Baltzer P, D’Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. Eur J Nucl Med Mol Imaging. 2018;45(2):235-242. February 2017 2.8
Translation initiation separates low and high grade colon and rectum carcinoma Golob-Schwarzl, N; Koller, C; Krassnig, S; Gogg-Kamerer, M; Gantenbein, N; Bergler, H; Pertschy, B; Uranitsch, S; Lackner, K; Puntschart, A; Stiegler, P; Keil, M; Hoffmann, J; Henderson, D; Lehrach, H; Reinhard, C; Schicho, R; Fickert, P; Lax, S; Haybaeck, J EUR J CANCER. 2017; 72: S57-S57.-ECCO European Cancer Congress; Amsterdam, NETHERLANDS. 27–30 January 2017 2.5
(PI3K)/AKT/mTOR pathway members and eukaryotic translation initiation factors as new liver cancer biomarkers Golob-Schwarzl N, Krassnig S, Nyun Park Y, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Lackner K, Schicho R, Fickert P, Haybaeck J. European Journal of Cancer 2017 2.5
Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia. Aberer, F; Kremser, S; Mader, JK; Zinke-Cerwenka, W; Greinix, H; Tripolt, NJ; Pieber, TR; Zebisch, A; Sill, H; Oulhaj, A; Sourij, H; Wölfler, A Diabetes Metab. 2017; 2017 3.2
Bronchoalveolar lavage triacetylfusarinine C (TAFC) determination for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies. Orasch, T; Prattes, J; Faserl, K; Eigl, S; Düttmann, W; Lindner, H; Haas, H; Hoenigl, M J Infect. 2017; 75(4):370-373 2017 3.11
Typ-2-Diabetes: Welche blutzuckersenkende Therapie für wen? Aberer, F; Sourij, H Die Punkte. 2017; 1/2017(1): 3-9. 2017 3.2
Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Eigl, S; Hoenigl, M; Spiess, B; Heldt, S; Prattes, J; Neumeister, P; Wolfler, A; Rabensteiner, J; Prueller, F; Krause, R; Reinwald, M; Flick, H; Buchheidt, D; Boch, T Med Mycol. 2017; 55(5):528-534 2017 3.11
New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Golob-Schwarzl, N; Krassnig, S; Toeglhofer, AM; Park, YN; Gogg-Kamerer, M; Vierlinger, K; Schröder, F; Rhee, H; Schicho, R; Fickert, P; Haybaeck, J Eur J Cancer. 2017; 83(9):56-70 2017 2.5
Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis. Heldt, S; Eigl, S; Prattes, J; Flick, H; Rabensteiner, J; Prüller, F; Niedrist, T; Neumeister, P; Wölfler, A; Strohmaier, H; Krause, R; Hoenigl, M Mycoses. 2017; 2017 3.11
Clinical Evaluation of the Newly Formatted Lateral-Flow Device for Invasive Pulmonary Aspergillosis. Hoenigl, M; Eigl, S; Heldt, S; Duettmann, W; Thornton, C; Prattes, J Mycoses. 2017; 2017 3.11
Semantic Technologies for Re-Use of Clinical Routine Data. Kreuzthaler, M; Martínez-Costa, C; Kaiser, P; Schulz, S Stud Health Technol Inform. 2017; 236:24-31 2017 1.2
Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. Lindheim, L; Bashir, M; Münzker, J; Trummer, C; Zachhuber, V; Leber, B; Horvath, A; Pieber, TR; Gorkiewicz, G; Stadlbauer, V; Obermayer-Pietsch, B PLoS One. 2017; 12(1):e0168390-e0168390 2017 3.5
High salivary testosterone-to-androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome. Münzker, J; Lindheim, L; Adaway, J; Trummer, C; Lerchbaum, E; Pieber, TR; Keevil, B; Obermayer-Pietsch, B Clin Endocrinol (Oxf). 2017; 86(4):567-575 2017 3.5
Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study. Prattes, J; Hoenigl, M; Krause, R; Buzina, W; Valentin, T; Reischies, F; Koidl, C; Zollner-Schwetz, I Med Mycol. 2017; 2017 3.11
1,3-ß-d-Glucan testing is highly specific in patients undergoing dialysis treatment. Prattes, J; Schneditz, D; Prüller, F; Jaindl, E; Sauseng, N; Hoenigl, M; Schilcher, G; Krause, R J Infect. 2017; 74(1):72-80 2017 3.11
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. Stauber, MN; Aberer, F; Oulhaj, A; Mader, JK; Zebisch, A; Pieber, TR; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wölfler, A Biol Blood Marrow Transplant. 2017; 23(7):1186-1192 2017 3.2
Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial Trummer, C; Schwetz, V; Pandis, M; Grubler, MR; Verheyen, N; Gaksch, M; Zittermann, A; Marz, W; Aberer, F; Lang, A; Friedl, C; Tomaschitz, A; Obermayer-Pietsch, B; Pieber, TR; Pilz, S; Treiber, G NUTRIENTS. 2017; 9(6): 623 2017 3.4
Lateral Flow Assays for the Diagnosis of Invasive Aspergillosis: Current Status. Heldt, S; Hoenigl, M Curr Fungal Infect Rep. 2017; 11(2): 45-51. 2017 3.11
Crosstalk between Stem and Progenitor Cellular Mediators with Special Emphasis on Vasculogenesis Rohban, R; Prietl, B; Pieber, TR TRANSFUS MED HEMOTH. 2017; 44(3): 174-182. 2017 1.6
Dysbiosis of the gut microbiota and increased gut permeability characterize secondary sclerosing cholangitis in critically ill patients (SSC-CIP) Blesl, A; Horvath, A; Jungst, C; Leber, B; Schmerboeck, B; Tawdrous, M; Stiegler, P; Rainer, F; Spindelboeck, W; Fickert, P; Lammert, F; Reichert, M; Stadlbauer, V J HEPATOL. 2017; 66(1): S354-S355. 2017 3.1/3.10
Impaired gut permeability and alterations of the gut microbiota in secondary sclerosing cholangitis of critically ill patients (SSC-CIP) Blesl, A; Horvath, A; Jungst, C; Rainer, F; Leber, B; Stadlbauer, V MED KLIN-INTENSIVMED. 2017; 112(4): 396-396. 2017 3.1/3.10
Persistence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Hofler, G; Zebisch, A; Sill, H; Wolfler, A ONCOL RES TREAT. 2017; 40: 140-141. 2017 2.4
High fat diet-induced depression-like behaviour in mice: Roles of intestinal microbiome, neuropeptide Y, and brain metabolome Hassan, AM; Mancano, G; Kashofer, K; Frohlich, EE; Matak, A; Mayerhofer, R; Reichmann, F; Olivares, M; Neyrinck, AM; Delzenne, NM; Claus, SP; Holzer, P NEUROGASTROENT MOTIL. 2017; 29: 27-27. 2017 3.9
Intestinal colonisation by Veillonella spp. is predictive for mortality in stable cirrhosis and could be partially reduced by a multispecies probiotic in a randomized placebo controlled trial Horvath, A; Bashir, M; Schmerboeck, B; Rainer, F; Krones, E; Baumann-Durchschein, F; Douschan, P; Spindelboeck, W; Zollner, G; Stauber, RE; Fickert, P; Stiegler, P; Leber, B; Stadlbauer, V J HEPATOL. 2017; 66(1): S128-S128. 2017 3.1/3.10
Disruption of colonic microbiome and circulating metabolome in antibiotic-treated mice Jacan, A; Zenz, G; Frohlich, EE; Bordag, N; Magnes, C; Kashofer, K; Mayerhofer, R; Reichmann, F; Holzer, P NEUROGASTROENT MOTIL. 2017; 29: 4-4. 2017 3.9
NOD2 variants as novel genetic risk factors for secondary sclerosing cholangitis in critically ill patients Jungst, C; Stadlbauer, V; Reichert, M; Weber, S; Ofner-Ziegenfuss, L; Voigtlander, T; Spindelbock, W; Fickert, P; Kirchner, G; Lammert, F; Lankisch, TO; Krawczyk, M J HEPATOL. 2017; 66(1): S358-S358. 2017 3.10
Direct acting antivirals improve neutrophil phagocytic capacity in chronic hepatitis C Leber, B; Horvath, A; Schmerbock, B; Tawdrous, M; Streit, A; Posch, A; Fickert, P; Spindelbock, W; Stiegler, P; Stauber, RE; Stadlbauer, V J HEPATOL. 2017; 66(1): S293-S293. 2017 3.1/3.10
Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis Rainer, F; Horvath, A; Sandahl, TD; Leber, B; Schmerboeck, B; Blesl, A; Krones, E; Baumann-Durchschein, F; Douschan, P; Spindelboeck, W; Zollner, G; Stauber, RE; Fickert, P; Stiegler, P; Moller, HJ; Gronbaek, H; Stadlbauer, V J HEPATOL. 2017; 66(1): S368-S369. 2017 3.1/3.10
Candica albicans induced failure of extracorporeal membrane oxygenation: a case report Schilcher, G; Eisner, F; Valentin, T; Krause, R; Eller, P MED KLIN-INTENSIVMED. 2017; 112(4): 394-394. 2017 3.11
Drop of FGF19 levels in patients with HCC development following DAA therapy for chronic hepatitis C Stadlbauer, V; Schmerbock, B; Leber, B; Kipperer, M; Stiegler, P; Posch, A; Streit, A; Spindelbock, W; Fickert, P; Stauber, R J HEPATOL. 2017; 66(1): S710-S711. 2017 3.10
The Effect of Linagliptin on the Endothelial Function and Arginine Bioavailability Ratio in CHD Patients with Early Type 2 Diabetes Mellitus – A Randomized Controlled Trial Aberer, F; Tripolt, N; Riedl, R; Hutz, B; Url, J; Brodmann, M; Meinitzer, A; Stojakovic, T; Dimsity, G; Hodl, R; Hafner, F; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129: 162-162. 2017 3.2
Combined serum free light chain levels are associated with carotid atherosclerosis in type 2 diabetes mellitus. Aberer, F; Tripolt, NJ; Scharnagl, H; Zedler, J; Eder, M; Oulhaj, A; Stojakovic, T; Sourij, H Diab Vasc Dis Res. 2017; 132(6):1479164117743939-1479164117743939 2017 3.2
Continuous sampling of immune cells in the skin by dermal open flow microperfusion Birngruber, T; Prietl, B; Bodenlenz, M; Florian, P; Subramaniam, A; Kainz, S; Rauter, G; Pieber, TR; Sinner, F J INVEST DERMATOL. 2017; 137(10): S275-S275. 2017 1.6
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology? Blesl, A; Krones, E; Pollheimer, MJ; Haybaeck, J; Wiesspeiner, U; Lipp, RW; Kump, P CASE REP ONCOL. 2017; 10(3): 1121-1126. 2017 2.5
The Role of Intestinal Reg3 lectins for Non-Alcoholic-Steatohepatitis Bluemel, S; Wang, L; Martino, C; Lee, S; Williams, B; Horvath, A; Stadlbauer, V; Zengler, K; Schnabl, B HEPATOLOGY. 2017; 66: 452A-453A. 2017 3.1/3.10
Characterization of the Psoriasis-like Inflammation in the Imiquimod Rat Model using Dermal Open Flow Microperfusion Bodenlenz, M; Prietl, B; Florian, P; Subramaniam, A; Kainz, S; Rauter, G; Pieber, TR; Sinner, F J INVEST DERMATOL. 2017; 137(10): S278-S278. 2017 1.6
Comparison of Glucagon Values of healthy Study Participants and Patients with Diabetes Mellitus by means of ELISA and RIA Brunner, M; Haberlander, M; Svehlikova, E; Lipp, R; Stach, L; Obermayer-Pietsch, B; Pieber, TR; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129: 178-179. 2017 3.6
Impact of chronic liver disease on pulmonary hemodynamics and exercise tolerance – results from a prospective cross-sectional study Douschan, P; Kovacs, G; Stauber, R; Foris, V; Pfeiffer, S; Gruber, F; Sassmann, T; Revelant, F; Stadlbauer, V; Kniepeiss, D; Fickert, P; Avian, A; Olschewski, A; Olschewski, H WIEN KLIN WOCHENSCHR. 2017; 129(19-20): 768-769. 2017 3.1/3.10
Therapy-associated Errors in an internal Normal Ward from the Diabetics Point of View – A Questionnaire Survey Drechsler, K; Aberer, F; Trummer, C; Schwetz, V; Pandis, M; Glantschnig, K; Kiesling, L; Lanz, C; Pilz, S; Sourij, H; Mader, JK WIEN KLIN WOCHENSCHR. 2017; 129: 180-180. 2017 3.2
Eukaryotic translation initiation factors impact non small cell lung cancer Gantenbein, N; Bernhart, E; Anders, I; Golob-Schwarzl, N; Gogg-Kammerer, M; Lindenmann, J; Fink-Neuboeck, N; Brcic, L; Gollowitsch, F; Stacher-Priehse, E; Rolff, J; Hoffmann, J; Silvestri, A; Regenbrecht, C; Reinhard, C; Pehserl, AM; Pichler, M; Mitterer, V; Pertschy, B; Bergler, H; Popper, H; Sattler, W; Haybaeck, J VIRCHOWS ARCH. 2017; 471: S104-S104. 2017 2.5
Potential role of ctDNA in therapy management Gerger, A ONCOL RES TREAT. 2017; 40: 193-193. 2017 2.2
PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors as new biomarkers in liver cancer Golob-Schwarzl, N; Krassnig, S; Park, Y; Gogg-Kamerer, M; Wodlej, C; Vierlinger, K; Schroeder, F; Rhee, H; Schicho, R; Fickert, P; Haybaeck, J VIRCHOWS ARCH. 2017; 471: S164-S164. 2017 2.5
Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Golob-Schwarzl, N; Schweiger, C; Koller, C; Krassnig, S; Gogg-Kamerer, M; Gantenbein, N; Toeglhofer, AM; Wodlej, C; Bergler, H; Pertschy, B; Uranitsch, S; Holter, M; El-Heliebi, A; Fuchs, J; Punschart, A; Stiegler, P; Keil, M; Hoffmann, J; Henderson, D; Lehrach, H; Reinhard, C; Regenbrecht, C; Schicho, R; Fickert, P; Lax, S; Haybaeck, J Oncotarget. 2017; 8(60): 101224-101243. 2017 2.5
1,5-anhydroglucitol correlates with postprandial glucose in subjects with type 1 diabetes irrespective of HbA(1c) responder status Heller, S; Bowering, K; Raskin, P; Liebl, A; Buchholtz, K; Demissie, M; Pieber, TR DIABETOLOGIA. 2017; 60: S312-S313. 2017 3.6
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Hoenigl, M; Prattes, J; Neumeister, P; Wölfler, A; Krause, R Mycoses. 2017; 2017 3.11
Visceral Inflammation and Immune Activation Stress the Brain. Holzer, P; Farzi, A; Hassan, AM; Zenz, G; Jacan, A; Reichmann, F Front Immunol. 2017; 8:1613-1613 2017 3.9
IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Kessler, SM; Lederer, E; Laggai, S; Golob-Schwarzl, N; Hosseini, K; Petzold, J; Schweiger, C; Reihs, R; Keil, M; Hoffmann, J; Mayr, C; Kiesslich, T; Pichler, M; Kim, KS; Rhee, H; Park, YN; Lax, S; Obrist, P; Kiemer, AK; Haybaeck, J Oncotarget. 2017; 8(52): 89736-89745. 2017 2.7
Mycobiota analysis of samples from different body regions in ICU patients Krause, R; Horvath, L; Halwachs-Wenzl, B; Gorkiewicz, G; Kashofer, K; Moissl-Eichinger, C; Koskinen, K; Eisner, F; Vonlewinski, D; Hogenauer, C MYCOSES. 2017; 60: 157-158. 2017 3.11
Candica albicans induced failure of extracorporeal membrane oxygenation Krause, R; Schilcher, G; Valentin, T; Prettenthaler, H; Hackl, G; Brcic, L; Zollner-Schwetz, I; Eller, P MYCOSES. 2017; 60: 158-158. 2017 3.11
GlucoTab((R))-based Basic Bolus Insulin Therapy with Insulin glargin U300 increases the Time in the Target Area in hospitalized Female Patients with Type 2 Diabetes mellitus Mader, JK; Donsa, K; Aberer, F; Smajic, E; Lichtenegger, KM; Lanz, C; Holl, B; Beck, P; Pieber, TR; Plank, J WIEN KLIN WOCHENSCHR. 2017; 129: 171-171. 2017 3.2
Exercise Prescription in Type 1 Diabetes: Should We Use Percentages of Maximum Heart Rate? Moser, O; Mueller, A; Tschakert, G; Koehler, G; Lawrence, JB; Groeschl, W; Pieber, TR; Bracken, RM; Hofmann, P MED SCI SPORT EXER. 2017; 49(5): 1020-1020. 2017 3.6
Standardized Evaluation of a retrospective versus prospectively calibrated continuous Glucose System at the Research Center and at Home Pandis, M; Elsayed, H; Munzker, J; Puffing, A; Motschning, M; Kojzar, H; Schadler, HP; Pieber, TR; Sourij, H; Treiber, G; Mader, JK WIEN KLIN WOCHENSCHR. 2017; 129: 173-173. 2017 3.2
Endobarrier in obese People with Type-2 Diabetes: Short- and Medium-term Effects on the Glucose Metabolism Pferschy, PN; Tripolt, NJ; Aberer, F; Url, J; Högenauer, C; Schreiber, F; Eherer, A; Svehlikova, E; Obermayer, AM; Stadlbauer, V; Sourij, C; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129(19-20):732-732. 2017 3.2
Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart Pieber, TR; Basu, A; Hansen, AK; Sach-Friedl, S; Thomsen, KMD; Basu, R; Haahr, H DIABETOLOGIA. 2017; 60: S315-S315. 2017 3.2
Switching to Insulin Degludec improves glycemic control in patients with type 2 diabetes (T2dm) in a real-world setting. Results of the EU-TREAT study from six European countries with special emphasis on the Austrian sub-cohort Pusarnig, S; Stechemesser, L; Vonbank, A; Weitgasser, R; Schonherr, HR; Sourij, H; Tikkanen, CK; Brugger, A; Prager, R WIEN KLIN WOCHENSCHR. 2017; 129: 177-177. 2017 3.2
Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation. Rainer, F; Horvath, A; Sandahl, TD; Leber, B; Schmerboeck, B; Blesl, A; Groselj-Strele, A; Stauber, RE; Fickert, P; Stiegler, P; Møller, HJ; Grønbaek, H; Stadlbauer, V Aliment Pharmacol Ther. 2017; 2017 3.10
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting Riedl, JM; Posch, F; Moik, F; Bezan, A; Szkandera, J; Smolle, MA; Kasparek, AK; Pichler, M; Stoger, H; Stotz, M; Gerger, A ONCOTARGET. 2017; 8(56): 96048-96061. 2017 2.2
Aspergillus in airway material : Ignore or treat? Salzer, HJF; Lange, C; Hönigl, M Internist (Berl). 2017; 58(11):1150-1162 2017 3.11
Cardiovascular Disease in Female Patients with Type 2 Diabetes Mellitus at a tertiary Diabetes Center – Data from the Graz Diabetes Register for Biomarker Research (GIRO) Sourij, C; Pferschy, P; Tripolt, N; Kojzar, H; Weber, B; Aberer, F; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129: 178-178. 2017 3.2
Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis. Stadlbauer, V; Horvath, A; Ribitsch, W; Schmerböck, B; Schilcher, G; Lemesch, S; Stiegler, P; Rosenkranz, AR; Fickert, P; Leber, B Sci Rep. 2017; 7(1): 15601-15601. 2017 3.1/3.10
Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus. Stauber, RE; Fauler, G; Rainer, F; Leber, B; Posch, A; Streit, A; Spindelboeck, W; Stadlbauer, V; Kessler, HH; Mangge, H Wien Klin Wochenschr. 2017; 129(21-22):848-851 2017 3.10
A novel stepwise eu-, hyper- and hypoglycaemic clamp using stable tracer method to compare glucose fluxes and lipolysis in type 1 and type 2 diabetes Svehlikova, E; Sach-Friedl, S; Schadler, HP; Augustin, T; Magnes, C; Eberl, A; Narath, S; Urschitz, M; Wolf, M; Treiber, G; Pieber, TR DIABETOLOGIA. 2017; 60: S115-S116. 2017 3.6
Geographic Differences for Patients Enrolled in STOP-HE: A Randomized, Phase 2 Study of OCR-002 for Hepatic Encephalopathy Thabut, D; Stadlbauer, V; Bhamidimarri, KR; Potthoff, A; Bukofzer, S HEPATOLOGY. 2017; 66: 274A-274A. 2017 3.10
Digitization of Processes in clinical Trials Tripolt, N; Pferschy, P; Kojzar, H; Url, J; Weber, B; Sourij, C; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129: 173-174. 2017 3.2
Glucose Metabolism after a Fasting Day and after a Day of Eating in healthy Alternate Day Fasting practicing People Tripolt, N; Stekovic, S; Aberer, F; Url, J; Pferschy, P; Obermayer-Pietsch, B; Pieber, T; Madeo, F; Sourij, H WIEN KLIN WOCHENSCHR. 2017; 129: 178-178. 2017 3.2
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Tsourdi, E; Langdahl, B; Cohen-Solal, M; Aubry-Rozier, B; Eriksen, EF; Guañabens, N; Obermayer-Pietsch, B; Ralston, SH; Eastell, R; Zillikens, MC Bone. 2017; 105(11):11-17 2017 3.4
Cryptococcal Bursitis in an immunocompetent 22-year-old Painter. Wunsch, S; Zollner-Schwetz, I; Prattes, J; Krause, R. MYCOSES. 2017; 60: 90-91.-TIMM; Belgrade, Serbia. 2017 3.11
Metabolic phenotyping of first degree relatives of patients with type 1 diabetes Zgner, EE; Treiber, G; Prietl, B; Gander, E; Bordag, N; Magnes, C; Pieber, TR DIABETOLOGIA. 2017; 60: S99-S100. 2017 1.5/1.6
Eukaryotic translation initiation factors impact non small cell lung cancer. Gantenbein, N; Bernhart, E; Anders, I; Lindenmann, J; Fink-Neuböck, N; Brcic, L; Gollowitsch, F; Stacher-Priehse, E; Rolff, J; Hoffmann, J; Reinhard, C; Popper, H; Sattler, W; Haybaeck, J Journal of Thoracic Oncology. 2016; 12: S599-S599.-17th World Conference on Lung cancer; Vienna, AUSTRIA. 4–7 December 2016 2.5
NOD2 confers risk for sclerosing cholangitis in critically ill patients: genetic study in two independent cohorts Jungst, C; Stadlbauer, V; Reichert, MC; Ofner-Ziegenfuss, L; Voigtlander, T; Spindelboeck, W; Fickert, P; Kirchner, GI; Lammert, F; Lankisch, T; Krawczyk, M HEPATOLOGY. 2016; 63(1 SUPP):191A-192A.-67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD); Boston, MA. 11–15 November 2016 3.10
Welche Faktoren beeinflussen die Entscheidung über die Fortsetzung der Insulintherapie bei Entlassung aus dem Krankenhaus bei Patienten mit Diabetes Mellitus Typ 2? Mader, JK; Donsa, K; Neubauer, KM; Aberer, F; Schaupp, L; Sourij, H; Spat, S; Höll, B; Beck, P; Pieber, TR; Plank, J Wiener Klinische Wochenschrift. 2016; 44(Supp 6):S400-S401.-44. Jahrestagung der Österreichischen Diabetes Gesellschaft (ÖDG); Salzburg, AUSTRIA. 17–19 November 2016 1.2
Retrospektive Analyse von glykämischen Entgleisungen bei Diabetes in der internistischen Notaufnahme am LKH Universitätsklinikum Graz. Cigler, M; Schwetz, V; Aberer, F; Zenz, S; Lueger, A; Eller, P; Pieber, TR; Sourij, H; Mader, JK Wiener Klinische Wochenschrift. 2016; 44(Supp 6):S410-S410.-44. Jahrestagung der Österreichischen Diabetes Gesellschaft (ÖDG); Salzburg, AUSTRIA. 17–19 November 2016 1.2
Pilotstudie zur Überprüfung der Machbarkeit und Effizienz_x000D_ einer normnahen Blutzuckereinstellung mittels eines_x000D_ automatisierten Entscheidungsunterstützungsalgorithmus_x000D_ in der Insulintherapie von Patienten mit Graft-versus-host_x000D_ Erkrankung Aberer, F; Holzgruber, J; Mader, JK; Wölfler, A; Greinix, H; Tripolt, N; Pieber, TR; Sourij, H Wiener klinische Wochenschrift: 2016; 44(6):410-410.-Jahrestagung der Österreichischen Diabetes Gesellschaft (ÖDG); Salzburg . 17–19 November 2016 3.3
Leveraging Genetic Associations to Evaluate Clinical Risk Factors for Osteoporotic Fractures Trajanoska K, Morris J, Oei L, Zheng HF, Forgetta V, Leong A, Ahmad SO, Laurin AC, Mokry L, Ross S, Elks C, Bowden J, Warrington N, Willems S, Wright D, Ruth KS, Murray A, Day FR, Ackert-Bicknell CL, Basset D, van der Eerden B, Gautvik K, Reppe S, Williams G, GENOMOS Consortium (Trummer O, Obermayer-Pietsch B et al.), Medina-Gómez C, Estrada K, van der Velde N, Nielson CM , Hsu YH, Amin N, Bis J, Esko T, Kaptoge S, Lehtimäki T, Minster RL, Kammerer C, Kung AW, Smith AV, Tranah GJ, Trompet S, Brown MA, Chasman D, Ridker P, Cummings SR, van Duijn CM, Gudnason V, Harris TB, Jukema W, Ikram MA, Jackson RD, Karasik D, Lacroix AZ, Lips P, Lorentzon M, Metspalu A, Orwoll E, Psaty BM, Raitakari O, Robbins JA, Sham PC, Spector TD, Thorsteinsdottir U, Zillikens MC, Uitterlinden AG, Duncan EL, Ralston SW, Styrkarsdottir U, Ntzani EE, Vangelis E, Ioannidis JP, GEFOS Consortium, , Tung JY, Kleinmaan A, Hinds DA, Perry JRB, Scott R, Evans DM, Kiel DP, Ohlsson C, Richards JB and Rivadeneira F New England Journal of Medicine 24 November 2017 3.4
Biobanking of different body fluids within the frame of IVF-a standard operating procedure to improve reproductive biology research Schenk, M; Huppertz, B; Obermayer-Pietsch, B; Kastelic, D; Hörmann-Kröpfl, M; Weiss, G J Assist Reprod Genet. 26 November 2016 3.5
In Situ Characterization of Tissue-Resident Immune Cells by MALDI Mass Spectrometry Imaging. Holzlechner M, Strasser K, Zareva E, Steinhäuser L, Birnleitner H, Beer A, Bergmann M, Oehler R, Marchetti-Deschmann M Journal of Proteome Research 16(1):65-76 November 2016 1.9
Anti-mullerian hormone concentrations in individual follicles within one menstrual cycle – a pilot study Schenk, M; Kröpfl, M; Obermayer-Pietsch, B; Feldmeier, E; Weiss, G Human Reproduction November 2016 3.5
Persitence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML. Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Höfler, G; Zebisch, A; Sill, H; Wölfler A Oncol Res Treat 2016. 2016; 39(suppl3):140–Jahrestagung DGHO; Leipzig. (ISBN: 2296-5270 ) 14–18 October 2016 2.4
Mode of renal replacement therapy determines endotoxemia and neutrophil dysfunction in chronic kidney disease Lemesch, S; Ribitsch, W; Schilcher, G; Spindelböck, W; Hafner-Gießauf, H; Marsche, G; Pasterk, L; Payerl, D; Schmerböck, B; Tawdrous, M; Rosenkranz, AR; Stiegler, P; Kager, G; Hallström, S; Oettl, K; Eberhard, K; Horvath, A; Leber, B; Stadlbauer, V. Sci Rep. 2016; 6(1):34534-34534 4 October 2016 3.10
Pulmonary malignancy versus pulmonary infection: a case report Prattes, J ÖGP Jahrestagung 2016; Vienna, AUSTRIA . 6–8 October 2016 3.11
Systematische Ursachenerhebung von Hämatochezie im Kindes- und Jugendalter mit besonderem Augenmerk auf Antibiotika-assoziierte Kolitis und den Pathobioten Klebsiella oxytoca Stampfer L, Deutschmann A, Dür E, Eitelberger F, Fürpass T, Gorkiewicz G, Heinz-Erian P, Heller I, Herzog K, Hopfer B, Kerbl R, Klug E, Krause R, Leitener E, Mache C, Müller T, Pansy J, Pocivalnik M, Scheuba E, Schneditz G, Schweitzger G, Serniczky E, Zechner E, Hauer A. C, Högernauer C, Hofmann K Pädiatrie Hautnah 2016; 28 (SH1). 2016; -31. Jahrestagung der GPGE; Hamburg, GERMANY. 14–17 September 2016 3.11
Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and Hfd-Induced Obesity, and Impairs the Feeding-Fasting Transition. Mueller KM, Hartmann K, Kaltenecker D, Vettorazzi S, Bauer M, Mauser L, Amann S, Jall S, Fischer K, Esterbauer H, Müller TD, Tschöp MH, Magnes C, Haybaeck J, Scherer T, Bordag N, Tuckermann JP, Moriggl R Diabetes (PMID: 27650854) 20 September 2016 1.5
1,3-beta-D-glucan testing is highly specific in patients undergoing dialysis treatment Prattes, J; Schilcher, G; Schneditz, D; Prüller, F; Jaindl, E; Hoenigl, M; Krause, R ÖGIM Jahrestagung 2016; Salzburg, AUSTRIA. 22–24 September 2016 3.11
Evaluierung der Blutzuckereinstellung von PatientInnen mit Diabetes mellitus Typ 2 mittels klinischem Entscheidungsunterstützungssystem auf einer plastisch-chirurgischen Station. Tuca, AC; Neubauer, KM; Aberer, F; Pieber, TR; Kamolz, LP Wien Klin Wochenschr . 2016; 128(S05):S383-S383.-47. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin (OEGIM); Salzburg, AUSTRIA. 22–24 September 2016 3.3
Biomarker in der Diagnostik invasiver Mykosen Prattes, J 50. wissenschaftliche Tagung der deutschsprachigen mykologischen Gesellschaft; Essen, GERMANY. 8–10 September 2016 3.11
Characterization of Yeasts and Filamentous Fungi using MALDI Lipid Phenotyping Gerald Stübiger, Michael Wuczkowski, Luis Mancera, Ksenija Lopandic, Katja Sterflinger, Omar Belgacem Journal of Microbiological Methods August 2016 1.9
Exploiting cross-talk between lipid metabolism and oncogenic signaling for treatment of ovarian cancer R. Wagner, G. Stübiger, P. Lanzerstorfer, J. Weghuber, E. Karteris, K. Nowikovsky, N. Wilfinger, R. Colomer, M.L. López-Rodríguez, T.W. Grunt European Journal of Cancer July 2016 1.9
Hyperglycemia during the First Month after Allogeneic Hematopoietic_x000D_ Stem Cell Transplantation Is an Independent Risk Factor for_x000D_ Overall Survival in Patients with Acute Myeloid Leukemia. Aberer, F; Kremser, S; Zebisch, A; Mader, JK; Sill, H; Greinix, H; Zinke-Cerwenka, W; Pieber, TR; Oulhaj, A; Wölfler, A; Sourij, H Diabetes. 2016; 65(S1):A410-A411.-76th Scientific Sessions of the American Diabetes Association (ADA); New Orleans, LA, USA. 10–14 June 2016 3.1
Factors Influencing Continuation of Insulin Therapy in Patients with_x000D_ Diabetes Mellitus Type 2 at Hospital Discharge. Mader, JK; Donsa, K; Neubauer, KM; Aberer, F;_x000D_ Schaupp, L; Sourij, H; Spat, S; Hoell, B; Beck, P; Pieber, TR; Plank, J Diabetes. 2016; 65(S1):A248-A249.-76th Scientific Sessions of the American Diabetes Association (ADA); New Orleans, LA, USA. 10–14 June 2016 3.3
In-Hospital Hyperglycemia Is Associated with Adverse Outcome in_x000D_ Patients with Acute or Chronic Graft vs. Host Disease after Hematopoeietic Stem Cell Transplantation. Aberer, F; Stauber, M; Zebisch, A; Greinix, H; Sill, H; Mader, JK; Oulhaj, A; Pieber, TR; Wölfler, A; Sourij, H Diabetes. 2016; 65(S1):A390-A390.-76th Scientific Sessions of the American Diabetes Association (ADA); New Orleans, LA, USA. 10–14 June 2016 3.1
A multispecies probiotic enhances antimicrobial activity in cirrhosis: A randomized, double blind placebo-controlled study Horvath, A; Leber, B; Schmerboeck, B; Tawdrous, M; Zettel, G; Hartl, A; Madl, T; Stryeck, S; Fuchs, D; Lemesch, S; Douschan, P; Krones, E; Spindelboeck, W; Durchschein, F; Rainer, F; Zollner, G; Stauber, RE; Fickert, P; Stiegler, P; Stadlbauer, V Zeitschrift für Gastroenterologie . 2016; (5):385-520.-Jahrestagung der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie; , ; Wien. 16–18 June 2016 3.10
Alcohol consumption and liver damage: A balancing act for the innate immune system Horvath, A; Hartmann, P; Schnabl, B; Stadlbauer, V; Zeitschrift für Gastroenterologie. 2016; (5):385-520.-Jahrestagung der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie; Wien, Austria. 16–18 June 2016 3.10
Screening for acute HIV infection: algorithms and cost-effectiveness. Hoenigl, M Clinical Chemistry and Laboratory Medicine. 2016; -ISMD; Graz, AUSTRIA. 26–28 May 2016 1.7
LIVER DISEASE ALTERS HIGH-DENSITY LIPOPROTEIN COMPOSITION, METABOLISM AND FUNCTION Trieb, M; Stadlbauer, V; Birner-Gruenberger, R; Marsche, G ATHEROSCLEROSIS. 2016; 252: E225-E225.-Congress of the European-Atherosclerosis-Society (EAS); Innsbruck, AUSTRIA. 29 May – June 01 2016 3.10
MONOGLYCERIDE LIPASE REGULATES ENDOCANNABINOID TONE AND ATHEROSCLEROTIC PLAQUE STRUCTURE IN APOLIPOPROTEIN E-DEFICIENT MICE Vujic, N; Schlager, S; Eichmann, TO; Goeritzer, M; Madreiter-Sokolowski, CT; Schauer, S; Lass, A; Zimmermann, R; Hoefler, G; Graier, WF; Radovic, B; Kratky, D ATHEROSCLEROSIS. 2016; 252: E259-E259.-Congress of the European-Atherosclerosis-Society (EAS); Innsbruck, AUSTRIA. 29 May – June 01 2016 2.7
Multispecies probiotic maintains health related quality of life in cirrhosis better than placebo Horvath, A; Leber, B; Fuchs, D; Schmerboeck, B; Tawdrous, M; Yueksel, O; Sherzay, K; Hartl, A; Lemesch, S; Spindelboeck, W; Fickert, P; Stauber, RE; Stiegler, P; Durchschein, F; Krones, E; Douschan, P; Zollner, G; Stadlbauer, V Journal of Hepatology. 2016; 64(2):425-629.-EASL – ILC2016; Barcelona, SPAIN. 12–17 April 2016 3.10
Are eIFs Ingredients for Neuroendocrine Tumorigenesis? Gantenbein, N;Smolle, E;Thalhammer, M;Kornprat, P;Lackner, C;Spindelboeck, W;Kump, P;Lipp, R;Haybaeck, J NEUROENDOCRINOLOGY. 2016; 103: 2-3.-13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; Barcelona, SPAIN. 09–11 March 2016 2.5
Infections with C. difficile in inflammatory bowel disease patients are difficult to treat and frequently recur Gombotz, E; Leitner, E; Zollner-Schwetz, I; Krause, R; Kornschober, C; Wenzl, H; Kump, P; Petritsch, W; Hogenauer, C J CROHNS COLITIS.: 2016; 10: S484-S485.-11th Congress of ECCO; Amsterdam, Netherlands. 16–19 March 2016 3.11
Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication Fröhlich EE, Farzi A, Mayerhofer R, Reichmann F, Jačan A, Wagner B, Zinser E, Bordag N, Magnes C, Fröhlich E, Kashofer K, Gorkiewicz G, Holzer P Brain Behav Immun (PMID: 26923630) 23 February 2016 1.5
PAQ®, A Simple 3-Day Basal/Bolus Insulin Delivery Device for People with Type 2 Diabetes. Mader, JK; Lilly, LC; Aberer, F; Poettler, T; Becvar, S; Lanz, C; Trautmann, M; Pieber, TR DIABETES TECHNOL THE.: 2016; 18: A109-A109.-9th International Conference of Advanced Technologies and Treatments for Diabetes (ATTD) ; Milan, ITALY. 3–6 February 2016 3.1
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Zannad, F; Stough, WG; Lipicky, RJ; Tamargo, J; Bakris, GL; Borer, JS; Alonso García, Mde L; Hadjadj, S; Koenig, W; Kupfer, S; McCullough, PA; Mosenzon, O; Pocock, S; Scheen, AJ; Sourij, H; Van der Schueren, B; Stahre, C; White, WB; Calvo, G Eur Heart J Cardiovasc Pharmacother. 2016; 2(3):200-205 2016 3.1
The Influence of Dialysis Treatment on Serum (1¿3)-ß-D-Glucan Levels Jaindl, E Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2016. pp. 2016 3.11
FGF21 and its connection to alcohol consumption Grande, P; Horvath, A; Wagner, M; Stadlbauer, V WIEN KLIN WOCHENSCHR. 2016; 128: S384-S384. 2016 3.10
Luteal phase-specific reduced NF-kappa B P65 activation in women studied across the menstrual cycle Winklhofer-Roob, BM; Faustmann, G; Tiran, B; Maimari, T; Kieslinger, P; Obermayer-Pietsch, B; Gruber, HJ; Roob, JM FREE RADICAL BIO MED. 2016; 96: S65-S66. 2016 3.5
LIPOPROTEINS AND LIPID METABOLISM: APOB CONTAINING LIPOPROTEINS. NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM Sachdev, V; Leopold, C; Bauer, R; Patankar, JV; Iqbal, J; Obrowsky, S; Doktorova, M; Goeritzer, M; Scheicher, B; Kolb, D; Hoefler, G; Turnbull, AV; Zimmer, A; Hussain, MM; Groen, AK; Kratky, D ATHEROSCLEROSIS. 2016; 252: E98-E99. 2016 2.7
Application of the GeneReader NGS System in Analyzing a Diverse Set of Cancer Clinical Samples Oberauner-Wappis, L; Loibner, M; Ulz, C; Abuja, P; Wieczorek, G; Groelz, D; Krenz, T; Wieczorek, G; Oelmueller, U; Zatloukal, K J MOL DIAGN. 2016; 18(6): 1038-1038. 2016 1.4
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A ONCOL RES TREAT. 2015; 38: 129-129. 2016 3.1
SYSTEMATIC STUDY TO OPTIMIZE INSULIN DELIVERY THROUGH A CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) CATHETER Hauzenberger, JR; Torjman, MC; McCue, PA; Pieber, TR; Joseph, JI DIABETES TECHNOL THE.: 2016; 18: A19-A20. 2016 3.3
Therapeutic response to chemotherapeutic drugs of glioma-PDX and correlation to common mutations identified by panel sequencing Orthmann, A; Hoffmann, A; Ernst, C; Golob-Schwarzl, N; Krassnig, S; Haybaeck, J; Jodicke, A; Kuhn, S; Linnebacher, M; Fichtner, I; Hoffmann, J ONCOL RES TREAT.: 2016; 39: 160-160. 2016 2.5
Insulintherapie beim Typ-2-Diabetiker im Krankenhaus Aberer, F; Köhler, G; Sourij, H Klinik. Zeitschrift für das Krankenhaus. 2016; 4/2016(4): 16-19. 2016 3.1
An Untargeted Metabolomics Approach to Characterize Short-Term and Long-Term Metabolic Changes after Bariatric Surgery. Narath, SH; Mautner, SI; Svehlikova, E; Schultes, B; Pieber, TR; Sinner, FM; Gander, E; Libiseller, G; Schimek, MG; Sourij, H; Magnes, C PLoS One.: 2016; 11(9): e0161425-e0161425. 2016 1.5
The Salivary Microbiome in Polycystic Ovary Syndrome (PCOS) and Its Association with Disease-Related Parameters: A Pilot Study. Lindheim, L; Bashir, M; Münzker, J; Trummer, C; Zachhuber, V; Pieber, TR; Gorkiewicz, G; Obermayer-Pietsch, B Front Microbiol.: 2016; 7: 1270-1270. 2016 3.5
Diagnostic performance of 1,3-beta-D-glucan serum screening in patients receiving hematopoietic stem cell transplantation. Reischies, FM; Prattes, J; Woelfler, A; Eigl, S; Hoenigl, M Transpl Infect Dis.: 2016; 18(3):466-470 2016 3.11
Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. Fröhlich, EE; Farzi, A; Mayerhofer, R; Reichmann, F; Jačan, A; Wagner, B; Zinser, E; Bordag, N; Magnes, C; Fröhlich, E; Kashofer, K; Gorkiewicz, G; Holzer, P Brain Behav Immun.: 2016; 56(5):140-155 2016 3.9 & 1.5
Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta-d-Glucan Levels? Prattes, J; Raggam, RB; Vanstraelen, K; Rabensteiner, J; Hoegenauer, C; Krause, R; Prüller, F; Wölfler, A; Spriet, I; Hoenigl, M J Clin Microbiol.: 2016; 54(3):798-801 2016 3.11
Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels. Prattes, J; Duettmann, W; Hoenigl, M Antimicrob Agents Chemother.: 2016; 60(9):5595-5599 2016 3.11
Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Horvath, A; Leber, B; Schmerboeck, B; Tawdrous, M; Zettel, G; Hartl, A; Madl, T; Stryeck, S; Fuchs, D; Lemesch, S; Douschan, P; Krones, E; Spindelboeck, W; Durchschein, F; Rainer, F; Zollner, G; Stauber, RE; Fickert, P; Stiegler, P; Stadlbauer, V Aliment Pharmacol Ther.: 2016; 44(9):926-935 2016 3.10
suPAR remains uninfluenced by surgery in septic patients with bloodstream infection Rabensteiner, J; Prüller, F; Prattes, J; Valentin, T; Zollner-Schwetz, I; Krause, R; Hönigl, M GMS Infectious Diseases. 2016; 2016 3.11
1,3-ß-D-Glucan testing is highly specific in patients undergoing dialysis treatment. Prattes, J; Schneditz, D; Prueller, F; Jaindl, E; Sauseng, N; Hoenigl, M; Schilcher, G; Krause, R J Infect. 2016; 2016 3.11
The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial. Tripolt, NJ; Aberer, F; Riedl, R; Hutz, B; Url, J; Dimsity, G; Meinitzer, A; Stojakovic, T; Hödl, R; Brodmann, M; Hafner, F; Sourij, H Trials. 2016; 17(1): 495-495. 2016 3.1
Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Eigl, S; Hoenigl, M; Spiess, B; Heldt, S; Prattes, J; Neumeister, P; Wolfler, A; Rabensteiner, J; Prueller, F; Krause, R; Reinwald, M; Flick, H; Buchheidt, D; Boch, T Med Mycol. 2016; 2016 3.11
Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet? Prattes, J; Heldt, S; Eigl, S; Hoenigl, M Curr Fungal Infect Rep. 2016; 10: 43-50. 2016 3.11
Zirkulierende Tumor-DNA – ready for prime time in colorectal cancer? Gerger, A; Bauernhofer, T Jatros Haematologie und Onkologie. 2016; 1(16): 67-68. 2016 2.2
Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma Barghash, A; Golob-Schwarzl, N; Helms, V; Haybaeck, J; Kessler, SM. ONCOTARGET. 2016; 7(31): 49743-49750 2016 2.5
Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: A model of steatohepatitis-associated liver carcinogenesis Bettermann, K; Mehta, AK; Hofer, EM; Wohlrab, C; Golob-Schwarzl, N; Svendova, V; Schimek, MG; Stumptner, C; Thuringer, A; Speicher, MR; Lackner, C; Zatloukal, K; Denk, H; Haybaeck, J. ONCOTARGET. 2016; 7(45): 73309-73322. 2016 2.5
Effects of formalin fixation and temperature on MR relaxation times in the human brain Birkl, C; Langkammer, C; Golob-Schwarzl, N; Leoni, M; Haybaeck, J; Goessler, W; Fazekas, F; Ropele, S NMR Biomed. 2016; 29(4):458-465 2016 2.5
Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Themanns, M; Mueller, KM; Kessler, SM; Golob-Schwarzl, N; Mohr, T; Kaltenecker, D; Bourgeais, J; Paier-Pourani, J; Friedbichler, K; Schneller, D; Schlederer, M; Zebedin-Brandl, E; Terracciano, LM; Han, X; Kenner, L; Wagner, KU; Mikulits, W; Kozlov, AV; Heim, MH; Gouilleux, F; Haybaeck, J; Moriggl, R. Sci Rep. 2016; 6: 34719-34719. 2016 2.5
Therapeutic response to chemotherapeutic drugs of glioma-PDX and correlation to common mutations identified by panel sequencing Orthmann, A; Hoffmann, A; Ernst, C; Golob-Schwarzl, N; Krassnig, S; Haybaeck, J; Jodicke, A; Kuhn, S; Linnebacher, M; Fichtner, I; Hoffmann, J ONCOL RES TREAT. 2016; 39: 160-160. 2016 2.5
Chemotherapy induced intestinal mucosal barrier damage: a cause of falsely elevated serum 1,3-beta-d-glucan levels? Prattes, J; Raggam, RB; Vanstraelen, K; Rabensteiner, J; Hoegenauer, C; Krause, R; Prueller, F; Woelfler, A; Spriet, I; Hoenigl, M J Clin Microbiol December 2015 3.11
Clear Links between Starting Methamphetamine and Increasing Sexual Risk Behavior: a cohort study among Men who have Sex with Men Hoenigl, M; Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ. J Acquir Immune Defic Syndr. November 2015 3.11
Lactobacillus casei Shirota Supplementation Does Not Restore Gut Microbiota Composition and Gut Barrier in Metabolic Syndrome: A Randomized Pilot Study. Stadlbauer, V; Leber, B; Lemesch, S; Trajanoski, S; Bashir, M; Horvath, A; Tawdrous, M; Stojakovic, T; Fauler, G; Fickert, P; Högenauer, C; Klymiuk, I; Stiegler, P; Lamprecht, M; Pieber, TR; Tripolt, NJ; Sourij, H PLoS One October 2015 3.10
Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study. Tripolt, NJ; Leber, B; Triebl, A; Köfeler, H; Stadlbauer, V; Sourij, H Atherosclerosis September 2015 3.10
Acquisition of Character Translation Rules for Supporting SNOMED CT Localizations Miñarro-Giménez, JA; Hellrich, J; Schulz, S Stud Health Technol Inform. 2015 1.2
Acquiring Plausible Predications from MEDLINE by Clustering MeSH Annotations Miñarro-Giménez, JA; Kreuzthaler, M; Bernhardt-Melischnig, J; Martínez-Costa, C; Schulz, S Stud Health Technol Inform. 2015 1.2

Reviewed Conference Papers

2020 2019 2018 2017 2016 2015 Top of page
Title Author(s) Publication Date Project
Functional dynamics of dopamine synthesis during reward processing. Hahn A, Reed MB, Pichler V, Michenthaler P, Rischka L, Godbersen GM, Wadsak W, Hacker M, Lanzenberger R. EANM Congress, Oct 22-30, 2020 22-23 October 2020 2.21
Multimodal assessment of test-retest reliability using functional PET, ASL and BOLD imaging in a complex visuo-spatial motor task. Rischka L, Godbersen GM, Pichler V, Michenthaler P, Klug S, Klöbl M, Ritter V, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Hahn A. EANM Congress, Oct 22-30, 2020 22-23 October 2020 2.21
Surface-based smoothing of brain imaging data in voxel space. Stöhrmann P, Rischka L, Gryglewski G, Vanicek T, Hienert M, Klöbl M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Lanzenberger R, Hahn A. MIC Festival, MUW, Dec 10, 2020 10 December 2020 2.21
Hydrobenzoin esters of arecaidine as potential PET tracers for muscarinic acetylcholine receptors: synthesis, characterization and docking experiments Ozenil M, Aronow J, Piljak D, Vraka C, Holzer W, Spreitzer H, Mitterhauser M, Wadsak W, Hacker M, Pichler V. MIC Festival, MUW, Dec 10, 2020 10 December 2020 2.21
Multimodal In Ovo Imaging: The chicken embryo as an alternative model in preclinical research Balber T, Christl J, Bugayong S, Friske J, Fröhlich V, Zacher A, Nics L, Wadsak W, Hacker M, Helbich T, Mitterhauser M EANM Congress, Oct 22-30, 2020 22-23 October 2020 2.21
Multimodal in ovo imaging for PET-tracer development: a feasibility study Balber T, Christl J, Bugayong S, Friske J, Zacher A, Berroterán-Infante N, Cardinale J, Koziolek E, Wadsak W, Helbich T, Hacker M, Nics L, Mitterhauser M 34th International Austrian Winter Symposium, Jan 22-25, 2020 22-25 January 2020 2.21
Development of small molecule PET-tracers targeting PD-L1 Bamminger K, Nehring T, Weiss T, Pichler V, Vraka C, Kenner L, Mitterhauser M, Hacker M, Wadsak W MIC Festival, MUW, Dec 10, 2020 10 December 2020 2.21
2-[18F]FDG metabolism: The role of alternative metabolic pathways Klebermass EM, Mahmudi M, Miller M, Pichler V, Vraka C, Balber T, Haschemi A, Wadsak W, Hacker M, Viernstein H, Mitterhauser M EANM Congress, Oct 22-30, 2020 22-23 October 2020 2.21
2-[18F]FDG-Metabolismus: Ein komplexes Thema neu aufgerollt Klebermass EM, Mahmudi M, Miller M, Pichler V, Vraka C, Balber T, Haschemi A, Wadsak W, Hacker M, Viernstein H, Mitterhauser M 58. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin (DGN), Jul 7-9, 2020 7-9 July 2020 2.21
Design, computational evaluation and synthesis of 4,4′-difluorobenzhydrol carbamates as potential imaging agents for muscarinic acetylcholine receptors Aronow J, Ozenil M, Holzer W, Spreitzer H, Langer T, Wadsak W, Hacker M, Pichler V MIC Festival, MUW, Dec 10, 2020 10 December 2020 2.21
cell2grid: A Spatial, Cell-Based Data Representation for Multiplex Immunohistochemistry Images. Herbsthofer, L, Prietl, B, Tomberger, M, Pieber, T, Lopez-Garcia, P. 4th Annual Meeting of the ÖPPM, Nov 2020 (online) November 2020 1.22
Automated digital quantification of insulin granules using transmission electron micrographs. Ehall, B, Herbsthofer, L, Karacay, C, Prietl, B, Pernitsch, D, Hingerl, K, Kolb, D, Kotzbeck, P, Pieber, T. 4th Annual Meeting of the ÖPPM, Nov 2020 (online) November 2020 1.22
Character-Level Neural Language Modelling in the Clinical Domain Kreuzthaler, M; Oleynik, M; Schulz, S Medical Informatics Europe; APR 28 – MAY 01, 2020; Geneva, SWITZERLAND. 28 April-01 May 2020 1.20
Isoflavon-Stoffwechsel und Hormone. Teschl, S; Borzan, V; Brunner, J; Gumpold, R; Haudum, CW; Schweighofer, N; Stiegelbauer, V; Obermayer-Pietsch, B https://www.oeges.at. 2020; -ÖGES; APR 15-17, 2020; Graz, AUSTRIA. 15-17 April 2020 3.22
Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET Weißbach, J; Schmitz, RL; Haybäck, J; Perren, A; Blank, A; Michl, P; Krug,
S
17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; MAR 11-13, 2020; Barcelona, SPAIN (virtual). 11-13 March 2020 2.5
Annotating German Clinical Narratives with SNOMED CT Schulz, S https://confluence.ihtsdotools.org/display/FT/SNOMED+CT+Expo+2020. 2020; -SNOMED EXPO 2020; 08. – 09.10.2020; London, UK. 8-9 October 2020 1.20
Total versus uc-dpMGP: Associations with Cardiovascular Parameters. Schweighofer, N; Strasser, M; Haudum, CW; Schmidt, A; Kolesnik, E; Pieske, B; Pieber, TR; Obermayer-Pietsch, B https://www.ects2020.org/wp-content/uploads/2020/10/Abstracts-of-the-ECTS-Congress-2020_highres.pdf. 2020; -ECTS digital; OCT 22-24; Praque, CZECH REPUBLIC. 22-24 October 2020 3.22
Matrix-GLA-protein and cardiovascular parameters: uc-dpMGP versus totalMGP. Schweighofer, N; Strasser, M; Haudum, CW; Schmidt, A; Kolesnik, E; Pieske, B; Pieber, TR; Obermayer-Pietsch, B Ece2020@endocrinology.org. 2020; -eECE; SEP 5-9; Marseilles, FRANCE. 5-9 September 2020 3.22
Body composition and anthropometric data – Influence of total and uc-dpMGP. Schweighofer, N; Strasser, M; Haudum, CW; Schmidt, A; Mursic, I; Pieske, B; Pieber, TR; Obermayer-Pietsch, B https://www.ects2020.org/wp-content/uploads/2020/10/Abstracts-of-the-ECTS-Congress-2020_highres.pdf. 2020; -ECTS digital; OCT 22-24; Prague, CZECH REPUBLIC. 22-24 October 2020 3.22
Antitumorigenic effect of glycine in a combined colorectal liver metastasis and FOLFOX model Bausys, A; Maneikyte, J; Stiegler, P; Horvath, A; Feldbacher, N; Hoefler, G; Strupas, K; Schemmer, P; Leber, B 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Translationsinitiationsfaktoren und Gynäkologische Neoplasien: Aktuelle Kenntnisse Haybaeck, J Gynäkologie: Oncocafé; NOV 4, 2020; Innsbruck, AUSTRIA. 2020. 4 November 2020 2.5
Chair der Session „What‘s New in Breast Pathology: WHO 2019“ Haybaeck, J Frühjahrstagung 2020 der Österreichischen Gesellschaft für Pathologie ; SEP 11-12, 2020; Vienna, AUSTRIA. 2020. 11-12 September 2020 2.5
Chair der Sitzung zu Personalisierte Tumorbehandlung – vom Experiment zur Klinik, Translationale Onkologie Haybaeck, J 34. Deutscher Krebskongress; FEB 21, 2020; Berlin, GERMANY. 2020. 21 February 2020 2.5
Liver machine perfusion of the fatty or cirrhotic liver in a minipig model Jakubauskas, M; Jakubauskiene, L; Leber, B; Schemmer, P; Stiegler, P 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Effects of probiotic supplementation on chemotherapy side effects in a rat Jakubauskas, M; Jakubauskiene, L; Leber, B; Strupas, K; Stiegler, P; Schemmer, P 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Probiotic supplementation decreases tumor volume in a rat colorectal cancer liver metastasis model Jakubauskas, M; Jakubauskiene, L; Leber, B; Strupas, K; Stiegler, P; Schemmer, P 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Relaxin and Erythropoetin reduces ischemia-reperfusion injury in rat uterus Jakubauskiene, L; Jakubauskas, M; Leber, B; Strupas, K; Stiegler, P; Schemmer, P 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
The role of melatonin and glycine in colorectal cancer liver metastases treatment Kvietkauskas, M; Zitkute, V; Strupas, K; Stiegler, P; Schemmer, P; Leber, B 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Glycine has a cardioprotective properties against chemotherapy induced cardiotoxicity: a colorectal cancer liver metastasis treatment by FOLFOX model in rats Maneikyte, J; Bausys, A; Stiegler, P; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Strupas, K; Schemmer, P; Leber, B 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Subnormothermic machine perfusion of non-transplantable human liver grafts: setup of a protocol Schlechter, S; Leber, B; Koter, C; Cupac, M; Schemmer, P; Stiegler, P 55th Congress of the European Society for Surgical Research & 44th Congress of the Austrian Society for Surgical Research; DEZ 10-11, 2020; Innsbruck. 2020. 10-11 December 2020 2.23
Abklärung Abdomineller Schmerz Stadlbauer V FOMF Turnusärzte; Feb 20, 2020; Wien. 2020. 20 February 2020 3.23
Abklärung erhöhter Leberwerte Stadlbauer V FOMF Allgemeinmedizin Update Refrescher; MAY 17, 2020; online. 2020. 17 May 2020 3.23
Das Mikrobiom bei chronischen Lebererkrankungen Stadlbauer V 1. online Fachakademie; MA 28, 2020; online. 2020. 21-22 February 2020 3.23
Kann das Mikrobiom bei der Gewichtsabnahme helfen? Stadlbauer V 6. deutsche Mikrobiomtage; FEB 21-22, 2020; Berlin. 2020. 21-22 February 2020 3.23
Bauchschmerz: Orchideen Stadlbauer V Bauchschmerz für Fortgeschrittene; Feb 7, 2020; Graz. 2020. 17 May 2020 3.23
Wichtige Lebererkrankungen: Diagnose und Therapie Stadlbauer V FOMF Innere Medizin Update Refresher; MAY 17, 2020; online. 2020. 6 November 2020 3.23
CF – Comorbiditäten
Leber und andere gastroenterologische Probleme
Stadlbauer V Interdisziplinäre Fortbildung für CF Teams 2020; NOV 6, 2020; online. 2020. 29 January 2020 3.23
Abklärung erhöhter Leberwerte Stadlbauer V FOMF Allgemeinmedizin Update Refresher; Jan 29, 2020; Graz. 2020. 2 December 2020 3.23
Covid-19 in gastroenterology and hepatology Stadlbauer V Structural Biology Meets Clinic; Dec 2, 2020; online. 2020. 2 December 2020 3.23
Porphyria care at the Medical University of Graz, Austria Stadlbauer V Virtual AHP Workshop; Nov 25, 2020; online. 2020. 25 November 2020 3.23
Mikrobiom und Immunsystem Stadlbauer V Jahrestagung Adler Pharma; Sep 27, 2020; Zell am See. 2020. 21-22 February 2020 3.23
Rückblick BMSD 2019 Stadlbauer V 6. deutsche Mikrobiomtage; FEB 21-22, 2020; Berlin. 2020. 21-22 February 2020 3.23
Lebertransplantation Stadlbauer V Fortbildung BHB St Veit; Sep 21, 2020; St Veit an der Glen. 2020. 21 September 2020 3.23
Stellenwert der Mikrobiommodulation bei Diabetes und Adipositas Stadlbauer V 6. Internationalen Symposiums der österreichischen Gesellschaft für probiotische Medizin; NOV 21, 2020; online. 2020. 21 November 2020 3.23
Covid-19 in der gastroenterologie und hepatologie Stadlbauer V Intensiver Sommer 2020; JUL 3, 2020; online. 2020. 3 July 2020 3.23
Gastrointestinale Blutungen Stadlbauer V FOMF Turnusärzte; Feb 20, 2020; Wien. 2020. 20 February 2020 3.23
Wissenschaftliche und Medizinische Relevanz von Standards in der Diagnostik. Zatloukal, K LISAvienna Regulatory Conference for in-vitro Diagnostics; OCT 21, 2020; Vienna, AUSTRIA. 2020. 21 October 2020 1.22
Welcome and Introduction to the INSTAND-NGS4P Satellite Workshop: NGS for Personalized Medicine. Zatloukal, K INSTAND-NGS4P Satellite Workshop: NGS for Personalized Medicine; JAN 29, 2020; Graz, AUSTRIA. 2020. 29 January 2020 2.20
Localising the Clinical Terminology SNOMED CT by Semi-automated Creation of a German Interface Vocabulary Schulz, S; Hammer, L; Nik-Hashemian David; Kreuzthaler M In: Melero, M editors(s). Proceedings of the LREC 2020 Workshop on Multilingual Biomedical Text Processing (MultilingualBIO 2020). Luxemburg: European Language Resources Association; p. 15-20. 2020(ISBN: 979-10-95546-65-8) 2020 1.20
ABATACEPT ALTERS THE FREQUENCY OF IMMUNOREGULATORY AND EFFECTOR T CELL SUBPOPULATIONS IN RHEUMATOID ARTHRITIS Dreo, B; Prietl, B; Kofler, S; Sourij, H; Lackner, A; Moazedi-Furst, F; D’orazio, M; Stradner, M; Graninger, W; Brezinschek, HP. Annual European Congress of Rheumatology (EULAR); JUN 03, 2020 3 June 2020 1.22
Acid-base changes during diabetic ketoacidosis in type 1 diabetes with/without SGLT2 inhibitor Mursic, I; Svehlikova, E; Regittnig, W; Urschitz, M; Wolf, M; Brunner, M; Augustin, T; Magnes, C; Eberl, A; Heise, T; Klein, O; Sourij, H; Pieber, T 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD); SEP 21-25, 2020 21-25 September 2020 3.20
„Atypischer“ Diabetes – es gibt noch mehr als Typ 1 und Typ 2 – Ein Fallbericht Treiber, G; Verheyen,N; Verheyen, S; Mader, JK, Sourij, H 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24.-26., 2020 24-26 September 2020 3.20
DRUG DEPENDENT ALTERATIONS IN B-CELL REPERTOIRE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH LOW DISEASE ACTIVITY Zenz, S; Dreo, B; Prietl, B; Kofler, S; Sourij, H; Lackner, A; D’orazio, M; Brickmann, K; Gretler, J; Furst-Moazedi, F; Stradner, M; Graninger, W; Brezinsek, HP Annual European Congress of Rheumatology (EULAR); JUN 03, 2020 3 June 2020 3.20
What Makes a Top-Performing Precision Medicine Search Engine? Tracing Main System Features in a Systematic Way. Faessler, E; Oleynik, M; Hahn, U Proceedings of the 43rd International ACM SIGIR Conference on Research and Development in Information Retrieval. 2020; 459-468.-SIGIR; Jul 25-30, 2020; Virtual Event, China. (ISBN: 9781450380164 ) [Oral Communication] 25-30 July 2020 1.20
Liquid biopsy workflows to analyze stabilized circulating nucleic acids El-Heliebi, A European Human Genetics Virtual Conference; JUN 6-9, 2020; virtual. 2020. 6-9 June 2020 2.20
Liquid biopsy workflows to analyze stabilized cell free nucleic acids El-Heliebi, A QIAGEN Cancer Research Virtual Event; NOV 5-6, 2020; virtual. 2020. 5-6 November 2020 2.20
Use-cases based on actual collaborative research with clinical departments. El-Heliebi, A Implementing Biomedical Research Projects: The Complete Workflow from Concept, ELSI and Privacy Considerations to High-Quality Biobanking; MAY 11-14, 2020; Graz, AUSTRIA, online. 2020. 11-14 May 2020 2.20
Improved sensitivity of liquid biopsies in prostate cancer: A multi-analyte approach. Hofmann, L; Sallinger, K; Haudum, C; Smolle, M; Heitzer, E; Moser, T; Novy, M; Gesson, K; Kroneis, T; Bauernhofer, T; El-Heliebi, A EACR Liquid Biopsies Virtual Event; NOV 18-19, 2020; Nottingham, UK. 2020. 18-19 November 2020 2.20
Another step towards personalized medicine: A multi-analyte approach for improved sensitivity of liquid biopsies in prostate cancer Hofmann, L; Sallinger, K; Haudum, C; Smolle, M; Heitzer, E; Moser, T; Novy, M; Gesson, K; Kroneis, T; Bauernhofer, T; El-Heliebi, A 4th Annual Meeting of the ÖPPM; Vienna, AUSTRIA. 2020. 2020 2.20
C2G-Net: Exploiting Morphological Properties for Image Classification. Herbsthofer, L, Prietl, B, Tomberger, M, Pieber, T, Lopez-Garcia, P. arXiv . 2020. e-prints 20202007.03: 2020 1.22
Nr4a1 is implicated in the regulation of immune checkpoints in aggressive lymphomas Pansy, K; Fechter, K; Kargl, J; Wenzl, K; Prochazka, K; Greinix, H; Haybaeck, J; Prokesch, A; Beham-Schmid, C; Feichtinger, J; Neumeister, P; Deutsch, A;. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; OKT 11-14, 2019; Berlin, GERMANY. 2019. 13 November 2019 2.5
Onkologie – 3D Tumormodelle Haybaeck, J Symposium Labormedizin Seggauberg bei Graz, “Personalisierte Medizin – Fakten versus Vision”; NOV, 13, 2019; Seggauberg, AUSTRIA. 2019. 13 November 2019 2.5
Individualization of follow-up in patients with high-grade soft tissue sarcoma Szkandera, J; Smolle, MA; van de Sande, M; Callegaro, D; Wunder, J; Hayes, A; Leitner, L; Bergovec, M; Tunn, PU; van Praag, V; Panotopoulos, J; Willegger, M; Windhager, R; Riedl, J; Stotz, M; Gerger, A; Pichler, M; Dijkstra, S; van Houdt, W; Stöger, H; Liegl-Atzwanger, B; Smolle, J; Leithner, A; Gronchi, A; Haas, R CTOS; NOV 13-16, 2019; Tokyo, JAPAN. 2019. 13–16 November 2019 2.5
Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver Haybaeck, J Sino-German Cooperation Meeting; NOV 1-4, 2019; Beijing, CHINA. 2019. 1–4 November 2019 2.5
Tumor suppressive function of Nr4a1 is mediated by the regulation of immune checkpoints in aggressive lymphomas Pansy, K; Fechter, K; Kargl, J; Wenzl, K; Prochazka, K; Greinix, H; Haybaeck,J; Prokesch, A; Beham-Schmid, C; Feichtinger, J; Neumeister, P; Deutsch, AJ; ÖGAI Annual Meeting; NOV 21-23; 2019; Graz, AUSTRIA. 2019. 21–23 November 2019 2.5
CXCR2 expression in diabetic and nondiabetic NOD mice Harer, C; Lechner E; Prietl B; Pieber T Annual Meeting of the Austrian Society for Allergology and Immunology; NOV 21-23, 2019; Graz. 21–23 November 2019 1.22
Knochenmetastasen aus Sicht des Pathologen Haybaeck, J 9. Jahrestagung der AMSOS; NOV 22, 2019; Innsbruck, AUSTRIA. 2019. 22 November 2019 2.5
Die vielen Facetten der Digitalen Pathologie Haybaeck, J 4th IMAGE-GUIDED INTERVENTIONS CONFERENCE: DIGITALIZATION IN MEDICINE; NOV 4-5, 2019; Mannheim, GERMANY. 2019. 4–5 November 2019 2.5
Infektionspatienten in der Notaufnahme 2019 – Warum ist Impfen_x000D_ wichtig? Zollner-Schwetz, I Pflege in Notaufnahme und Ambulanzen; Nov 8-9, 2019; Graz, Austria. 2019. 8–9 November 2019 3.11
Interaktive Falldiskussion Haybaeck, J Autoimmune und nicht-virale Lebererkrankungen; OCT, 23, 2019; Berlin, GERMANY. 2019. 23 October 2019 2.5
Hypoglycaemia leads to delayed increase in platelet and coagulation activation markers in subjects with type 2 diabetes – results from a stepwise hypoglycaemic clamp study Aberer, F; Pferschy, PN; Tripolt, NJ; Sourij, C;_x000D_ Obermayer, A; Prüller, F; Novak, E; Reitbauer, P; Kojzar, H; Prietl, B; Kofler, S; Brunner, M; Svehlikova, E; Stojakovic, T; Scharnagl, H; Oulhaj, A; Aziz, F; Riedl, R; Sourij, H Scientific Programme of the 5th CVOT Summit 2019. 2019; 28: 28-28.-CVOT Summit 2019; OCT 24-25, 2019; Munich, GERMANY. 24–25 October 2019 3.20
STAT3-dependent systems-level analysis reveals PDK4 as an independent predictor of biochemical recurrence in prostate cancer Oberhuber, M 2 nd AustroMetabolism Workshop | October 9 th, 2019 9 October 2019 1.23
Entwicklung von niedermolekularen PET-Tracern für den PD-1/PD-L1 Immuncheckpoint Bamminger, K AGRR Kongress 12-14.09.2019 12–14 September 2019 2.21
Chairman in Session „Cell transformation & Cancer“ Haybaeck, J 1. Cold Shock Protein Symposium; SEP 12-15, 2019; Magdeburg, GERMANY. 2019. 12–15 September 2019 2.5
YB-1 and translation initiation in the context of cancer Haybaeck, J 1. Cold Shock Protein Symposium; SEP 13, 2019; Magdeburg, GERMANY. 13 September 2019 2.5
Tumor suppressive function of Nr4a1 is mediated by regulation of Pd1-Pdl1-Pdl2 and Ctla4-Cd80-Cd86 axis in aggressive lymphomas Pansy, K; Fechter, K; Kargl, J; Wenzl, K; Prochazka, K; Greinix, H; Haybaeck, J; Prokesch, A; Beham-Schmid, C; Feichtinger, J; Neumeister, P; Deutsch, A; ÖGMBT Annual Meeting; SEP 16-18, 2019; Salzburg, AUSTRIA. 2019. 16–18 September 2019 2.5
Cholezystitis und Appendicitis OP – Contra Zollner-Schwetz, I Österreichische Gesellschaft für Innere Medizin; Sept19-21, 2019; Salzburg, Austria. 2019. 19–21 September 2019 3.11
Hypoglykämie führt zu einer Plättchen- und Gerinnungsaktivierung bei PatientInnen mit Typ 2 Diabetes unter Metformin-Monotherapie – Ergebnisse einer hyperinsulinämischen hypoglykämischen Clamp-Studie Aberer, F; Pferschy, PN; Tripolt, N; Sourij, C; Obermayer, AM; Prüller, F; Novak, E; Reitbauer, P; Kojzar, H; Prietl, B; Kofler, S; Brunner, M; Svehlikova, E; Stojakovic, T; Scharnagl, H; Oulhaj, A; Aziz, F; Riedl, R; Sourij, H Freier Vortrag. 2019; 131 (Suppl5) : 461-462.-47. Jahrestagung der Österreichischen Diabetes_x000D_ Gesellschaft; NOV 21-23, 2019; Salzburg . 21–23 November 2019 3.20
Inference of tumor cell-specific transcription factor binding from cell-free DNA enables tumor subtype prediction Peter Ulz, Samantha Perakis, Qing Zhou, Tina Moser, Jelena Belic, Isaak Lazzeri, Albert Wölfler, Armin Zebisch, Armin Gerger, Gunda Pristauz, Edgar Petru, Brandon White, Charles Roberts, John St. John, Michael Schimek, Jochen Geigl, Thomas Bauernhofer, Heinz Sill, Christoph Bock, Ellen Heitzer, Michael Speicher Circulating Nucleic Acids in Plasma and Serum (CNAPS); SEP 23-25, 2019; Jerusalem, Israel. 2019. 23–25 September 2019 2.2
Inference of tumor cell-specific transcription factor binding from cell-free DNA enables tumor subtype prediction Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, C; St. John, J; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher,M Circulating Nucleic Acids in Plasma and Serum (CNAPS); SEP 23-25, 2019; Jerusalem, Israel. 2019. 23–25 September 2019 2.2
Chairman: Session Biobanking: Perspektiven und Herausforderungen; Gemeinsame Sitzung mit der Deutschen Gesellschaft für Pathologie (DGP) Haybaeck, J 16. Jahrestagaung der Deutschen Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V.; SEP 26, 2019 ; Magdeburg, GERMANY. 2019. 26 September 2019 2.5
Secondary Use of Clinical Problem List Entries for Data-Driven Learning Approaches Kreuzthaler, M; Oleynik, M; Vera Ramos, JA; Kasac, Z; Schulz, S 10th International Workshop on Simulation and Statistics_x000D_ ; SEP 2-6, 2019; Salzburg, AUSTRIA. 2–6 September 2019 1.20
Breaking the Wall of Clinical Biomarker Research. Herbsthofer, L Technologiegespräche Alpbach 22.August 2019 22 August 2019 1.23
Post ASCO Meeting: Liquid biopsy, ctDNA Haybaeck, J Regionales Expertenmeeting – Topics der Jahrestagung 2019 der Amerikanischen Gesellschaft für klinische Onkologie; JUL 03, 2019; Magdeburg, GERMANY. 2019. 3 July 2019 2.5
Brain banking and research approaches in human brain tissue / neuropathology Haybaeck, J Human Brain Project (HBP) Workshop „New horizons in brain medicine: From research to clinics“; JUL 04, 2019; Innsbruck, AUSTRIA. 2019. 4 July 2019 2.5
Chairman in der Session Personalisierte Medizin II – Zwischen Versprechen und Wirklichkeit – die vielen Gesichter der personalisierten Medizin Haybaeck, J 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 2019. 13–15 June 2019 2.5
Translation imnitiation factors and cancer -Current knowledge Haybaeck, J 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Eukaryotic initiation factor 4A1 might represent a novel therapeutic target in neuroblastoma Wodlej, C; Krassnig, S; Kleinegger, F; Birkl-Toeglhofer, AM; Singer, G; Till, H; Benesch, M; Izycka-Swieszewska, E; Czapiewski, P; Haybaeck, J 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
A distinct pattern of eukaryotic initiation factors impact on the pathogenesis of follicular lymphoma Skrobar, K; Unterluggauer, J; Prochazka, K; Waldhart, J; Neumeister, P; Beham-Schmid, C; Haybaeck, J; Deutsch, A 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Nr4a1 is implicated in the regulation of the Pd1-Pdl1-Pdl2 and Ctla4-Cd80-Cd86 axis in aggressive lymphomas Pansy, K: Fechter, K; Wenzl, K; Prochazka, K; Beham-Schmid, C; Neumeister, P; Haybaeck, J; Deutsch, A Virchows Archive. 2019; -103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
High eIF2B5 expressing DLBCLs possess an enrichment of AKT and JNK target genes Deutsch, A; Unterluggauer, J; Pansy, K; Fechter, K; Beham-Schmid, C; Neumeister, P; Haybaeck, J 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Expression des Rezeptors für Insulin-like growth factor in Mamma Karzinomen und Modell-Zelllinien Nass, N; Drewes, L; Weissenborn, C; Vo, DK; Ignatov, A; Haybaeck, J; Kalinski, T 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
The mechanism of MCF-7 breast cancer cell death induced by G-protein-coupled estrogen receptor (GPER)-specific agonist G1 Vo, K; Hartig, R; Haybaeck, J; Nass, N 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Die prognostische Relevanz der Protein Deglycase PARK7/DJ-1 beim Mamma Karzinom Nass, N; Sprung, S; Andreas, L; Scherfele, C; Cui, W; Haybaeck, J; Kalinski, T 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Feedback-based self-improving CNN algorithm for breast cancer lymph node metastasis detection in real clinical environment Sadeghi, M; Maldonado Zambrano, I; Abele, N; Haybaeck, N; Friebe, M 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Molecular analysis of radon-induced lung carcinoma: a regional study of lung carcinoma induction by natural radon exposure in a Tyrolean village Manzl, C; Sprung, S; Gamerith, G; Kloppenburg, M; Merkelbach-Bruse, S; Büttner, R; Haybaeck, J; Pall, G 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Association of DNA mismatch repair and MGMT onto clinical outcome in glioblastoma patients Manzl, C; Brawanski, K; Moser, P; Haybaeck, J; Thomè, C 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
Molekularpathologie von ZNS-Metastasen des Lungenkarzinoms Hanke, B; Haybaeck, J; Mawrin, C 103. Jahrestagung der Deutschen Gesellschaft für Pathologie (DGP); JUN 13-15, 2019; Frankfurt am Main, GERMANY. 13–15 June 2019 2.5
The gut-liver axis as a novel therapeutic target in chronic liver disease and diabesity Stadlbauer, V Webinar Invivo; May 1, 2019; London (als Webinar von Graz aus). 2019. 1 May 2019 3.23
Das Mikrobiom und Medikamente Stadlbauer, V Burgenländischer Ärztetag; MAY 11, 2019; Deutschkreutz. 2019. 11 May 2019 3.23
Accuracy of magnetic resonance imaging for detection of intraarticular involvement in juxta-articular located malignant mesenchymal tumors Igrec J, Brcic I, Igrec R, Bergovec M, Viertler C, Liegl-Atzwanger B, Leithner A, Fuchsjäger M 32nd Annual Meeting of the European Musculo Skeletal Oncology Society (EMSOS) ; May 15-17, 2019; Florenz, Italien. 15–17 May 2019 2.7
Advancing soft-tissue sarcoma aftercare using flexible parametric survival models. Smolle, MA; van de Sande, M; Callegaro, D; Wunder, J; Hayes, AJ; Leitner, L; Bergovec, M; Tunn, PU; van Praag, VM; Panotopoulos, J; Willegger, M; Windhager, R; Riedl, JM; Stotz, M; Gerger, A; Pichler, M; Stöger, H; Liegl-Atzwanger, B; Smolle, J; Leithner, A; Gronchi, A; Haas, RL; Szkandera, J 32. Annual Meeting of the European Musculoskeletal Tumour Society (EMSOS); MAY 15-17, 2019; Florence, ITALY. 15–17 May 2019 2.2
Elevated mean glucose level predicts decreased disease free survival in soft tissue sarcoma patients. Riedl, J; Stelzl, A; Aziz, F; Smolle, M; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stöger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Sourij, H; Szkandera, J 32nd Annual Meeting of the European Musculo Skeletal Oncology Society; MAY 15-17, 2019; Florence, ITALY . 15–17 May 2019 2.2
Virushepatitiden Stadlbauer, V Update Refresher Innere Medizin; MAY 22, 2019; Wien. 2019. 22 May 2019 3.23
Probiotika in der Praxis Stadlbauer, V Update Refresher Innere Medizin; MAY 24, 2019; Köln. 2019. 24 May 2019 3.23
Neurotrophic Tyrosine-Receptor-Kinase (NTRK) Genfusionen: was ist das? Haybaeck. J Mittwochsseminar der Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Magdeburg; MAY 29, 2019; Magdeburg, GERMANY. 2019. 29 May 2019 2.5
The gut-liver axis in chronic liver disease: Pathophysiology and therapeutic target Stadlbauer, V International Student Congress; MAY 30 – JUN 1, 2019; Graz. 2019. 30 May–1 June 2019 3.23
Elevated mean glucose level predicts decreased disease free survival in soft tissue sarcoma patients_x000D_ Riedl, JM; Stelzl, A; Aziz, F; Smolle, MA; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stöger, H; Liegl-Atzwanger, B; Stotz,M; Gerger, A; Sourij, H; Szkandera, J_x000D_ EMSOS (Annual Meeting of the European Musculo-Skeletal Oncology Society. Florence, May 2019); 15.05.2019 – 17.05.2019; Florence, Italy. 2019. May 2019 2.2
Adipositas: _x000B_eine gastrointestinale Infektionserkrankung? Stadlbauer, V VEÖ Jahrestagung; APR 10, 2019; Wien. 2019. 10 April 2019 3.23
Nr4a1 is implicated in immune escape by regulating the Pd1-Pdl1-Pdl2 and Ctla4-Cd80-Cd86 axis in aggressive lymphomas Pansy, K; Fechter, K; Wenzl, K; Greinix, H; Prochazka, K; Haybäck, J; Prokesch, A; Feichtinger, J; Neumeister, P; Deutsch, A OeGHO- & AHOP-Frühjahrstagung 2019; APR 11-13, 2019; Linz. 2019. 11–13 April 2019 2.5
_x000D_ Elevated mean glucose level predicts decreased disease free survival in soft tissue sarcoma patients_x000D_ Riedl, JM; Stelzl, A; Aziz, F; Smolle, MA; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stöger, H; Liegl-Atzwanger, B; Stotz,M; Gerger, A; Sourij, H; Szkandera, J OeGHO- & AHOP-Frühjahrstagung 2019; 11.04.2019 – 13.04.2019; Linz, Austria. 2019. 11–13 April 2019 2.2
Mikrobiommodulation durch Probiotika in der Praxis Stadlbauer, V Update Refresher Innere Medizin; APR 12, 2019; Graz. 2019. 12 April 2019 3.23
Favourable Response to Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory Fungal Diseases, Interim Analysis by Pathogen from a Phase 3 Open-label Study (FURI) Cornely OA; Ostrosky-Zeichner, L; Miller, R; Spec, A; Thompson, G; Walsh, TJ; Richardson7, R; Krause, R; Pappas, PG; Mullane, K; Morse, CG; Sanders, JW; Weiss, G; Witzke, O; Vazquez, J; Miceli, MH; Patterson, T; Hoenigl, M; Alexander, B; Angulo Gonzalez, D 29th ECCMID; APR 13-16, 2019; Amsterdam, NETHERLANDS. 13–16 April 2019 3.11
Accuracy of T2Candida in invasive candidiasis: a clinical trial. Zurl, C; Prattes, J; Zollner-Schwetz, I; Valentin, T; Rabensteiner, J; Hoenigl, M; Wunsch, S; Krause, R 29th ECCMID; APR 13-16, 2019; Amsterdam, NETHERLANDS. 13–16 April 2019 3.11
CHARACTERISATION OF IMMUNE RESPONSE AND RESIDUAL BETA CELL FUNCTION IN FEMALE AND MALE PATIENTS WITH NEW ONSET TYPE 1 DIABETES. Harer, C; Prietl, B; Mader, JK; Lechner, E; Leitgeb, S; Fröhlich-Reiterer, E; Treiber, G; Pieber, TR 24. Jahrestagung der ÖGES gemeinsam mit der OSDG und ANETS; APR 24-26, 2019; Graz, AUSTRIA. 24–26 April 2019 1.22
Vergleich von Analysemethoden zur direkten Messung von freiem Testosteron Borzan, V; Herbsthofer, L; Goschnik, M; Missbrenner, C; Gumpold, R; Obermayer-Pietsch, B ÖGES Jahrestagung 26. April 2019 26 April 2019 3.22
Medikamente und Mikrobiom Stadlbauer, V Graz Zahn 2019; APR 26-27, 2019; Graz. 2019. 26–27 April 2019 3.23
FUSION Technology Feurer, V; Pfeifer, B; Herbsthofer, L; Lopez-Garcia, P; Bordag, N; Kreuzthaler, M; Magnes, C; Prietl, B; Tomberger, M; Ulz, C; Oberhuber, M; Kenner, L; El-Heliebi, A; Wadsak, W; Wallner, M; Schulz, S; Pieber, TR; Brehme, M 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 1.23
Digital Biomarkers for Precision Medicine DBM4PM Schulz, S; Kreuzthaler, M; Jauk, S; Leodolter, W; Kramer, D; Wadsak, W; Brehme, M; Lobnig, R; Pieber, TR 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 1.20
Mass Spectrometry Based Technologies for Systems-Level Clinical Biomarker Discovery Oberhuber, M; Mitulović, G; El-Heliebi, A; Kenner, L; Sawada, M; Brehme, M 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 1.21
Multi-parameter Core Technologies:Immunology, Digital PathologyandMetabolomics Prietl, B; Kofler, S; Lechner, E; Pfeifer, V; Tomberger, M; Magnes, C; Zügner, E; Bordag, N; Pieber, TR 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 1.22
Liquid Biopsy in Cancer Smolle, MA; Prietl, B; Ulz, C; Wodlej, C; Bauernhofer, T; Haybäck, J; Oelmüller, U; Schmitz, M; Renner, W; Novy, M; Oberkanins, C; Kim, M; Noh, H; Oberauner-Wappis, L; Nam, DH; Shin, YJ; Al-Zoughbi, W; Kroneis, T; Abuja, P; Zatloukal, K; Gerger, A; El-Heliebi, A 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 2.20
Translational Molecular Imaging Agents forin-vitro and in-vivo Applications Wadsak, W; Bamminger, K; Nehring, T; Weiss, T; Pichler, V; Kenner, L; Hacker, M 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 2.21
Biomarkers in cardiometabolic health and disease Sourij, C; Tripolt, N; Kojzar, H; Pferschy, P; Aziz, F; Obermayer, AM; Pöttler, T; Aberer, F; Sourij, H 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 3.20
Biomarkers in Acute Cardio-Reno-Metabolic Disease States Pflanzl-Knizacek, L; Bergmoser, K; Pein, L; Ballach, M; Hafner, M; Mattersdorfer, K; Schilcher, G; Eller, P; Baumgartner, C; Hebenstreit, E; Ellmerer, M; Sourij, H; Pieber, TR 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 3.21
Diagnostic and predictive biomarkers in disorders of fertility and metabolism Haudum, CW; Ascani, A; Borzan, V; Goschnik, M; Gumpold, R; Schweighofer, N; Obermayer-Pietsch, B 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 3.22
Microbiome-based Biomarkers Horvath, A; Feldbacher, N; Stradner, M; Stadlbauer, V 4th International CBmed Biomarker Conference on Personalized Drug Screening and Monitoring in Oncology, Graz, Austria 3. April 3 April 2019 3.23
Mikrobiom und Medikamenteninteraktionen Stadlbauer, V Verdauungstag; APR 5, 2019; Wien. 2019. 5 April 2019 3.23
Medikamente und Darmflora – verträgt sich das? Stadlbauer, V Verdauungstag; APR 5, 2019; Wien. 2019. 5 April 2019 3.20
Breaking the Wall of Clinical Biomarker Research Herbsthofer, L Falling Walls Lab Austria. 9. April 2019 9 April 2019 1.23
Blick ins Gehirn: Was sieht der Neuropathologe? Haybaeck, J Woche des Gehirns; MAR 11, 2019; Innsbruck, AUSTRIA. 2019. 11 March 2019 2.5
Rapid testing for Candida and Aspergillus Prattes, J Fungal Update 2019; MAR 14-15, 2019; London, UK. 2019. 14–15 March 2019 3.11
Salz oder kein Salz bei Zirrhose? Stadlbauer, V Frühling der Hepatologie; MAR 16, 2019; Graz. 2019. 16 March 2019 3.23
Neues aus der Pathologie aus der Praxis für die Praxis Haybaeck, J Klinisch-pathologischer Workshop; MAR 1-2, 2019; Magdeburg, GERMANY. 2019. 1–2 March 2019 2.5
Was kann ein molekulares Tumorboard leisten? Haybaeck, J Klinisch-pathologischer Workshop; MAR 1-2, 2019; Magdeburg, GERMANY. 2019. 1–2 March 2019 2.5
Relevance of sample quality in personalized medicine. Zatloukal, K Cancer-Related Biobanks: a Value for Translational Research and Precision Oncology; MAR 21, 2019; Milan, ITALY. 2019. 21 March 2019 1.22
Multicenter clinical experience of real life Dalbavancin use in gram-positive infections _x000D_ Wunsch, S; Krause, R; Valentin, T; Prattes, J; Janata, O; Lenger, A; Bellmann-Weiler, R; Weiss, G; Zollner-Schwetz , I_x000D_ 13. Österreichischer Infektionskongress; March 27-30, 2019; Saalfelden, Austria. 2019. 27–30 March 2019 3.11
Durch Zecken übertragene bakterielle Infektionen Zollner-Schwetz,I 13. Österreichischer Infektionskongress; March 27-30, 2019; Saalfelden, Austria. 2019. 27–30 March 2019 3.11
Serum 1,3-beta-D-Glucan values during and after laparoscopic and open intestinal surgery Szyszkowitz A, Zurl C, Herzeg A, Berger A, Gemes G, Mitteregger M, Prüller F, Prattes J, Zollner-Schwetz I, Valentin T, Hoenigl M, Krause R 13. Österreichischer Infektionskongress; MAR 27-30,2019; Saalfelden, AUSTRIA. 27–30 March 2019 3.11
T2Candida Magnetic Resonance in Patients with Invasive Candidiasis: Strengths and Limitations in a Real World Setting Zurl C, Prattes J, Zollner-Schwetz I, Valentin T, Rabensteiner J, Wunsch S, Hoenigl M, Krause R 13. Österreichischer Infektionskongress; MAR 27-30,2019; Saalfelden, AUSTRIA. 27–30 March 2019 3.11
Immuntherapie und Mikrobiom Stadlbauer, V 36. Ernährungskongress des Verbands der Diaetologen Österreichs ; MAR 29, 2019; Wien. 2019. 29 March 2019 3.23
Management leberspezifischer Symptome Stadlbauer, V UPDATE XV Chronisch entzündliche Darmerkrankungen und Hepatologie; MAR 29-30, 2019; Leoben. 2019. 29-30 March 2019 3.23
Pathohistologische Grundlagen der Urinzytologie Haybaeck, J 206. Fort- und Weiterbildungsseminar Urinzytologie in Praxis und Klinik; MAR 30, 2019; Magdeburg, GERMANY. 2019. 30 March 2019 2.5
PREDICTORS OF LONG-TERM HIV PrEP ADHERENCE AFTER TRIAL_x000D_ PARTICIPATION IN MSM Hoenigl, M; Hassan, A; Moore, D; Anderson, P; Corado, K; Dube, M; Ellorin, E; Blumenthal, J; Morris, SR; for the California Collaborative Treatment Group (CCTG) 601 Team 26th Conference on Retroviruses and Opportunistic Infections (CROI); MAR 4-7, 2019; Seattle, USA. 4–7 March 2019 3.11
PLASMA (1→3)-Β-D-GLUCAN LEVELS CORRELATE WITH NEUROCOGNITIVE PERFORMANCE IN HIV Hoenigl, M; Letendre, S; Iudicello, J; Franklin, D; Porrachia, M; Vargas, M; Ellis, RJ; Finkelman, M; Gianella, S . 2019; -26th Conference on Retroviruses and Opportunistic Infections (CROI); MAR 4-7, 2019; Seattle, USA. 4–7 March 2019 3.11
BENEFICIAL EFFECTS OF CANNABIS ON BLOOD-BRAIN BARRIER AND INFLAMMATION IN HIV Ellis, RJ; Iudicello, J; Morgan E; Henry, B; Schrier, R; Cherner, M; Hoenigl, M; Letendre, SL 26th Conference on Retroviruses and Opportunistic Infections (CROI); MAR 4-7, 2019; Seattle, USA. 4–7 March 2019 3.11
EBV AND CMV LEVELS IN BLOOD ARE ASSOCIATED WITH NON-AIDS EVENTS DURING ART. Gianella, S; Moser, C; Vitomirov, A; McKhann, A; Layman, L; Scott, B; Lada, S; Bosch, R; Hoenigl, M; Lurain, N; Landay, A; Lederman, MM; Hunt, PW; Smith DM 26th Conference on Retroviruses and Opportunistic Infections (CROI); MAR 4-7, 2019; Seattle, USA. 4–7 March 2019 3.11
GEOSPATIAL DISPERSAL OF HIV-1 TRANSMISSION IN 6 MAJOR CITIES IN GERMANY. Stecher, M; Chaillon, A; De Leuw, P; Bogner, J; Eis-Hübinger, AM; Lehmann, C; Behrens, G; Degen, O; Spinner, CD; Stephan, C; Vehreschild, JJ; Mehta, SR; Hoenigl, M_x000D_ 26th Conference on Retroviruses and Opportunistic Infections (CROI); MAR 4-7, 2019; Seattle, USA. 4–7 March 2019 3.11
PRETREATMENT HIV DRUG RESISTANCE SPREAD IN 6 GERMAN METROPOLITAN REGIONS. Stecher, M; Hoenigl, M; De Leuw, P; Eberle, J; Wasmuth, JC; Behrens, G; Schäfer, G; Spinner, CD; Stephan, C; Knops, E; Metha, S; Vehreschild, JJ; Chaillon, A_x000D_ 26th Conference on Retroviruses and Opportunistic Infections (CROI); MAR 4-7, 2019; Seattle, USA. 4–7 March 2019 3.11
Biomarkers and Novel Study Endpoints of Interest Hoenigl, M; Freeman, M; Gianella, S 2019 Annual AIDS CLINICAL TRIAL GROUP (ACTG) Scientific Retreat; MAR 8, 2019; Seattle, USA. 2019. 8 March 2019 3.11
Chairman in Gynäkopathologie-Session Haybaeck, J Frühjahrstagung der Österreichischen Gesellschaft für Pathologie (OeGPath); MAR 9, 2019; 2019. 9 March 2019 2.5
HPV in neuroendocrine neoplasms Haybaeck, J 10th Scientific Exchange Meeting on Neuroendocrine Tumours; FEB 14-15, 2018; Hamburg, GERMANY. 2019. 14–15 February 2019 2.5
Chairman der Session 1 Haybaeck, J 10th Scientific Exchange Meeting on Neuroendocrine Tumours; FEB 14-15, 2019; Hamburg, GERMANY. 2019. 14–15 February 2019 2.5
Einfluss von Medikamenten auf das Mikrobiom Stadlbauer, V Interne Fortbildung BHB Wien; FEB 20, 2019; Wien. 2019. 20 February 2019 3.23
Chronische Medikamenteneinnahme: _x000B_Der säurefreie Magen Stadlbauer, V DEPROM 2019; FEB 22-23, 2019; Berlin. 2019. 22–23 February 2019 3.23
Rückblick BMSD 2018 Stadlbauer, V DEPROM 2019; FEB 22-23, 2019; Berlin. 2019. 22–23 February 2019 3.23
Das Mikrobiom bei chronischen Lebererkrankungen Stadlbauer, V Fachakademie für Ärzte; MAY 23-24, 2019; Graz. 2019. 23–24 February 2019 3.23
Knochentumoren – Basiskurs mit MOPA Haybaeck, J; Roessner, A 55. Symposium der Internationalen Akademie für Pathologie, Deutsche Abteilung e.v.; FEB 24, 2019; Bonn, GERMANY. 2019. 24 February 2019 2.5
Molekulares Tumorboard- Gensequenzierung, BRCA, Chemosensitivitätstestung – individualisierte Therapie bei Prostatakarzinom Haybaeck, J Qualitätszirkel des DKG-zertifizierten Prostatakrebszentrums des Universitätsklinikums Magdeburg; FEB 27, 2019; Magdeburg, GERMANY. 2019. 27 February 2019 2.5
Aktuelles zu Neuroendokrinen Neoplasien Haybaeck, J 18. Onkologische Wintergespräche; JAN 18, 2019; Salzburg, AUSTRIA. 2019. 18 January 2019 2.5
Differentialdiagnose der hepatischen Steatosen Haybaeck, J Leber im Zentrum, Expertenmeeting Nord-Ost; JAN 19, 2019; Lübeck, GERMANY. 2019. 19 January 2019 2.5
Yield of Universal HIV and HCV Screening at San Diego Emergency Departments._x000D_ Hoenigl, M; Coyne, C; Blumenthal, J Vilke, G; Little, S_x000D_ 2019 Miami Winter Symposium; JAN 27-30, 2019; Miami, USA. 27–30 January 2019 3.11
Sustainability of HIV (re)linkage to care following universal ED HIV screening._x000D_ Hoenigl, M; Coyne, C; Blumenthal, J; Wagner, G; Horton, L; McCauley, M; Vilke, G; Little, S Miami Winter Symposium; JAN 27-30, 2019; Miami, USA. 27–30 January 2019 3.11
PPI und Mikrobiom Stadlbauer, V. Bezirksärztetagung Graz Umgebung; JAN 28, 2019; Friesach, Austria. 2019. 28 January 2019 3.23
Management der Immunsuppression nach Lebertransplantation Stadlbauer, V LTX Kurs ; JAN 31-FEB 1, 2019; Innsbruck, Austria. 2019. 31 January–1 February 2019 3.23
Aktuelles zu Neuroendokrinen Neoplasien Haybaeck. J Jahrestreffen des Arbeitskreises Neuroendokrine Tumore; JAN 9, 2019; Magdeburg, DEUTSCHLAND. 2019. 9 January 2019 2.5
GLP-1 Receptor Scintigraphy helpful in the Localization Diagnostics of insulin-producing neuroendocrine Tumors – A Case Report Hetzel, V; Treiber, G; Rainer, F; Aberer, F; Sourij, H WIEN KLIN WOCHENSCHR. 2019; 131: S435-S435. 2019 3.20
Association of serum glucose levels with disease free survival in soft tissue sarcoma patients Aziz, F; Stelzl, A; Riedl, JM; Smolle, MA; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stoger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Szkandera, J; Sourij, H DIABETOLOGIA. 2019; 62: S562-S563. 2019 2.2
Glucose impairment and early diastolic dysfunction in a large cohort at cardiovascular risk Haudum, CW; Kolesnik, E; Schweighofer, N; Colantonio, C; Pieske, B; Schmidt, A; Zirlik, A; Obermayer-Pietsch, B; Pieber, TR DIABETOLOGIA. 2019; 62: S516-S516. 2019 3.22
THE IMMUNE REGULATION COHORT STUDY ALTERATIONS IN LYMPHOCYTE SUBPOPULATIONS IN TRANSPLANT-LISTED DIALYSIS PATIENTS COMPARED TO HEALTHY CONTROLS Kirsch, A; Prietl, B; Strauch, M; Pieber, TR; Muller, H; Schemmer, P; Rosenkranz, AR; Sourij, H; Eller, K TRANSPL INT. 2019; 32: 9-9. 2019 1.22
A clinical Decision Support System for Basal Bolus Insulin Therapy in Routine Inpatient Care: Proven Efficacy, Safety, and User Adherence Lichtenegger, KM; Aberer, F; Tuca, AC; Donsa, K; Holl, B; Schaupp, L; Beck, P; Fruhwald, F; Plank, J; Pieber, TR; Mader, JK WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S466-S466. 2019 3.20
Performance of the Freestyle (R) Libre intermittently-viewed continuous glucose monitoring (iCGM) system in people with type 1 diabetes: hypoglycaemia and acute exercise remain the Achilles’ heel Moser, O; Eckstein, M; McCarthy, O; Rachel, D; Pitt, J; Williams, D; Hayes, J; Sourij, H; Bain, S; Bracken, R WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S478-S479. 2019 3.20
Effects of an eight-week Endurance Training on Fructosamine Content in People with Type 1 Diabetes Muller, A; Moser, O; Eckstein, ML; Birnbaumer, P; Aberer, F; Kohler, G; Sourij, C; Kojzar, H; Pferschy, P; Hofmann, P; Sourij, H WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S483-S483. 2019 3.20
Diabetes is a predictor for survival in soft tissue sarcoma patients Aziz, F; Stelzl, A; Riedl, J; Smolle, M; Stojakovic, T; Posch, F; Terbuch, A; Pichler, M; Leithner, A; Stoger, H; Liegl-Atzwanger, B; Stotz, M; Gerger, A; Szkandera, J; Sourij, H WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5):S477-S477. 2019 3.20
Diastolic Dysfunction in a large cardiovascular Risk Cohort and Conversion to Type 2 Diabetes mellitus Haudum, C; Kolesnik, E; Schweighofer, N; Colantonio, C; Pieske, B; Schmidt, A; Obermayer-Pietsch, B; Pieber, TR WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S468-S468. 2019 3.22
A randomized, double-blind, placebo-controlled pilot study on the effects of a multispecies synbiotic in diabesity Horvath, A; Leber, B; Feldbacher, N; Tripolt, N; Rainer, F; Blesl, A; Trieb, M; Marsche, G; Sourij, H; Stadlbauer, V WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S470-S470. 2019 3.23
Evolocumab in clinical Practice in Austria in Comparison to Total Evaluation from 10 Countries: 12-Month Interim Data Ebenbichler, C; Kedenko, L; Hanusch, U; Sourij, H; Drexel, H; Prager, R; Hemetsberger, M; Ratzinger, M; Toplak, H WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S465-S466. 2019 3.20
Quantification of Type 1 Diabetes in Professional Cycling: Prospective Analysis of a 9-day Training Camp Eckstein, ML; McCarthy, O; Bracken, R; Sourij, H; Moser, O WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S481-S481. 2019 3.20
The GlucoTab (R) System in Routine Use to Support Diabetes Management for Patients with Diabetes Mellitus Type 2 in a regional Hospital Kopanz, J; Lichtenegger, KM; Konig, C; Libiseller, A; Mader, JK; Donsa, K; Truskaller, T; Bauer, N; Hahn, B; Sendlhofer, G; Beck, P; Sinner, F; Feichtner, F; Pieber, TR WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S467-S467. 2019 3.20
GlucoTab@MobileCare – The Potential of Decision Support to Reduce Hospital Admissions and inpatient Admissions Libiseller, A; Kopanz, J; Lichtenegger, KM; Donsa, K; Truskaller, T; Lackner, B; Aberer, F; Pandis, M; Reinisch-Gratzer, J; Ambrosch, GC; Sinner, F; Pieber, TR; Mader, JK WIEN KLIN WOCHENSCHR. 2019; 131(SUPPL 5): S469-S469. 2019 3.20
Information Retrieval for Precision Oncology Lopez-Garcia, P; Oleynik, M; Kasáč, Z; Schulz, S ÖPPM – Gemeinsame Impulse für Personalisierte Medizin_x000D_ 2. Jahrestagung. 2018; -ÖPPM – Gemeinsame Impulse für Personalisierte Medizin_x000D_ 2. Jahrestagung; OCT 11-12, 2018; Graz, AUSTRIA. 11–12 October 2018 1.2
Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients receiving Mold-active Antifungals: Performance of Interleukins 6 and 8, Asp LFD, and Aspergillus PCR in Same Day Blood and Bronchoalveolar Lavage Fluid Samples. Hoenigl, M; Heldt, S; Prattes, J; Eigl, S; Spiess, B; Johnson, G; Krause, R; Buchheidt, D_x000D_ ID Week; OCT 3-7, 2018; San Francisco, USA. 3–7 October 2018 3.11
Elevated expression of IMP-1 in thyroid cancer Bracic, S; Kessler, S; Krassnig, S; Gantenbein, N; Mangge, H; Gruber, HJ; Haybaeck, J Virchows Archive. 2018; -30th European Conference of Pathology, Pathology: Path to Precision medicine; SEP 10, 2018; Bilbao, SPAIN. 10 September 2018 2.5
eIF6 is overexpressed in melanoma of the the skin and might be a novel therapeutic target Bracic, S; Woltsche, N; Krassnig, S; Seeboeck, R; Zalaudek, I; Haybaeck, J Virchows Archive. 2018; -30th European Conference of Pathology, Pathology: Path to Precision medicine; SEP 9, 2018; Bilbao, SPAIN. 9 September 2018 2.5
IL-2 Signaling is Specifically Impaired in Regulatory T Cells From T1D Patients Prietl, B; Kofler, S; Stanzer, S; Obermayer-Pietsch, B; Pieber, TR; Sourij, H Proceedings. 2018; -78th scientific session of the American Diabetes Association; June 22-26, 2018; Orlando, USA. 22–26 June 2018 1.6
Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Eigl, S; Prattes, J; Boch, T; Buchheidt, D; Hoenigl M ISHAM 2018 Ira F. Salkin Award Lecture; Jun 30 – JUL 4, 2018; Amsterdam, NETHERLANDS. 30 June–4 July, 2018 3.11
Expression levels of eukaryotic initation factors are altered in paediatric medulloblastoma Krassnig, S; Baehr, A; Schinlauer, A; Golob-Schwarzl, N; Wodlej, C; Raicht, A; Speicher, I; Poehlmann-Nitsche, A; Asslaber, M; Mawrin, C; Benesch, M; Haybaeck, J Der Pathologe 39: 89-89. 2018; -102. Jahrestagung der Deutschen Gesellschaft für Pathologie; MAY 24-26, 2018; Berlin, GERMANY. 24–26 May 2018 2.5
Molecular expression analysis reveals potential of translation initiation factors to serve as novel biomarkers for aggressive B-cell lymphomas. Unterluggauer, J; Prochazka, K; Tomazic, PV; Huber, HJ; Seeboeck, R; Fechter, K; Steinbauer, E; Gruber, V; Rinner, B; Pichler, M; Weniger, M; Kueppers, R; Sill, H; Schicho, R; Neumeister, P; Beham-Schmid, C; Deutsch, A; Haybaeck, J; Der Pathologe 39:67-68. 2018; -102. Jahrestagung der Deutschen Gesellschaft für Pathologie; MAY 24-26, 2018; Berlin, GERMANY. 24–26 May 2018 2.5
Die Rolle von eukaryotischen Translations-Initiationsfaktoren als potentielles neues therapeutisches Target beim Neuroblastom Wodlej, C; Krassnig, S; Golob-Schwarzl, N; Herzl, A; Kleinegger, F; Birkl-Toeglhofer, AM; Gantenbein, N; Speicher, I; Singer, G; Till, H; Izycka-Swieszewska, E; Czapiewski, P; Haybaeck, J; Der Pathologe 39: 94-94. 2018; -102. Jahrestagung der Deutschen Gesellschaft für Pathologie; MAY 24-26,2018; Berlin, GERMANY. 24–26 May 2018 2.5
Die Rolle des Interleukin-6 Rezeptors im Zuge der Cholangiozellulären Karzinogenese. Kleinegger, F; Wodlej, C; Golob-Schwarzl, N; Birkl-Töglhofer, AM; Krassnig, S; Niedrist, T; Thalhammer, M; Aigelsreiter, A; Rose-John, S; Fickert, P; Rinner, B; Haybäck, J; Jahrestagung der Deutschen Gesellschaft für Pathologie. 2018; -102. Jahrestagung der DGP; MAI 24-28, 2018; Berlin. 24–28 May 2018 2.5
Classic and Trans Interleukin-6 Signaling Promotes Cholangiocarcinoma Kleinegger, F; Wodlej, C; Golob-Schwarzl, N; Birkl-Töglhofer, AM; Krassnig, S; Niedrist, T; Thalhammer, M; Aigelsreiter, A; Rose-John, S; Fikert, P; Rinner, B; Haybäck, J; 6th International Students Congress. 2018; -6th International Students Congress; MAY 31 – JUNE 2; Graz, AUSTRIA. 31 May–2 June, 2018 2.5
Circulating Nucleic Acids as Early Diagnostic Markers for Sepsis Ullrich, E; Heidinger, P; Villanova, L; Soh, J; Bachler, T; Hirschböck, E; Leitner, E; Sensen, C; Krause, R 12. Österreichischer Infektionskongress; APR 11-14, 2018; Saalfelden, Austria. 11–14 April 2018 3.11
The microbiome of ascites is distinctly different from stool and skin mircobiome in patients with liver-cirrhosis. Mannert, L; Klymiuk, I; Krause, R; Prattes, J; Zollner-Schwetz, I 12. Österreichischer Infektionskongress; APR 11-14, 2018; Saalfelden am Steinernen Meer, AUSTRIA. 11–14 April 2018 3.11
Generische Candine: Brauchen wir Fluconazol noch in der Candida Therapie? Prattes, J 12. Österreichischer Infektionskongress ; APR 11-14, 2018; Saalfelden am Steinernen Meer, AUSTRIA. 11–14 April 2018 3.11
Metabolomics as platform technology for biomarker research Bordag N., Jacan A., Stalz H., Klimacek M., Zügner E., Trausinger G., Magnes M. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.5
Core Lab Digital Pathology Dolznig I., Tomberger M., Rohban R., Tangermann S., Kenner L., Wadsak W., Pieber T. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.8
Next generation sequencing-based biomarkers in molecular pathology Oberauner-Wappis L., Abuja P., Ulz C., Loibner M., Grölz D., Krenz T., Wieczorek G., Oelmüller U., Zatloukal K. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.4
HTA-type early assessment of biomarkers Schmidt L., Neubauer S., König C., Pieber T. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.7
Innovative use of Information for Clinical Care and Biomarker Research Schulz, S. et al. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.2
Development of a MALDI-MS based clinical applications platform Stübiger G., Herzig B., Wuczkowski M., Strasser K., Oehler R. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.9
Clinical Data Management for Biomarker Research Tschapeller B., Krainer C., Pieber T. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.1
FUSION Technology – Showcase Study Colon Cancer Stage II Brehme M.; et al. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 2.51
Tracking the Trace: Analysis of Circulating Tumour Cells and mRNA for Androgen Receptors and Splice Variants in Prostate Cancer Smolle M.; et al. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 2.2
Genomic, Transcriptomic and Proteomic Evaluation of Eukaryotic Initiation Factors (eIFs) in Various Tumor Entities Golob-Schwarzl N., Gantenbein N., Wodlej C., Reinhard C., Hoffmann J., Vierlinger K., Haybaeck J. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 2.5
Establishment of autopsy derived xenograft models representing late-stage cancer Viertler C. et al 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 2.7
Core Lab Proteomics & in-vivo Imaging: Biomarker and Radiotracer Development Pencik J. et al 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 2.8
A new method for residual disease detection and identification of GPR56 as a stem cell marker in acute myeloid leukemia Shruti D., Rosenberger A., Krisper N., Prietl B., Heitzer E., Kashofer K., Zebisch A., Sill H., Warner N., Wölfler A. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 2.4
Biomarkers for probiotic effects on microbiome-gut-brain-axis Jacan A., Zenz G., Fröhlich EE., Kashofer K., Mayerhofer R., Reichmann F., Holzer P. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.9
Mycobiota analysis of samples from different body regions in ICU patients Krause R., Horvath L., Halwachs B., Gorkiewicz G., Kashofer K., Moissl-Eichinger C., Koskinen K., Eisner F., von Lewinski D., Högenauer C. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.11
Minimally-invasive biomarkers for liver function Merle DA., Narath SH., Svehlikova E., Ekardt E., Regittnig W., Heise T., Sourij H., Pieber T. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.6
Electrochemical Biomarker Detection in Common Metabolic Disorders Haudum C. W., Siegl I., Christandl G., Holweg G., Obermayer-Pietsch B. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.12
Biomarkers in bone metabolism & related organ systems: Common vitamin D-related genetic variants and vitamin D status in women and men Koschka K., Schweighofer N., Trummer O., Obermayer-Pietsch B. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.4
Biomarkers in the regulation of fertility: Specific Oct1 gene variants are associated with cardiovascular and death risk in metformin users Schweighofer N., Genser B., Maerz W., Kleber M.E., Pieber T., Obermayer-Pietsch B. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.5
Biomarkers in Diabesity: EndoBarrier® in obese subjects with type 2 diabetes: Short- and midterm effects on glucose metabolism Tripolt N., Aberer F., Url J., Högenauer C., Schreiber F., Eherer A., Sourij C., Obermayer A., Stadlbauer-Köllner V., Kojzar H., Pferschy P., Sourij H. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.1
Biosensors for short-living biomarkers Pflanzl-Knizacek L., Bergmoser K., Pein L., Ballach M., Hafner M., Mattersdorfer K., Schilcher G., Eller P., Fruhwald S., Ellmerer M., Sourij H., Pieber T. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.3
Pre-existing cardiovascular comorbidities in patients with type 2 diabetes in a tertiary diabetes centre -GIRO Sourij C., Pferschy P., Tripolt N., Kojzar H., Unteregger C., Weber B., Dzankovic F., Aberer F., Sourij H. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.2
The effect of binge drinking on innate host defense mechanisms Leber B., Horvath A., Schmerböck B., Stadlbauer-Köllner V. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.10
Biomarkers for early sepsis detection Leber B., Horvath A., Komarvoa I., Schmerböck B., Klymiuk I., Durdevic M., Rainer F., Blesl A., Stiegler P., Stadlbauer-Köllner V. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.10
Fluid balance as a biomarker for critically ill patients Mattersdorfer K., Pflanzl-Knizacek L., Bergmoser K., Hafner M., Sourij H. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.3
Quantification of dilutional effects in biomarkers caused by fluid management in critically ill Hafner M., Pflanzl-Knizacek L., Mattersdorfer K., Pein L., Bergmoser K., Sourij H. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.3
Assessing the kidney’s function in the ICU – dilutional effects on biomarkers Pein L., Pflanzl-Knizacek L., Mattersdorfer K., Schober M., Bergmoser K., Hafner M., Schilcher G., Eller P. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 3.3
Immunology Platform for Biomarker Research Prietl B., Lechner E., Kofler S., Krisper N., Pfeifer V., Pieber T. 3rd CBmed Biomarker Conference, Vienna, 2018 14–16 March 2018 1.6
Siderophore-mediated diagnosis of invasive aspergillosis in urine samples. Orasch, T; Prattes, J; Faserl, F; Lindner, H; Loeffler, J; Springer, J; Reischies, F; Duettmann, W; Raggam, RB; Rabensteiner, J; Hoenigl, M; Haas, H 8th Advances Against Aspergillosis; FEB 1-3, 2018; Lisbon, PORTUGAL. 1–3 February 2018 3.11
Eukaryotic Translation Initiation Factors and Their Potential Role as Targets in Neuroblastoma Wodlej, C; Krassnig, S; Golob-Schwarzl, N; Kleinegger, F; Birkl-Toeglhofer, AM; Sygulla, S; Singer, G; Till, H; Izycka-Swieszewska, E; Czapiewski, P; Haybaeck, J Proceedings of the Doctoral Day. 2017; -Doctoral Day; Graz, AUSTRIA. 13 December 2017 2.5
Eukaryotic Translation Initiation Factors and Their Potential Role as Targets in Neuroblastoma Wodlej, C; Krassnig, S; Golob-Schwarzl, N; Kleinegger, F; Birkl-Toeglhofer, AM; Sygulla, S; Singer, G; Till, H; Izycka-Swieszewska, E; Czapiewski, P; Haybaeck, J Proceedings of the Doctoral Day. 2017; -Doctoral Day; Graz, AUSTRIA. 13 December 2017 2.5
Glukosestoffwechsel nach einem Fasttag und nach einem Esstag bei gesunden Alternate Day Fasting praktizierenden Personen Tripolt, N; Stekovic, S; Aberer, F; Url, J; Pferschy, P; Obermayer-Pietsch, B; Pieber, T; Madeo, F; Sourij, H Wiener klinische Wochenschrift 129 (Suppl. 4). 2017; 178-178.-Jahrestagung Österreichische Diabetesgesellschaft (ÖDG); Salzburg, AUSTRIA. 16–18 November 2017 3.2
Untersuchung des Benefits der adjuvanten Radiotherapie in Bezug auf Lokalkontrolle, Fernmetastasierung und Überleben bei PatientInnen mit lokalisiertem Weichteilsarkom mittels vergleichender Effektivitätsanalyse Partl R, Posch F, Döller C, Riedl JM, Smolle M, Leitner L, Bergovec M, Liegl-Atzwanger B, Stotz M, Bezan A, Gerger A, Pichler M, Kapp KS, Stöger H, Leithner A, Szkandera J Abstractband. 2017; -34. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie, Radiobiologie und Medizinische Radiophysik ; Linz, AUSTRIA. 6–7 October 2017 2.2
Levels of interleukin-­6 and ­-8 in serum and bronchoalveolar lavage fluid are elevated in haematological malignancy patients with invasive pulmonary aspergillosis: A nested case control study. Heldt, S; Eigl, S; Prattes, J; Flick, H; Rabensteiner, J; Prueller, F; Niedrist, T; Neumeister, P; Obersteiner, S; Ober, J; Wölfler, A; Krause, R; Strohmaier, H; Hoenigl, M 8th Trends in Medical Mycology; Belgrade, SERBIA. 6–9 October 2017 3.11
Metabolic phenotyping of first degree relatives of patients with type 1 diabetes Zügner EE; Treiber G; Prietl, B; Gander E; Bordag N; Magnes C; Pieber, TR 53rd Annual Meeting of the European Association for the Study of Diabetes; Lisbon, Portugal 11–15 September 2017 1.6
Response to IL-2-signaling in Tregs is specifically impaired in type 1 diabetes Prietl, B; Kofler, S; Stanzer, S; Brezinschek, HP; Münzker, J; Pieber, TR; Sourij H 53rd Annual Meeting of the European Association for the Study of Diabetes; Lisbon, Portugal 11–15 September 2017 1.6
Eukaryotic initiation factors might not only represent novel targets for glioma therapies but might also monitor drug effectiveness Haybaeck, J Abstract book and Virchows Archive. 2017; -29th European Congress of Pathology: Pathology for Patient Care; Amsterdam, NETHERLANDS. 2–6 September 2017 2.5
Interleukin-6 Receptor Influences Cholangiocarcinoma Progression. Kleinegger, F; Golob-Schwarzl, N; Toeglhofer, AM; Baran, P; Niedrist, T; Krassnig, S; Speicher, I; Rinner, B; Thalhammer, M; Aigelsreiter, A; Scheller, J; Rose-John, S; Fickert, P; Haybäck, J; Proceedings of the 29th European Congress of Pathology. 2017; -29th European Congress of Pathology; Amsterdam, THE NETHERLANDS. 2–6 September 2017 2.5
Eukaryotic initiation factors are altered in Alzheimer’s disease. Toeglhofer, AM; Krassnig, S; Golob-Schwarzl, N; Wodlej, C; Birkl, C; Kalev, O; Leoni, M; Flunkert, S; Hutter-Paier, B; Weis, S; Haybaeck, J; Proceedings of the 29th European Congress of Pathology. 2017; -29th European Congress of Pathology; Amsterdam, THE NETHERLANDS. 2–6 September 2017 2.5
Eukaryotic initiation factors might not only represent novel targets for glioma therapies but might also monitor drug Kraßnig, S; Orthmann, A; Toeglhofer, A; Wohlrab, C; Golob-Schwarzl, N; Wodlej, C; Pennauer, M; Raicht, A; Mahdy Ali, K; von Campe, G; Gogg-Kamerer, M; Leoni, M; Sygulla, S; Hoffmann, J; Weis, S; Benesch, M; Haybaeck, J European Congress of Pathology, Amsterdam 2–6 September 2017 2.5
Levels of Interleukin-6 and -8 in bronchoalveolar lavage fluid are elevated in haematological patients with invasive pulmonary aspergillosis: A case control study. Heldt, S; Eigl, S; Prattes, J; Rabensteiner, J; Flick, H; Neumeister, P; Niedrist, T; Ober, J; Obersteiner, S; Prueller, F; Strohmaier, H; Krause, R; Wölfler, A; Hoenigl, M 51. Wissenschaftliche Tagung der Deutschsprachigen Mykologischen Gesellschaft e. V.; Münster, GERMANY. 31 August–2 September 2017 3.11
Unsupervised expansion of clinical abbreviations M Oleynik, M Kreuzthaler, S Schulz MEDINFO 2017 August 2017 1.2
Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors Golob-Schwarzl, N; Schweiger, C; Koller, C; Kraßnig, S; Gogg-Kamerer, M; Gantenbein, N; Bergler, H; Pertschy, B; M; Uranitsch, S; Lackner, K; Punschart, A; Stiegler, P; Keil, M; Hoffmann, J; Henderson, D; Lehrach, H;Regenbrecht,C; Reinhard, CH; Schicho, R; Fickert, P; Lax, S; Haybaeck, J Jahrestagung der deutschen Pathologie Gesellschaft 22–24 June 2017 2.5
Eukaryotic initiation factors might be a relevant target for the development of new glioma therapies Kraßnig, S; Wohlrab, C; Orthmann, A; Golob-Schwarzl, N; Toeglhofer, A; Wodlej, C; Pennauer, M; Raicht, A; Mahdy Ali, K; von Campe, G; Leoni, M; Sygulla, S; Hoffmann, J; Weis, S; Benesch, M; Haybaeck, J Jahrestagung der Deutschen Gesellschaft für Pathologie 22–24 June 2017 2.5
Die Expression des Interleukin 6 Rezeptors hat Auswirkungen auf das Cholangiozelluläre Karzinom. Kleinegger, F; Golob-Schwarzl, N; Toeglhofer, AM; Krassnig, S; Niedrist, T; Speicher, I; Rinner, B; Thalhammer, M; Aigelsreiter, A; Lackner, C; Rose-John, S; Fickert, P; Haybaeck, J; 101. Jahrestagung der deutschen Gesellschaft für Pathologie . 2017; Erlangen, GERMANY. 22–24 June 2017 2.5
Adherence and Risk for Incident Sexually Transmitted Infection among Methamphetamine using Men who have Sex with Men on HIV Pre-Exposure Prophylaxis. Hoenigl, M; Jain, S; Sun, X; Moore, D; Anderson, P; Dube, M; Collins, D; Corado, K; Morris, SR; for the California Collaborative Treatment Group (CCTG) 595 Team. ADHERENCE 2017; Miami, United States. 4–6 June 2017 3.11
NEUROBEHAVIORAL ALTERATIONS, BUT NOT ILLICIT SUBSTANCE USE, HAVE A NEGATIVE IMPACT ON LINKAGE TO HIV PRE-EXPOSURE PROPHYLAXIS. Hoenigl, M; Morgan, E; Franklin, D; Heaton, R; Dawson, M; Hanashiro, M; Ellorin, E; Pasipanodya, E; Morris, S; Moore, D; for the California Collaborative Treatment Group (CCTG) 601 Team. ADHERENCE 2017; Miami, United States. 4–6 June 2017 3.11
Eukaryotic initiation factors might represent a novel marker to monitor the effectiveness of glioma therapy Kraßnig, S; Orthmann, A; Wohlrab, C; Golob-Schwarzl, N; Toeglhofer, A; Wodlej, C; Pennauer, M; Raicht, A; Mahdy Ali, K; von Campe, G; Gogg-Kamerer, M; Leoni, M; Sygulla, S; Hoffmann, J; Weis, S; Benesch, M; Haybaeck, J Brain Tumor Meeting, Berlin 18–19 May 2017 2.5
Eukaryotic Translation Initiation is Critical in Gliomagenesis Haybaeck, J Abstract Book: Session 302: Neuro Oncology and Brain Tumors; Chairman of this session. 2017; -BIT´s 8th Annual World Congress of Neurotalk 2017; Barcelona, SPAIN. 22–24 May 2017 2.5
Eukaryotic Translation Initiation Factors trigger Non Small Cell Lung Cancer (NSCLC) Gantenbein, N; Bernhart, E; Anders, I; Golob-Schwarzl, N; Lindenmann, J; Fink-Neuboeck, N; Brcic, L; Gollowitsch, F; Stacher-Priehse, E; Rolff, J; Hoffmann, J; Reinhard, C; Popper, H; Sattler, W; Haybaeck, J International Student Congress, Graz 25–27 May 2017 2.5
Eukaryotic Translation Initiation Factors Might Represent Novel Targets in Neuroblastoma Wodlej, C; Kraßnig, S; Golob-Schwarzl, N; Sygulla, S; Singer, G; Till, H; Izycka-Swieszewska, E; Czapiewski, P; Haybaeck, J International Student Congress, Graz 25–27 May 2017 2.5
Immune-phenotyping for local nanomedical applications Prietl, B; Mautner, S; Birngruber, T Conference proceedings of the 10th European and global summit for clinical nanomedicine and targeted medicine. 2017; -10th European and global summit for clinical nanomedicine and targeted medicine; Basel, Switzerland. 7–10 May 2017 1.6
Semantic Technologies for Re-Use of Clinical Routine Data K Kreuzthaler, C Martínez-Costa, P Kaiser, S Schulz eHealth 2017 May 2017 1.2
Development and Validation of a Multivariable Prediction Model for the Occurrence of Delirium in Hospitalized Gerontopsychiatry and Internal Medicine Patients D Kramer, S Veeranki, D Hayn, F Quehenberger, W Leodolter, C Jagsch and G Schreier eHealth 2017 May 2017 1.2
Progress in knowledge on antimicrobial therapy from medical students to specialists Prattes, J; Reischies, F; Zollner-Schwetz, I 21st Graz Conference on Medical Education 2017; Szeged, HUNGARY. 20–22 April 2017 3.11
Levels of IL-6, IL-8, IL-10 and IL-17A in serum and IL-8 in bronchoalveolar lavage fluid are elevated in haematological patients with invasive pulmonary aspergillosis Heldt, S; Eigl, S; Prattes, J; Flick, H; Rabensteiner, J; Neumeister, P; Prueller, F; Strohmaier, H; Krause, R; Wölfler, A; Hoenigl, M 27th ECCMIDLive Programme Overview, Session Diagnostic mycology I, Abstract and ePoster. 2017; -27th European Congress of Clinical Microbiology and Infectious Diseases; Vienna, AUSTRIA. 22–25 April 2017 3.11
Evaluation of a new multiplex PCR kit for detection of clinically relevant Aspergillus species in BAL fluid Prattes, J; Hönigl, M; Zinke, SEM; Eigl, S; Johnson, G; Bustin, S; Stelzl, E; Kessler, H 27th ECCMID; Vienna, AUSTRIA. 22–25 April 2017 3.11
Application of the GeneReader NGS system in analyzing a diverse set of cancer samples Lisa Oberauner-Wappis, Martina Loibner, Christine Ulz, Peter M. Abuja, Daniel Grölz, Tomasz Krenz, Georg AMP Global Meeting (Association for Molecular Pathology), Berlin, 3–5 April 17 1.4
Semantic Technologies for Improved Primary and Secondary Use of Clinical Data S Schulz, M Kreuzthaler, D Kramer, W Leodolter, M Pedevilla, B Huppertz, K Sargsyan, D Becker, R Fasching, T Pieber MIE 2017 April 2017 1.2
Phenotypical and Functional Characterization of Normal and Tumor-Infiltrating Immune Cells by Flow Cytometry and Mass Spectrometry Katharina Strasser, Lukas Unger, Elitsa Zareva, Matthias Holzlechner, Hanna Birnleitner, Andrea Beer, Anton Stift, Thomas Bachleitner-Hofmann, Bela Teleky, Martina Marchetti-Deschmann, Michael Bergmann and Rudolf Oehler European Federation for coloRectal Cancer April 2017 1.9
Eukaryotic Initiation factors (eIFs) in colorectal carcinoma  Golob-Schwarzl, N; Schweiger, C; Koller, C; Kraßnig, S; Gogg-Kamerer, M; Gantenbein, N; Bergler, H; Pertschy, B; M; Uranitsch, S; Lackner, K; Punschart, A; Stiegler, P; Keil, M; Hoffmann, J; Henderson, D; Lehrach, H; Reinhard, CH; Schicho, R; Fickert, P; Lax, S; Haybaeck, J 19th International AEK Cancer Congress 2017 1–3 March 2017 2.5
Aspergillus fumigatus induces elevated cytokine-levels in serum and bronchoalveolar lavage fluid of hematological malignancy patients: A prospective study. Heldt, S; Eigl, S; Prattes, J; Rabensteiner, J; Flick, H; Neumeister, P; Prueller, F; Strohmaier, H; Krause, R; Wölfler, A; Obersteiner, S; Hoenigl, M Programmheft 11. Österreichischer Infektionskongress 2017 mit Abstracts. 2017; 55–11. Österreichischer Infektionskongress; Saalfelden, AUSTRIA. 29 March–1 April 2017 3.11
Update Mykologie: Prophylaxe: bei wem, wann und womit? Hoenigl M 11. Österreichischer Infektionskongress; Saalfelden, AUSTRIA. 29 March–1 April 2017 3.11
Eukaryotic initiation factor 4G (eIF4G) is altered in Alzheimer’s disease and might therefore be involved in pathological mechanisms Krassnig, S; Toeglhofer, AM; Golob-Schwarzl, N; Wodlej, C; Kalev, O; Leoni, M; Flunkert, S; Hutter-Paier, B; Weis, S; Haybaeck, J 13th International Conference on Alzheimer’s and Parkinson’s Diseases 29 March–2 April 2017 2.5
CBmed – IICCAB: Semantic Technologies for Re-Use of Clinical Routine Data S Schulz et al. 2nd CBmed Biomarker Conference, Graz 13 February 2017 1.2
Next generation sequencing as a tool in molecular pathology Lisa Oberauner-Wappis, Christine Ulz, Martina Loibner, Georg Wieczorek, Peter M. Abuja, Uwe Oelmüller, Kurt Zatloukal 2nd CBmed Biomarker Conference, Graz 13 February 2017 1.4
Interleukin-2 signalling of regulatory T cells in autoimmunity and cancer Kofler S., Lechner E., Prietl B. 2nd CBmed Biomarker Conference, Graz 13 February 2017 1.6
Core Lab Digital Pathology Dolznig I., Tomberger M., Wael A. 2nd CBmed Biomarker Conference, Graz 13 February 2017 1.8
Clinical Data Management for Biomarker Research – A Show Case Bernd Tschapeller, Christian Krainer, Harald Sourij, Thomas Pieber 2nd CBmed Biomarker Conference, Graz 13 February 2017 1.1
Health Technology Assessment of a biomarker for AML Louise Schmidt, Sandra Neubauer, Constanze König, Thomas Pieber 2nd CBmed Biomarker Conference, Graz 13 February 2017 1.7
Fusion Technology: Colon Cancer Stage 2 Maria A Smolle, Thomas Weber, Isabell Dolznig, Natalie Bordag, Angela Jacan, Lisa Oberauner-Wappis, Barbara Prietl, Wolfgang Wadsak, Brigitte Hantusch, Gerald Stübiger, Armin Gerger 2nd CBmed Biomarker Conference, Graz 13 February 2017 2.51
Analysis of Circulating Tumour Cells and mRNA for Androgen Receptors and Splice Variants in Prostate Cancer Amin El-Heliebi, Maria A Smolle, Armin Gerger, Christian Oberkanins, Michael Novy, Peter Sedelmayr, Christoph Haudum, Erkan Ercan, Thomas Kroneis, Shukun Chen, Mats Nilsson, Jessica Svedlund, Tomasz Krzywkowski, Annika Ahlford, Navya Laxman, Evangelia Darai, Inge Dekruiff, Stephan Jahn, Thomas Bauernhofer 2nd CBmed Biomarker Conference, Graz 13 February 2017 2.2
Graz Diabetes Registry for Biomarker Research – GIRO Caren Sourij1, Norbert Tripolt1, Felix Aberer1, Barbara Weber1, Jasmin Url2, Peter Pferschy2, Harald Kojzar2, Harald Sourij 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.2
Electrochemical Biomarker Detection in Common Metabolic Disorders Haudum C. W., Siegl I. , Holweg G., Obermayer-Pietsch B. 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.12
Project 3.4 n-oxPTH as a potential biomarker in bone and cardiovascular disease V. Francic, S. Ursem, S. Pilz, A. Heijboer, B. Obermayer-Pietsch 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.4
Project 3.5 Specific Oct1 gene variants are associated with CV death risk in metformin users N. Schweighofer, B. Genser, W. Maerz, M.E. Kleber, T.R. Pieber, B. Obermayer-Pietsch 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.5
Advantages of Tracer Technology: Ra Glycerol to assess Lipolysis in T2DM patients Sophie H. Narath, Stefanie Sach-Friedl, Thomas Augustin, Christoph Magnes,Anita Eberl, Werner Regittnig, Michael M. Schober, Thomas R. Pieber 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.6
Effects on the circulating metabolome in an antibiotic-induced mouse dysbiosis model Angela Jačan, Esther E. Fröhlich, Natalie Bordag, Christoph Magnes, Karl Kashofer, Raphaela Mayerhofer, Florian Reichmann, Peter Holzer 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.9
EndoBarrier® in obese subjects with type 2 diabetes: Short-term effects on glucose metabolism – a pilot trial Tripolt NJ, Aberer F, Url J, Högenauer C, Schreiber F, Eherer A, Sourij C, Obermayer AM, Stadlbauer V, Kojzar H, Pferschy PN, Sourij H 2nd CBmed Biomarker Conference, Graz 13 February 2017 3.2
GPR56 expression is high on leukemic stem cells and predicts adverse outcome in AML Shruti Daga, Nina Krisper, Armin Zebisch, Heinz Sill, Albert Wölfler 2nd CBmed Biomarker Conference, Graz 13 February 2017 2.4
SUBSTANCE-USING MSM ON HIV PREEXPOSURE PROPHYLAXIS HAVE GOOD ADHERENCE. Hoenigl, M; Jain, S; Moore, D; Collins, D; Sun, X; Anderson, P; Calvo, K; Dube, M; Morris, SR; for the California Collaborative Treatment Group (CCTG) 595 Team. 24th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, USA. 13–16 February 2017 3.11
REVEALING THE MOLECULAR EPIDEMIOLOGY OF THE COLOGNE, GERMANY, HIV EPIDEMIC. Stecher, M; Hoenigl, M; Vehreschild JJ; Lehmann, C; Faetkenheuer, G; Kaiser, R; Mehta, SR; Chaillon, A 24th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, USA. 13–16 February 2017 3.11
Analysis of Circulating Tumour Cells and mRNA for Androgen Receptors and Splice Variants in Prostate Cancer Amin El-Heliebi, Maria A Smolle, Armin Gerger, Christian Oberkanins, Michael Novy, Peter Sedelmayr, Christoph Haudum, Erkan Ercan, Thomas Kroneis, Shukun Chen, Mats Nilsson, Jessica Svedlund, Tomasz Krzywkowski, Annika Ahlford, Navya Laxman, Evangelia Darai, Inge Dekruiff, Stephan Jahn, Thomas Bauernhofer 2nd CBmed Biomarker Conference, Graz February 2017 2.2
Alterations in eukaryotic translation initiation might contribute to Parkinson’s disease pathology Toeglhofer AM, Krassnig S, Golob-Schwarzl N, Kalev O, Leoni M, Wodlej C, Weis S, Haybaeck J 13th International Conference on Alzheimer’s and Parkinson’s Diseases 2017 2.5
Evaluation of Critical Parameters for the Establishment of a Clinical MALDI Applications Platform for Liquid Biopsy Diagnostics Wuczkowski M, Herzig B, Méndez G, Mancera L, Balika W, Prinz I, Barborini E, Mader R, Stübiger G MSACL 2017 EU, 4th Annual European Congress & Exhibition 2017 1.9
Binding of Complement Component C1q to Secondary Necrotic Cells in vitro and in Multiple Myeloma Patients Ying Yu Liang, Hermine Agis, Rudolf Oehler Keystone Symposia on Molecular and Cellular Biology 2017 1.9
STAT3/LKB1-Dependent Metabolic Reprogramming Dictates Metastatic Potential and Therapeutic Response in Prostate Cancer Pencik J, Javaheri T, Noorizadeh R, Schlederer M, Malcolm T, Turner SD, Hantusch B, Moriggl R, Hacker M, Kenner L 13. Charles Rodolphe Brupbacher Symposium, 2017 2017 2.8
Aberrant STAT3-AMPK signaling targets distinct subgroups of lethal prostate cancer Pencik J, Javaheri T, Schlederer M, Roos S, Oberhuber M, Malcolm T, Turner SD, Moriggl R, Hantusch B, Hartenbach M, Moazzami A, Hacker M, Kenner L Österr. Gesellschaft für Pathol., Herbsttagung 2017 2017 2.8
Identification of diagnostic and prognostic biomarkers for prostate cancer by label free quantitative protein mass spectrometry of formalin fixed paraffin embedded tissue Oberhuber M, Pecoraro M, Wieselberg M, Pencik J, Haslinger P, Pollheimer J, Wiebringhaus R, Mann M, Hantusch B & Kenner L 9th MaxQuant Summer School, 2017 2017 2.8
Identification of diagnostic and prognostic biomarkers for prostate cancer by label free quantitative protein mass spectrometry of formalin fixed paraffin embedded tissue Oberhuber M, Pecoraro M, Wieselberg M, Pencik J, Haslinger P, Pollheimer J, Wiebringhaus R, Mann M, Hantusch B & Kenner L 9th ÖGBMT Annual Meeting, 2017 2017 2.8
Unsupervised Abbreviation Detection in Clinical Narratives Proceedings of the Clinical Natural Language Processing Kreuzthaler, M; Oleynik, M; Avian, A; Schulz S 2016 Workshop. 2016; -COLING 2016; Osaka, JAPAN. , 91 – 98 (ISBN:978-4-87974-710-5 ) 11 December 2016 1.2
Translation Initiation separates low and high grade and colon and rectum carcinoma Golob-Schwarzl, N; Schweiger, C; Koller, C; Krassnig, S; Gogg-Kamerer, Gantenbein, N; Bergler, H; Pertschy, B; M; Uranitsch, S; Lackner, K; Punschart, A, Stiegler, P; Keil, M; Hoffmann, J; Henderson, D; Lehrach, H; Reinhard, CH; Schicho, R; Fickert, P; Lax, S; Haybaeck, J. Talk:Doctoral Day ; 2016; Graz, AUSTRIA. 2016. December 2016 2.5
Unsupervised Abbreviation Detection in Clinical Narratives M Kreuzthaler, M Oleynik, A Avian, S Schulz Coling 2016 (Clinical NLP Workshop) December 2016 1.2
Diagnostic performance of BALF triacetylfusarinine C (TAFC) determination for invasive pulmonary aspergillosis in patients with hematological malignancies Prattes, J; Orasch, T; Lindner, H; Eigl, S; Düttmann, W; Faserl, K; Haas, H; Hoenigl, M Abstract (Webpublikation): IDWeek 2016; ; New Orleans, USA 26–30 October 2016 3.11
Standardized evaluation of three continuous glucose monitoring systems mimicking real-life conditions. Aberer, F; Hajnsek, M; Rumpler, M; Zenz, S; Puffing, A; Augustin, T; Baumann, P; Sinner, F; Sourij, H; Pieber, TR; Mader, JK; Abstract (Konferenzband): Keine. 2016; -52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), 2016 ; Munich, GERMANY. 12–16 September 2016 3.3
1,3-beta-D-glucan testing is highly specific in patients undergoing dialysis treatment Prattes, J; Schilcher, G; Schneditz, D; Prüller, F; Jaindl, E; Hoenigl, M; Krause R ÖGIM Jahrestagung 2016; Salzburg, AUSTRIA. 22–24 September 2016 3.11
Glucagon Response in C-Peptide Positive vs. C-Peptide Negative Patients with Type 1 Diabetes under Hypoglycemic Clamp vs. Real-Life Setting. Zenz, S; Baumann, P; Brunner, M; Puffing, A; Wolf, M; Rumpler, M; Hajnsek, M; Sourij, H; Pieber, TR; Mader, JK Abstract (Konferenzband): Proceedings of the 76th Scientific Sessions of the American Diabetes Association (ADA) – Late Breaking Abstracts. 2016; -76th Scientific Sessions of the American Diabetes Association (ADA); New Orleans, LA, USA. 10–14 June 2016 3.6
Translation Initiation and Urinary Bladder Cancer Haybaeck, J Abs+A99:K99tract (Konferenzband): Conference abstract book. 2016; -PSC 2nd World Pathology Conference 2016; Prague, CZECH REPUBLIC. 18–19 June 2016 2.5
eIF3a is Clinically Relevant in in Urinary Bladder Cancer Although Independent od Translation Initiation Haybaeck, J Abstract (Konferenzband): Conference Book Abstract. 2016; 154–BIT`s 9th Annual World Cancer Congress-2016 ; Shanghai, CHINA. 14–16 May 2016 2.5
Sesion 3-2: Cancer Diagnostic Biomarkers, Predictive Prognostic and Toxicity Biomarkers Haybaeck, J Abstract (Konferenzband): Confernce Book Abstract. 2016; 149-155.-BIT 9th Annual World Cancer Congress-2016 ; Shanghai, CHINA. 14–16 May 2016 2.5
Session 2-12: Circulating, Disseminated Tumor Cells and Metastasis Haybaeck Johannes (Chairman) Abstract (Konferenzband): Abstract Conference Book . 2016; 135-139.-BIT 9th Annual World Cancer Congress-2016; Shanghai, CHINA. 14–16 May 2016 2.5
The Brain and Clinically Relevant Physical Properties Haybaeck, J Abstract (Konferenzband): Abstract Book. 2016; -NeuroTalk 2016; Beijing, CHINA. 18–22 May 2016 2.5
Blood culture negative infective endocarditis in a kidney transplant recipient. Prattes, J; Zollner-Schwetz, I; Krause, R; Valentin, T Abstract (Konferezband): 2016; -Österreichischer Infektionskongress; Saalfelden am Steinernen Meer, Österreich. 27–30 April 2016 3.11
HSP72 OVEREXPRESSION PROTECTS FROM LIVER INJURY VIA ATTENUATION OF JNK SIGNALLING Kuscuoglu, D; Wenzel, K; Ensari, GK; Golob-Schwarzl, N; Hittatiya, K; Fischer, HP; Haybaeck, J; Trautwein, C; Strnad, P. Poster:Journal of Hepatology 2016, Abstract Book. 2016; 170–The International Liver Conference 2016; APR 13-17, 2016; Barcelona, SPAIN. 13–17 April 2016 2.5
Accumulation of hepatitis B surface antigen promotes the development of A1AT mutation-related liver disease Kuscuoglu, D; Wenzel, K; Ensari, GK; Golob-Schwarzl, N; Hittatiya, K; Fischer, HP; Haybaeck, J; Trautwein, C; Strnad, P. Talk: Journal of Hepatology 2016, Abstract Book. 2016; 64: 298–The International Liver Conference 2016; APR 13-17, 2016; Barcelona, SPAIN 13–17 April 2016 2.5
Labor für Klinische MALDI Anwendungen G. Stübiger, K. Strasser, R. Oehler Poster – Lange Nacht der Forschung (Wien 2016) 22 April 2016 1.9
Serum 1,3-β-D-glucan is a reliable biomarker in patients with ongoing hemodialysis, hemodiafiltration and peritoneal dialysis. Jaindl, E; Prattes, J; Schilcher, G; Prüller, F; Hönigl, M; Schneditz, D; Krause, R Abstract (Konferenzband): 2016; -Österreichischer Infektionskongress; Saalfelden am Steinernen Meer, AUSTRIA. 27–30 April 2016 3.11
Evaluation of the diagnostic and prognostic potential of the novel inflammatory biomarker suPAR in pleural effusion_x000D_ Matzkies, L; Raggam, RB; Rabensteiner, J; Feierl, G; Flick, H; Hoenigl, M; Prattes, J_x000D_ Abstract (Konferenzband): Österreichischer Infektionskongress; Saalfelden am Steinernen Meer, Österreich. 27–30 April 2016 3.11
Qiagen Gene Reader Workflow Lisa Oberauner-Wappis, Martina Loibner Talk: MIGrobeZ; ZMF; MUG, Graz, Austria. 2016 28 April 2016 1.4
Colonization by multidrug-resistant Gram-negative bacteria in residents of long-term care facilities in Graz, Austria_x000D_ Leitner, E; Ullrich, E; Schippinger, W; Pichler, G; Pux, C; Zechner, E; Krause, R; Zollner-Schwetz; Abstract (Webpublikation): www.escmid.org.; European Congress of Clinical Microbiology and Infectious Diseases ; Amsterdam, Netherlands. 9–12 April 2016 3.11
Regulatory T cells as potential biomarkers in type 1 diabetes Prietl, B; Treiber, G; Pieber, TR Abstract (Konferenzband): Conference Book 3rd AIT Biomarker Symposium. 2016; -AIT 3rd Biomarker Symposium; Vienna, Austria. 11–12 March 2016 1.6
Defects in Suppressive and Apoptotic Function of Regulatory T Cells in Children and Adults with Type 1 Diabetes Prietl, B; Treiber, G; Fröhlich-Reiterer, E; Lechner, E; Pieber, TR Abstract (Konferenzband): Final Program and Abstracts of the World Immune Regulation Meeting X. 2016; -World Immune Regulation Meeting X; Davos, Switzerland. 16–19 March 2016 1.6
Innovative use of Information for Clinical Care and Biomarker Research Schulz, S. et al. Poster – 1st CBmed Biomarker Conference (Graz 2016) March 2016 1.2
Next generation sequencing-based biomarkers in molecular pathology Abuja, PM; Oberauner-Wappis, L; Ulz, C; Greenberg, J; Abraham, R; Oelmüller, U; Zatloukal, K Poster: 1st CBmed Biomarker Conference; Graz. 2016 11 February 2016 1.4
NGS as a biomarker tool – Workshop in technologies and research concepts Oberauner-Wappis, L Talk within Workshop: 1st CBmed Biomarker Conference ; Graz. 2016 11 February 2016 1.4
Development of a novel MALDI-MS based liquid biopsy detection platform G. Stübiger, L. Mancera, O. Belgacem Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.9
Metabolomics & MALDI -Clinical MALDI Applications G. Stübiger, R. Öhler Talk within Workshop: 1st CBmed Biomarker Conference ; Graz. 2016 11 February 2016 1.9
Clinical Data Management for Biomarker Research Tschapeller, B.; Ackbar, R.; Pieber, T. Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.1
1.5 Metabolomics A platform technology for biomarkers Bordag, N.; Stalz, H.; Klimacez, M.; Magnes, C. Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.5
Defects in regulatory T cell function as potential biomarkers in Type 1 Diabetes Prietl, B.; Treiber, G.; Fröhlich-Reiterer, E.; Lechner, E.; Pieber, T. Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.6
Health Technology Assessment of minimal residual disease detection as a prognostic biomarker and therapeutic target in hematologic cancers Schmidt, L.; Helter, T.; Krahulec, E.; Neubauer, S.; Pieber, T. Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.7
Core Lab Digital Pathology Ackbar, R; Bounab, K; Krisper, N; Ballach, M Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.8
Intact Cell Mass Spectrometry as a Rapid Method for Leukocyte Characterization Strasser, K; Zareva, E; Holzlechner, M; Birnleitner, H; Beer, A; Marchetti-Deschmann, M; Bergmann, M; Oehler, R Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 1.9
Analysis of Circulating Tumour Cells and mRNA for Androgen Receptors and Splice Variants in Prostate Cancer Smolle, M; El-Heliebi, A; Gerger, A; Haudum, C; Ercan, E; Chen, S Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 2.2
Chimeric antigen receptors for the treatment of hematologic malignancies Fechter, K; Deutsch, A; Neumeister, P Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 2.4
Mutation clearance detected by parallel sequencing at end of treatment as a biomarker for relapse-free survival in AML patients Gaksch, L; Kashofer, K; Daga, S; Krisper, N; Hofer, S; Höfler, G; Zebisch, A; Sill, H; Wölfler, A Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 2.4
MR-PDX models for the evaluation of cancer therapies Viertler, C; Sadelmeyer, E; Al-Zoughbi, W; Kashofer, K; Schauer, S; Fackelmann, U; Bauernhofer, T; Samonigg, H; Jahn-Kuch, D; Schüler, J; Zühlsdorf, M; Höfler, G Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 2.7
Probiotics in Diabesity: A pilot study Leber, B; Schmerböck, B; Tawdrous, M; Horvath, A; Blesl, A; Rainer, F; Tripolt, N; Sourij, H; Stadlbauer, V Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.1
GIRO–The Graz Diabetes Registry for Biomarker Research Tripolt, NJ; Url, J; Sourij, H Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.2
SequencingofVitaminDMetabolizingGenes Trummer, O; Schweighofer, N; Kashofer, K; Lerchbaum, E; Obermayer-Pietsch, B Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.4
A Study of the Stool and Saliva Microbiome in Polycystic Ovary Syndrome (PCOS) Lindheim, L; Bashir, M; Zachhuber, V; Trummer, C; Groselj-Strele, A; Trajanoski, S; Gorkiewicz, G; Obermayer-Pietsch, B Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.5
Biomarkers for probiotic effects on microbiome-gut-brain-axis Jacan, A; Fröhlich, E; Reichmann, F; Hassan, A; Holzer, P Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.9
Modulation of Gut Microbiota in Early Sepsis: A pilot study Leber, B; Schmerböck, B; Tawdrous, M; Horvath, A; Blesl, A; Rainer, F; Krause, R; Stadlbauer, V Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.10
Serum 1,3-Beta-D-Glucan levels are reliable in patients undergoing hemodialysis or hemodiafiltration Prattes, J; Jaindl, E; Schneditz, D; Schilcher, G; Hoenigl, M; Prueller, F; Krause, R Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.11
Electrochemical Biomarker Detection in Common Metabolic Disorders Obermayer-Pietsch, B; Holweg, G; Koele, W Poster – 1st CBmed Biomarker Conference (Graz 2016) 11 February 2016 3.12
(1→3)-ß-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV Infection. Hoenigl, M; Faria De Oliveira, M; Perez-Santiago, J; Finkelman, M; Zhang, Y; Morris, S; Ellis, RJ; Gianella, S_x000D_ Abstracts (Konferenzband): 23rd Conference on Retroviruses and Opportunistic Infections (CROI) ; Boston, USA. 21–25 February 2016 3.11
SPIDIMAN: Clinical Trial of a Single-Port Glucose Sensor on a Commercial Insulin Infusion Set. Rumpler, M; Hajnsek, M; Mader, JK; Sinner, F; Pieber, TR DIABETES TECHNOL THE: 2016:18: A28-A28.-9th International Conference of Advanced Technologies and Treatments for Diabetes (ATTD); Milan, ITALY. 3–6 February 2016 3.3
Cartilage oligomeric matrix protein (COMP) in relation to bone markers and density in a large osteoarthritis cohort Obermayer-Pietsch B, Warnkross H, Renner W, Wolf M, Clar H, Trummer O, Leithner A Poster Award German-Austrian-Swiss Congress of Osteology 2016 2016 3.4
Cost-effectiveness of field-based screening for acute HIV infection among Men who have Sex with Men Hoenigl, M; Graff-Zivin, J; Little, SJ CDC – National HIV Prevention Conference, Atlanta, USA December 2015 3.11
Glykämie nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leukämie (AML) ist ein unabhängiger Prädiktor für das Überleben. Aberer, F; Mader, JK; Kremser, S; Zinke-Cerwenka, W; Greinix, H; Pieber, TR; Zebisch, A; Sill, H; Oulhaj, A; Wölfler, A; Sourij, H Wiener Klinische Wochenschrift; 43. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Austria November 2015 3.1
Assoziation zwischen Hyperglykämie und ungünstigem Outcome bei Patienten mit akuter oder chronischer Graft-versus-Host Erkrankung (GvHD) nach allogener Stammzelltransplantation. Aberer, F; Stauber, MN; Mader, JK; Greinix, H; Oulhaj, A; Wölfler, A; Sourij, H Wiener Klinische Wochenschrift; 43. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Austria November 2015 3.1
Genauigkeit und Performance von kontinuierlichem Glukosemonitoring bei drei Closed-Loop-Studienmit Heimphase unter normalen Lebensbedingungen. Kojzar, H; Thabit, H; Leelarathna, L; Wilinska, ME; Elleri, D; Allen, JM, Lubina-Solomon, A; Walkinshaw, E; Stadler, M; Choudhary, P; Holzer, M; MAder, JK; Dellweg, S; Benesch, C; Pieber, TR; Arnolds, S; Heller, SR; Amiel, SA; Dunger, D; Evans, ML; Hovorka, R Wiener Klinische Wochenschrift; 43. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Austria November 2015 3.3
Hohe Variabilität der Diabeteskurven im Krankenhaus Kopanz, J; Neubauer, KM; Sendlhofer, G; Semlitsch, B; Pieber, TR; Plank, J Wiener Klinische Wochenschrift, ÖDG Jahrestagung, Salzburg November 2015 1.6
Langzeit Follow-up diner Kohorte von Patienten mit diabetischem Fußsyndrom in der Steiermark. Mader, JK; Haas, W; Ribitsch, A; Samonigg, J; Höller, V; Horvath, K; Köhler, G; Sourij, H; Pieber, TR; Plank, J Wiener Klinische Wochenschrift; 43. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Austria November 2015 3.1
Polyclonal serum free light chain levels are associated with carotid atherosclerosis in type 2 diabetes mellitus Tripolt, N.; Zedler, J.; Scharnagl, H.; Stojakovic, T.; Sourij, H. Wiener Klinische Wochenschrift; 43. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Austria November 2015 3.1
Serum 1,3-Beta-D-Glucan levels are reliable in patients undergoing hemodialysis or hemodiafiltration Prattes, J; Jaindl, E; Schilcher, G; Prueller, F; Hoenigl, M; Schneditz, D; Krause, R MYCOSES, 7th Trends in Medical Mycology October 2015 3.11
C/EBP alpha-induced proinflammatory cytokines regulate early dendritic cell development Rosenberger, A; Geiger, O; Zebisch, A; Sill, H; Wolfler, A Oncology Research and Treatment October 2015 2.4
Tyrosin kinase inhibitors usage and response analysis in the Austrian CML registry cohort Schmidt, S; Wolfler, A; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Wiesholzer, M; Woll, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G Oncology Research and Treatment October 2015 2.4
Steroid-induced hyperglycemia adversely impacts outcome in graft-versus-host disease Stauber, M; Aberer, F; Zebisch, A; Neumeister, P; Greinix, HT; Sill, H; Sourij, H; Wolfler, A Oncology Research and Treatment October 2015 2.4
MiR-199a and miR-497 are associated with better overall survival due to increased chemosensitivity in aggressive non-Hodgkin’s lymphoma patients Troopan, K; Wenzl, K; Pichler, M; Pursche, B; Schwarzenbacher, D; Feichtinger, J; Thallinger, G; Beham-Schmid, C; Neumeister, P; Deutsch, A Oncology Research and Treatment October 2015 2.4
Efficacy of antibiotic prophylaxis in AML patients treated with low-intensity therapeutic regimens Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wolfler, A; Sill, H; Zebisch, A Oncology Research and Treatment October 2015 2.4
Identification of invasive fungal infections in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA microarray. Boch, T; Reinwald, M; Postina, P; Cornely, OA; Heussel, CP; Heinz, W; Hoenigl, M; Eigl, S; Lehrnbecher, T; Hahn, J; Claus, B; Lauten, M; Egerer, G; Muller, MC; Will, S; Merker, N; Hofmann, WK; Buchheidt, D; Spiess, B Oncology Research and Treatment; Jahrestagung der DGHO, OeGHO, SGMO und SGH, Basel, Switzerland October 2015 3.11
Galactomannan Testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples obtained from patients with hematological malignancies at risk for invasive mould infection Eigl, S; Prattes, J; Reischies, FM; Raggam, RB; Spiess, B; Reinwald, M; Buchheidt, D; Thornton, CR; Krause, R; Flick, H; Neumeister, P; Hoenigl, M MYCOSES October 2015 3.11
Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a Hatzl, S; Geiger, O; Kuepper, MK; Seime, T; Nussbaumer, E; Wieser, R; Pichler, M; Scheideler, M; Nowek, K; Jongen-Lavrencic, M; Wolfler, A; Troppmair, J; Sill, H; Zebisch, A Oncology Research and Treatment October 2015 2.4
Efficacy of antibiotic prophylaxis in AML patients treated with low-intensity therapeutic regimens Bainschab, A; Quehenberger, F; Greinix, HT; Krause, R; Wölfler, A; Sill, H; Zebisch, A Oncology Research and Treatment; 38th Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology October 2015 2.4
Whole-cell MALDI-TOF mass spectrometry as a rapid method for leukocyte typing Strasser, Zareva, Holzlechner, Birnleitner, Marchetti-Deschmann, Bergmann, Oehler 4th Eur. Congress of Immunology, Vienna September 2015 1.9
Whole-cell MALDI-TOF mass spectrometry as a rapid method for leukocyte typing Strasser, Zareva, Holzlechner, Birnleitner, Marchetti-Deschmann, Bergmann, Oehler 7th ÖGMBT Annual Meeting, Salzburg September 2015 1.9
Clinical utility of circulating tumor DNA in human cancers: A report of more than 300 plama-Seqs Heitzer, E; Ulz, P; Auer, M; Belic, J; Sumitra, M; Lax, S; Hoefler, G; Augustin, H; Edgar, P; Bauernhofer, T; Geigl, J; Speicher, M EUR J CANCER September 2015 2.2
Galactomannan Testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples obtained from patients with hematological malignancies at risk for invasive mould infection. Eigl, S; Prattes, J; Reischies, F; Raggam, RB; Spiess, B; Reinwald, M; Buchheidt, D; Thornton, CR; Krause, R; Flick, H.; Neumeister, P; Hoenigl, M ICAAC – Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA September 2015 3.11
Insulin Prescription Charts at a University Hospital: High Variability of Design Characteristics Kopanz, J; Neubauer, KM; Sendlhofer, G; Semlitsch, B; Pak, A; Pieber, TR; Plank, J Safety in Health, Supplement, Sicherheit im Krankenhaus – Von der Strategie zur Umsetzung; Graz, Austria September 2015 1.7
Helicobacter pylori Resistance in Southern Austria Zollner-Schwetz, I; Leitner, E; Plieschnegger,W; Semlitsch, G; Reiter, L; Stepan, V; Reicht, G; Bretterklieber, C; Mörth, E; Pavek, J; Parsche, P; Schneider, W; Grabner, S; Krause, R; Högenauer, C Wiener Klinische Wochenschrift; 43. Jahrestagung der Österreichischen Diabetes Gesellschaft, Salzburg, Austria September 2015 3.11
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium Wallner, M; Kolesnik, E; Ablasser, K; Khafaga, M; Ljubojevic, S; Sourij, H; Kapl, M; Kuzmiski, B; Griffith, A; Von Lewinski, D EUROPEAN HEART JOURNAL August 2015 3.2
Can SNOMED CT be squeezed without losing its shape? López-García, P; Schulz, S Proceedings of the International Conference on Biomedical Ontology, ICBO 2015, International Conference on Biomedical Ontology (ICBO), Lisbon, Portugal July 2015 1.2
Establishment of a comprehensive rare disease biomaterials online catalogue by RD-Connect The EXPOnential relevance of biobanking. Clinical biobanks for personalized medicine Wang, CM; Merino-Martinez, R; Reihs, R; Müller, H; Abuja, PM; Lopez-Martin, E; Posada de la Paz, M; Mora, M; Filocamo, M; Monaco, L HandsOn: Biobanks; Milano, Italy July 2015 1.4
Behavioral and molecular processing of visceral pain in the brain of mice: Impact of colitis and psychological stress Jain, P; Hassan, AM; Koyani, CN; Mayerhofer, R; Reichmann, F; Farzi, A; Schuligoi, R; Malle, E; Holzer, P NEUROGASTROENT MOTIL. June 2015 3.9
G UPDATED REPORT OF THE AUSTRIAN CML-REGISTRY Schmidt, S; Wolfler, A; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Pober, M; Woll, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G HAEMATOLOGICA, 20th Congress of the European Hematology Association Vienna, Austria June 2015 2.4
Long-Term follow-up of a Cohort with a History of Diabetic Foot Ulcer in Austria. Mader, JK; Haas, W; Ribitsch, A; Samonigg, J; Horvath, K; Köhler, G; Sourij, H; Pieber, TR; Plank, J Diabetes; 75th Scientific Sessions of the American Diabetes Association (ADA), Boston, USA June 2015 1.6
An untargeted metabolomics approach to detect biomarkers for the effects of bariatric surgery in humans Sophie H. Narath, Christoph Magnes, Harald Sourij, Thomas R. Pieber 11th Annual Biomarkers and Diagnostics World Congress 2015, Philadelphia May 2015 1.5
Regulatory T cells as potential biomarkers in type 1 diabetes Barbara Prietl, Gerlies Treiber and Thomas Pieber 11th Annual Biomarkers and Diagnostics World Congress 2015, Philadelphia May 2015 1.6
MORPHOMETRICAL QUANTIFICATION OF FIBROSIS CORRELATES WITH CLINICAL CIRRHOSIS STAGE AND PREDICTS LONG-TERM SURVIVAL IN PATIENTS WITH ALCOHOLIC CIRRHOSIS Binder, L; Rainer, F; Haybaeck, J; Xu, S; Spindelboeck, W; Wee, A; Stauber, R; Lackner, C JOURNAL OF HEPATOLOGY; 50th International Liver Congress of the European-Associationa for the Study of the Liver, Vienna Austria April 2015 2.5
MANIFESTATION OF DIET-ASSOCIATED NAFLD/AFLD IN DIFFERENT MOUSE STRAINS Fengler, VHI; Hayback, J; Lackner, C; Sargsyan, K JOURNAL OF HEPATOLOGY; 50th International Liver Congress of the European-Associationa for the Study of the Liver, Vienna Austria April 2015 2.5
METABOLIC DISTURBANCES AFTER FRUCTOSE OVERCONSUMPTION ARE NOT LINKED TO INTESTINAL PERMEABILITY IN HEALTHY YOUNG VOLUNTEERS Kienbacher, C; Dolak, W; Traussnigg, S; Steindl-Munda, P; Oettl, K; Stadlbauer, V; Knapp, S; Vogelsang, H; Trauner, M JOURNAL OF HEPATOLOGY April 2015 3.10
THE ROLE OF GROWTH HORMONE RECEPTOR IN LIVER FIBROSIS AND CANCER Stiedl, P; McMahon, R; Blaas, L; Stanek, V; Svinka, J; Grabner, B; Zollner, G; Kressler, S; Claudel, T; Muller, M; Mikulits, W; Esterbauer, H; Eferl, R; Haybaeck, J; Trauner, M; Casanova, E JOURNAL OF HEPATOLOGY; 50th International Liver Congress of the European-Associationa for the Study of the Liver, Vienna Austria April 2015 2.5
The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours. Passegger, C; Kump, P; Hayback, J; Lipp, R; Niederle, B; Pfragner, R; Sadjak, A; Schwach, G; Spindelbock, W; Tabrizi-Wizsy, NG NEUROENDOCRINOLOGY, 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease March 2015 2.5
Impact of linezolid on hematopoietic engraftment in patients after umbilical cord blood stem cell transplantation Vilits, T; Huber-Krassnitzer, B; Zinke-Cerwenka, W; Neumeister, P; Quehenberger, F; Hoenigl, M; Sill, H; Woffler, A BONE MARROW TRANSPLANTATION; 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, Turkey March 2015 2.4
Influenza, legionella, TNF-alpha inhibitors Hoenigl, M I MYCOSES 2015 3.11
Correlation between somatic comorbidities and anxiety and depression in patients after allogeneic hematopoietic stem cell transplantation Balsiger, C; Mumm, F; Holler, E; Herzberg, PY; Hilgendorf, I; Hemmati, P; von Harsdorf, S; Greinix, H; Mitchell, SA; Wolff, D; Heussner, P Oncology Research and Treatment 2015 1.6

Books

2019 2017 2016 Top of page
Title Author(s) Publication Date Project
Lehrserie Nr. 341, Knochentumoren – Basiskurs mit MOPA Haybäck, J; Roessner, A Internationale Akademie für Pathologie, Deutsche Abteilung e.v.; 2019. pp. 117. 2019
Translational Control and mTOR in Cancer Seeböck, R; Golob-Schwarzl, N; Krassnig, S Mechanisms of Molecular Carcinogenesis Volume 1. 1: Cham: Springer; p. 77-86. (ISBN: 978-3-319-53657-6) 2017 2.5
Neuroendokrine Tumorigenesis Gantenbein, N; Haybaeck, J Mechanisms of Molecular Carcinogenesis. 2(1) : Cham: Springer; p. 141-146. (ISBN: 978-3319536606) 2017 2.5
Hepatocellular Carcinogenesis Golob-Schwarzl, N; Kessler, SM; Haybaeck, J Mechanisms of Molecular Carcinogenesis. 2(1) : Cham: Springer; p. 119-140. (ISBN: 978-3319536606) 2017 2.5
Nonalcoholic Fatty Liver Disease Smolle, E; Kessler, SM; Golob, N; Haybäck, J. Rexford, SA editors(s). Metabolic Syndrome – A Comprehensive Textbook. 1(1) : Switzerland: Springer Reference; p. 641 – 657. (ISBN: 978-3-319-11250-3) 2016 2.5

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

Font Resize
Contrast